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Definitions
Advanced HIV disease: for adults, adolescents, and children aged 5 years or more, “advanced HIV 
disease” is defined as a CD4 cell count of less than 200 cells/mm3 or a WHO clinical stage 3 or 4 event 
at presentation for care. All children with HIV aged under 5 years should be considered as having 
advanced disease at presentation.
Age groups: the following definitions for adults and children are used in these guidelines for the 
purpose of implementing recommendations (countries may have other definitions under their national 
regulations)2:
• an adult is a person aged 15 years and older;
• a child is a person aged under 15 years.
Grading of Recommendations Assessment, Development and Evaluation (GRADE): a 
system for rating quality of evidence and strength of recommendations; the GRADE approach 
is explicit, comprehensive, transparent and pragmatic, and is increasingly being adopted by 
organizations worldwide.
Inpatient health care setting: a health care facility where patients are admitted and assigned a bed 
while undergoing diagnosis and receiving treatment and care, for at least one overnight stay.
Outpatient health care setting: a health care facility where patients are undergoing diagnosis and 
receiving treatment and care but are not admitted for an overnight stay (e.g. an ambulatory clinic 
or a dispensary). 
2 In Section 5. Lateral flow urine lipoarabinomannan assay the following definitions for adults, adolescents and children were used: an 
adult is a person older than 19 years of age; an adolescent is a person 10–19 years of age inclusive; and a child is a person under 10 
years of age.
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Executive summary
Background
The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held 
on 26 September 2018 included commitments by Member States to four new global targets.3 One of 
these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018–2022. The 
approximate breakdown of the target is about 7 million in 2018 and about 8 million in subsequent 
years. The traditional method for diagnosing TB using a light microscope, developed more than 100 
years ago, has in recent years been challenged by several new methods and tools. These methods are 
based on either the detection of mycobacterial antigens or on the detection of mycobacterial DNA. 
The novel tools to detect presence of Mycobacterium tuberculosis and resistance to anti-TB drugs call 
for evidence-based policy recommendations. The World Health Organization (WHO) has published a 
number of guidelines developed by WHO-convened Guideline Development Groups (GDGs), using 
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to 
summarize the evidence and to formulate policy recommendations and accompanying remarks. 
However, the growing number of published guidelines complicates the overview of recommendations 
for the intended audience (which includes health care personnel, national TB programmes and policy-
makers), and WHO recognized the need to consolidate the recommendations into one document. 
The recommendations in this document have been presented in five guidelines published by WHO 
between 2016 and 2020, as shown in the box below. Earlier guidelines on diagnostics that were not 
developed according to the GRADE approach have not been included in this consolidated document. 
 Î Molecular assays intended as initial tests for the diagnosis of pulmonary and 
extrapulmonary TB and rifampicin resistance in adults and children: Policy update 2020. 
Issued for the first time as a part of the present document, and corresponds to section 1. 
 Î The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of 
pulmonary tuberculosis: policy guidance (WHO/HTM/TB/2016.11). Geneva: World 
Health Organization; 2016. 
 Î The use of molecular line probe assays for the detection of resistance to isoniazid and 
rifampicin (WHO/HTM/TB/2016.12). Geneva: World Health Organization; 2016. 
 Î The use of molecular line probe assays for the detection of resistance to second-
line anti-tuberculosis drugs: policy guidance (WHO/HTM/TB/2016.07). Geneva: World 
Health Organization; 2016. 
 Î Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active 
tuberculosis in people living with HIV. Policy update 2019 (WHO/CDS/TB/2019.16). 
Geneva: World Health Organization; 2019. 
WHO diagnostic guidelines included in these consolidated guidelines
3 Global tuberculosis report 2019 (WHO/CDS/TB/2019.15). Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/
global_report/en/, accessed 26 May 2020).
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Introduction
Background
The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held 
on 26 September 2018 included commitments by Member States to four new global targets (1). 
One of these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018–
2022. The approximate breakdown of the target is about 7 million in 2018 and about 8 million in 
subsequent years. 
Globally in 2018, 7.0 million people with a new episode of TB (i.e. new and relapse cases) were notified 
to national TB programmes (NTPs) and reported to the World Health Organization (WHO), a 9% 
increase from 6.4 million in 2017. Based on these data, the 2018 target of 7 million new and relapse 
cases to achieve the cumulative target set at the UN high-level meeting on TB – of 40 million in the 
period 2018–2022 – was achieved (1).
WHO’s End TB Strategy calls for the early diagnosis of TB and for universal drug-susceptibility testing 
(DST), highlighting the critical role of laboratories in the post-2015 era in rapidly and accurately 
detecting TB and drug resistance (2). Of the 7.0 million new and relapse cases notified in 2018, 
5.9 million (85%) had pulmonary TB. Of these, 55% were bacteriologically confirmed, a slight decrease 
from 56% in 2017 and 58% in 2013.4 The remaining patients were diagnosed clinically; that is, based 
on symptoms, abnormalities on chest radiography or suggestive histology.
Activities to strengthen TB diagnosis must be viewed in the context of recent global initiatives to “find 
the missing cases”, and the new global target set at the UN high-level meeting on TB in September 
2018. In this context, the proportion of notified cases that are bacteriologically confirmed needs to 
be monitored. However, the microbiological detection of TB is critical because it allows people to be 
correctly diagnosed and started on the most effective treatment regimen as early as possible. Most 
clinical features of TB have low specificity, which may lead to false diagnoses of TB, and hence to 
people being enrolled in TB treatment unnecessarily. The aim should be to increase the percentage 
of TB cases confirmed bacteriologically (based on scaling up the use of recommended diagnostics 
that are more sensitive than smear microscopy).
A range of new diagnostic technologies have been endorsed by WHO during the past 10 years. The 
amplification and detection of M. tuberculosis complex (MTBC) nucleic acids is a technology that has 
proven to be highly sensitive and specific. Some amplification technologies have the great advantage 
of also being able to detect resistance to selected anti-TB drugs. The lateral flow technology detecting 
MTBC antigen in a point-of-care test format has also been endorsed for use in certain groups of 
presumptive TB patients. In total, four groups of technologies can be identified:
• real-time polymerase chain reaction (PCR) assays – for example, Xpert MTB/RIF® (Ultra) (cartridge-
based) and Truenat™ (chip-based);
• line probe assays (LPAs) – for example, GenoType® MTBDRplus v1 and v2, Genoscholar™ 
NTM+MDRTB II and GenoType® MTBDRsl;
• loop-mediated isothermal amplification (LAMP) – for example, TB-LAMP; and
4 A bacteriologically confirmed case is one for whom a biological specimen is positive by smear microscopy, culture or WHO-recommended 
rapid diagnostic test.
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• antigen detection in a lateral flow format (biomarker-based detection) – for example, Alere 
Determine™ TB LAM Ag.
The real-time PCR applied in some tools is the most widely used technology today. These tools 
detect MTBC DNA and can distinguish mutations in the gene linked to drug resistance to rifampicin. 
The available tools use software and hardware (computers) to report results, and they require well-
established laboratory networks and trained personnel.
LPAs are a family of DNA strip-based tests that can detect the MTBC strain and determine its drug 
resistance profile. The tests do this through the pattern of binding of amplicons (DNA amplification 
products) to probes that target the specific parts of the MTBC genome, common resistance-associated 
mutations to anti-TB agents or the corresponding wild-type DNA sequence (3). LPAs are more 
technically complex to perform than the Xpert MTB/RIF assay; however, they can detect resistance to 
a broader range of first-line and second-line agents (e.g. isoniazid, fluoroquinolones and injectable 
agents). Testing platforms have been designed for a reference laboratory setting and are most 
applicable to high TB burden countries. Results can be obtained in 5 hours (4). There are two large 
groups of assays: 
• those detecting MTBC and resistance to first-line anti-TB agents (known as first-line LPAs [FL-LPAs]) – 
for example, GenoType MTBDRplus v1 and v2, Genoscholar NTM+MDRTB II; and 
• those detecting resistance to second-line anti-TB agents (known as second-line LPAs [SL-LPAs]) – 
for example, GenoType MTBDRsl. 
A third technology is based on LAMP reaction, in which target DNA is amplified at a fixed temperature 
(in contrast to the PCR, which requires a thermocycler). Detection of amplified product is done 
visually, using an ultraviolet (UV) lamp, directly in the reaction tubes. The method requires only basic 
equipment and can be implemented at the lowest levels of the laboratory network. However, detection 
of mutations in resistance-associated genes is not possible with this technology.
The search for a point-of-care test (i.e. a lateral flow test detecting either MTBC antigen or antibodies 
to MTBC) has proven complicated. However, the mycobacterial lipoarabinomannan (LAM) antigen 
in urine has emerged as a potential candidate. The currently available urinary LAM assays have 
suboptimal sensitivity and specificity, and are therefore not suitable as diagnostic tests for TB in 
all populations. However, unlike traditional diagnostic methods, urinary LAM assays demonstrate 
improved sensitivity for the diagnosis of TB among individuals coinfected with HIV.
Scope of the document
This document provides background, justification and recommendations on novel diagnostic tools 
for the detection of MTBC and for the presence or absence of mutations in target genes proven to 
be associated with anti-TB drug resistance.
Target audience
The target audience for these guidelines includes laboratory managers, clinicians and other health care 
staff, HIV and TB programme managers, policy-makers, technical agencies, donors and implementing 
partners supporting the use of TB diagnostics in resource-limited settings. 
Individuals responsible for programme planning, budgeting, mobilizing resources and implementing 
training activities for the programmatic management of drug-resistant TB may also find this 
document useful.
Recommendations 3
Recommendations
Section 1. Molecular assays intended as initial tests 
for TB
The development of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, United States of America [USA]) 
was a major step forward for improving the diagnosis of TB and the detection of rifampicin resistance 
globally. However, Xpert MTB/RIF sensitivity is suboptimal, particularly in smear-negative and HIV-
associated TB patients. The Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, USA), hereafter referred to as 
Xpert Ultra, was developed by Cepheid as the next-generation assay to overcome these limitations. 
It uses the same GeneXpert® platform as the Xpert MTB/RIF. 
New molecular assays – the Truenat MTB, MTB Plus and MTB-RIF Dx assays (Molbio Diagnostics, 
Goa, India), hereafter referred to as Truenat – were developed in India, and may potentially be used 
at the same health system level as Xpert MTB/RIF. Of the above-mentioned assays, MTB and MTB 
Plus are used as initial diagnostic tests for TB, whereas MTB-RIF Dx is used as a reflex test to detect 
rifampicin resistance for those with positive results on the initial Truenat tests. Multisite international 
evaluations in settings of intended use are being implemented by the Foundation for Innovative New 
Diagnostics (FIND), a WHO collaborating centre for the evaluation of new diagnostic technologies. 
Given the similarity of the operational characteristics for Xpert MTB/RIF and Truenat, the results of the 
latter study were reviewed within the same Guideline Development Group (GDG) meeting.
1.1 Recommendations
This section contains five sets of recommendations, with each set being specific for a particular type 
of testing (initial or repeated) and type of TB (pulmonary or extrapulmonary).
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1.1.1 Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests in adults 
and children with signs and symptoms of pulmonary TB
1.1 In adults with signs and symptoms of pulmonary TB, Xpert MTB/RIF should 
be used as an initial diagnostic test for TB and rifampicin-resistance detection 
in sputum rather than smear microscopy/culture and phenotypic DST.  
(Strong recommendation, high certainty of evidence for test accuracy; moderate certainty 
of evidence for patient-important outcomes5)
1.2 In children with signs and symptoms of pulmonary TB, Xpert MTB/RIF should be used as an 
initial diagnostic test for TB and rifampicin-resistance detection in sputum, gastric aspirate, 
nasopharyngeal aspirate and stool rather than smear microscopy/culture and phenotypic DST. 
(Strong recommendation, moderate certainty for accuracy in sputum; low certainty of 
evidence for test accuracy in gastric aspirate, nasopharyngeal aspirate and stool)
1.3 In adults with signs and symptoms of pulmonary TB and without a prior history of TB 
(≤5 years) or with a remote history of TB treatment (>5 years since end of treatment), 
Xpert Ultra should be used as an initial diagnostic test for TB and for rifampicin-resistance 
detection in sputum, rather than smear microscopy/culture and phenotypic DST. 
(Strong recommendation, high certainty of evidence for test accuracy)
1.4 In adults with signs and symptoms of pulmonary TB and with a prior history 
of TB and an end of treatment within the last 5 years, Xpert Ultra may be 
used as an initial diagnostic test for TB and for rifampicin-resistance detection 
in sputum, rather than smear microscopy/culture and phenotypic DST. 
(Conditional recommendation, low certainty of evidence for test accuracy)
1.5 In children with signs and symptoms of pulmonary TB, Xpert Ultra should be used as 
the initial diagnostic test for TB and detection of rifampicin resistance in sputum or 
nasopharyngeal aspirate, rather than smear microscopy/culture and phenotypic DST. 
(Strong recommendation, low certainty of evidence for test accuracy in sputum; very low 
certainty of evidence for test accuracy in nasopharyngeal aspirate) 
Remarks
For recommendation 1.2: Sputum includes expectorated and induced sputum. Studies assessing 
the impact of Xpert MTB/RIF on patient-important outcomes in children are lacking. The choice of 
the specimen will depend on the acceptability (for children, parents, health care workers and other 
stakeholders) and the feasibility of collecting and preparing specimens in the local context. Regarding 
Xpert MTB/RIF, the certainty of evidence is higher for sputum and nasopharyngeal aspirates than 
for other specimen types. The recommendation can be extrapolated for children living with HIV. The 
direct benefit from testing for rifampicin resistance in sputum (very low certainty of evidence for test 
accuracy) can be extrapolated to other specimens.
For recommendation 1.4: The justification for a conditional recommendation is based on:
• low certainty of evidence for test accuracy; 
• uncertainty about the interpretation of Xpert Ultra trace results in patients with a prior history of 
disease and the associated high false-positivity rate; and 
• uncertainty about the required resources. 
5 Mortality, cure, pretreatment loss to follow-up, time to diagnosis, treatment, and mortality in PLHIV.
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For patients with Xpert Ultra trace results, decisions regarding treatment initiation should include 
considerations of the clinical presentation and the patient context (including prior treatment history, 
probability of relapse and other test results).
1.1.2 Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests in adults 
and children with signs and symptoms of extrapulmonary TB
1.6 In adults and children with signs and symptoms of TB meningitis, Xpert 
MTB/RIF or Xpert Ultra should be used in cerebrospinal fluid (CSF) as an 
initial diagnostic test for TB meningitis rather than smear microscopy/culture. 
(Strong recommendation, moderate certainty of evidence for test accuracy for Xpert 
MTB/RIF; low certainty of evidence for test accuracy for Xpert Ultra)
1.7 In adults and children with signs and symptoms of extrapulmonary TB, Xpert MTB/RIF 
may be used in lymph node aspirate, lymph node biopsy, pleural fluid, peritoneal fluid, 
pericardial fluid, synovial fluid or urine specimens as the initial diagnostic test for 
respective form of extrapulmonary TB rather than smear microscopy/culture. 
(Conditional recommendation, moderate certainty of evidence for test accuracy for pleural 
fluid; low certainty for lymph node aspirate, peritoneal fluid, synovial fluid, urine; very low 
certainty for pericardial fluid, lymph nodes biopsy)
1.8 In adults and children with signs and symptoms of extrapulmonary TB, Xpert 
Ultra may be used in lymph node aspirate and lymph node biopsy as the initial 
diagnostic test for lymph nodes TB rather than smear microscopy/culture. 
(Conditional recommendation, low certainty of evidence)
1.9 In adults and children with signs and symptoms of extrapulmonary TB, Xpert MTB/RIF or Xpert 
Ultra should be used for rifampicin-resistance detection rather than culture and phenotypic DST. 
(Strong recommendation, high certainty of evidence for test accuracy for Xpert MTB/RIF; 
low certainty of evidence for Xpert Ultra)
1.10 In HIV-positive adults and children with signs and symptoms of disseminated TB, 
Xpert MTB/RIF may be used in blood, as an initial diagnostic test for disseminated TB. 
(Conditional recommendation, very low certainty of evidence for test accuracy)
Remarks
For recommendation 1.6: This recommendation applies to all patients with signs and symptoms of 
TB meningitis. The recommendation in children with signs and symptoms of TB meningitis is based 
on very low certainty of evidence for test accuracy for Xpert MTB/RIF. No data were available on the 
accuracy of Xpert Ultra for TB meningitis in children. 
For recommendation 1.7: Clinical judgement and pretest probability should guide treatment. In a 
high pretest probability setting (>5%), a negative test result will not rule out the condition. Available 
data on Xpert MTB/RIF for children have included lymph node aspirate and lymph node biopsy 
specimens; given the similarity of the effects, the recommendation for adults is extrapolated for 
children. 
For recommendation 1.8: The composite reference standard for Xpert Ultra gave similar results 
when lymph nodes aspirate was compared to lymph nodes biopsy. 
For recommendation 1.9: Clinical judgement and pretest probability should guide treatment. In a 
high pretest probability setting, a negative test result will not rule out the condition. 
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For recommendation 1.10: Blood was only evaluated in people living with HIV (PLHIV) and under 
particular processing specifications (5), using third-generation Xpert MTB/RIF cartridges, based on 
one study with a small number of participants. The recommendation applies only to a particular 
population (HIV-positive adults with signs and symptoms of disseminated TB). This recommendation 
cannot be extrapolated to other patient populations.
1.1.3 Recommendations on Xpert MTB/RIF and Xpert Ultra repeated testing in adults 
and children with signs and symptoms of pulmonary TB6
1.11 In adults with signs and symptoms of pulmonary TB who have an Xpert Ultra trace 
positive result on the initial test, repeated testing with Xpert Ultra may not be used. 
(Conditional recommendation, very low certainty of evidence for test accuracy)
1.12 In children with signs and symptoms of pulmonary TB in settings with pretest probability below 
5% and an Xpert MTB/RIF negative result on the initial test, repeated testing with Xpert MTB/RIF 
in sputum, gastric fluid, nasopharyngeal aspirate or stool specimens may not be used.7 
(Conditional recommendation, low certainty of evidence for test accuracy for sputum and 
very low for other specimen types)
1.13 In children with signs and symptoms of pulmonary TB in settings with pretest 
probability 5% or more and an Xpert MTB/RIF negative result on the initial 
test, repeated testing with Xpert MTB/RIF (for total of two tests) in sputum, 
gastric fluid, nasopharyngeal aspirate and stool specimens may be used. 
(Conditional recommendation, low certainty of evidence for test accuracy for sputum and 
very low for other specimen types)
1.14 In children with signs and symptoms of pulmonary TB in settings with pretest probability 
below 5% and an Xpert Ultra negative result on the initial test, repeated testing 
with Xpert Ultra in sputum or nasopharyngeal aspirate specimens may not be used. 
(Conditional recommendation, very low certainty of evidence for test accuracy)
1.15 In children with signs and symptoms of pulmonary TB in settings with pretest probability 5% 
or more and an Xpert Ultra negative result on the first initial test, repeated one Xpert Ultra 
test (for a total of two tests) in sputum and nasopharyngeal aspirate specimens may be used. 
(Conditional recommendation, very low certainty of evidence for test accuracy)
Remarks
For recommendation 1.11: Xpert Ultra trace results will require follow-up, including reassessing 
clinical symptoms and information on prior history of TB. In the case of suspected rifampicin resistance, 
repeated testing may provide additional benefit for detection as well as an initial attempt to assess 
rifampicin resistance. 
For recommendation 1.13: The GDG felt that the implementation of the recommendation depends 
on the acceptability (for children, parents or caregivers, health care workers and other stakeholders) 
and the feasibility of conducting repeated testing in the local context. The evidence reviewed evaluated 
repeating the same test on the same type of specimen. However, from the data reviewed on comparing 
single tests on different specimen types, there appears to be no difference, regardless of which second 
specimen is obtained. The recommendation can be extrapolated for children living with HIV (for 
Xpert MTB/RIF). This includes consideration of the direct benefit from detecting rifampicin resistance 
6 Based on PICO questions 3 and 4.
7 In low prevalence settings the effect of the second test was less pronounced.
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in sputum samples (very low certainty of evidence for test accuracy), which can be extrapolated to 
other samples. The recommendation applies to a moderate or high pretest setting (>5%). If the 
first test result is positive, the test should not be repeated. In settings with moderate to high pretest 
probability, the incremental yield of more than two tests is unknown. 
For recommendation 1.15: Desirable and undesirable effects were judged to be moderate, but 
testing twice in the moderate and high pretest probability (>5%) settings on balance may provide more 
benefits than harms. The recommendation is applicable for sputum and nasopharyngeal aspirates. 
No evidence was identified for stool and gastric aspirates.
1.1.4 Recommendations on Xpert MTB/RIF and Xpert Ultra as initial tests for 
pulmonary TB in adults in the general population either with signs and symptoms of 
TB or chest radiograph with lung abnormalities or both8
1.16 In adults in the general population who had either signs or symptoms 
of TB or chest radiograph with lung abnormalities or both, the Xpert 
MTB/RIF or Xpert Ultra may replace culture as the initial test for pulmonary TB. 
(Conditional recommendation, low certainty of the evidence in test accuracy for Xpert 
MTB/RIF and moderate certainty for Xpert Ultra)
1.17 In adults in the general population who had either a positive TB symptom screen 
or chest radiograph with lung abnormalities or both, one Xpert Ultra test may 
be used rather than two Xpert Ultra tests as the initial test for pulmonary TB. 
(Conditional recommendation, very low certainty of evidence for test accuracy)
Remarks
For recommendation 1.16: This recommendation was informed by evidence from recent national 
surveys of TB disease prevalence in four high TB burden countries. Indirectness of the evidence 
was classified as serious, given that the methods applied in TB prevalence surveys differ from 
usual programmatic conditions (e.g. symptom screen limited to cough for 14 days or more, and a 
requirement in surveys to have the results of both symptom screen and chest radiography available). 
In addition, inconsistency of the evidence was also classified as serious, owing to variability of the 
data from different countries. As a result, certainty in the estimates of effect was downgraded to 
low for sensitivity and moderate for specificity. The recommendation applies only to the use of 
Xpert MTB/RIF or Xpert Ultra for clinical case management in situations where an immediate 
decision on patient treatment needs to be made and recourse to supplementary tests is not 
available or would incur delays. It does not apply to scientific studies with other objectives, such as 
the reliable estimation of the prevalence of TB disease in the community, for which alternative testing 
algorithms are required (in particular, to address the issue of false-positive results, as illustrated in 
Table 1.17). Recommendations about the screening and diagnostic algorithms to be used in such 
studies are beyond the scope of this GDG. Recommendations for the diagnostic algorithm(s) to 
recommend in national TB prevalence surveys specifically are being developed by WHO and are 
scheduled for release in 2020.
For recommendation 1.17: There are concerns about losing global and national capacity for 
culture testing – the current reference standard for identifying active TB disease. An Xpert Ultra 
trace result was considered as negative in these studies. More false-positive results are expected for 
Xpert Ultra for pulmonary TB. The recommendation applies only to the use of Xpert Ultra for 
clinical case management. When Xpert Ultra gives a positive result, clinical management should 
8 Based on PICO question 5.
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be followed according to national guidelines. When Xpert Ultra gives a negative result, the patient 
should be re-evaluated clinically. In the case of a culture-positive result, clinical management should 
be followed according to national guidelines. In the case of a culture-negative result, the patient 
should be re-evaluated clinically. The recommendation does not apply to scientific studies with other 
objectives, such as the reliable estimation of the prevalence of TB disease in the community, in which 
alternative testing algorithms (e.g. using more than one test) may be required. Recommendations 
for the diagnostic algorithm(s) to be used in such studies are beyond the scope of this GDG. 
Recommendations for the diagnostic algorithm(s) to recommend in national TB prevalence surveys 
specifically are being developed by WHO and are scheduled for release in 2020.
1.1.5 Recommendations on Truenat MTB, MTB Plus and Truenat MTB-RIF Dx in adults 
and children with signs and symptoms of pulmonary TB9
1.18 In adults and children with signs and symptoms of pulmonary TB, the Truenat MTB or MTB 
Plus may be used as an initial diagnostic test for TB rather than smear microscopy/culture. 
(Conditional recommendation, moderate certainty of evidence for test accuracy)
1.19 In adults and children with signs and symptoms of pulmonary TB and a 
Truenat MTB or MTB Plus positive result, Truenat MTB-RIF Dx may be used as 
an initial test for rifampicin resistance rather than culture and phenotypic DST. 
(Conditional recommendation, very low certainty of evidence for test accuracy)
Remarks
For recommendation 1.18: The recommendation includes patients who are smear negative. There is 
uncertainty about the use of these assays in PLHIV. In smear-negative patients, the sensitivity is lower 
than in all patients. The indirect data on test accuracy in smear-negative patients (given that there are 
no data on PLHIV for this version of Truenat) made it possible to extrapolate this recommendation to 
PLHIV. However, the certainty of evidence for test accuracy would need to be lowered to account for 
additional indirectness. In the case of children, there were no data available to assess the accuracy 
of the test in different specimens, and not enough indirect evidence to extrapolate for specimens 
other than sputum. This recommendation is extrapolated to children for sputum, although the tests 
are expected to be less sensitive in children.
For recommendation 1.19: The Truenat is a reflex (two-step) test for rifampicin resistance. Hence, 
the recommendation for Truenat MTB-RIF Dx is only applicable for those patients with positive Truenat 
MTB or MTB Plus results.
9 Based on PICO question 7.
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1.2 Test descriptions
Xpert MTB/RIF is an automated PCR test (molecular test) using the GeneXpert platform (Fig. 1.1). 
Xpert MTB/RIF is a single test that can detect both MTBC bacteria and rifampicin resistance within 
2 hours of starting the test, with minimal hands-on technical time (6).
Fig. 1.1. The GeneXpert four-module instrument and the Xpert MTB/RIF test cartridge
In Xpert MTB/RIF sample processing – in contrast to conventional nucleic acid amplification tests 
(NAATs) – PCR amplification and detection are integrated into a single self-enclosed test unit; that 
is, the Xpert MTB/RIF cartridge. Following sample loading, all steps in the assay are automated and 
contained within the cartridge. In addition, the assay’s sample reagent, used to liquefy sputum, 
is tuberculocidal (i.e. it has the ability to kill TB bacteria), which largely eliminates concerns about 
biosafety during the test procedure. These features allow the technology to be taken out of a central 
laboratory or reference laboratory, and to be used nearer to patients. However, Xpert MTB/RIF requires 
an uninterrupted and stable electrical power supply, temperature control and yearly calibration of 
the instrument’s modules (7).
Xpert Ultra uses the same GeneXpert platform as Xpert MTB/RIF; it was developed by Cepheid as 
the next-generation assay to overcome limitations in sensitivity for TB diagnosis. To improve assay 
sensitivity for the detection of MTBC, the Xpert Ultra assay incorporates two different multicopy 
amplification targets (IS6110 and IS1081) and has a larger DNA reaction chamber than Xpert MTB/RIF 
(50 µL PCR in Xpert Ultra versus 25 µL in Xpert MTB/RIF, Fig. 1.2). Xpert Ultra also incorporates fully 
nested nucleic acid amplification, more rapid thermal cycling, and improved fluidics and enzymes. 
This has resulted in Xpert Ultra having a limit of detection of 16 bacterial colony forming units (cfu) 
per millilitre (compared with 114 cfu/mL for Xpert MTB/RIF). To improve the accuracy of rifampicin-
resistance detection, the Xpert Ultra test incorporates melting-temperature-based analysis rather 
than real-time PCR. Specifically, four probes identify rifampicin-resistance mutations in the rifampicin-
resistance determining region of the rpoB gene by detecting shifts in the melting temperature away 
from the wild-type reference value (8).
Source: Courtesy of Cepheid.
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Fig. 1.2. (a) The Xpert MTB/RIF Ultra cartridge with its 50 µL reaction tube (green) and 
(b) the Xpert MTB/RIF cartridge with its 25 µL reaction tube (green)
a  b
The new molecular assays – the Truenat MTB, MTB Plus and MTB-RIF Dx assays – developed in India, 
may potentially be used at the same health system level as Xpert MTB/RIF. This policy focuses on the 
following Molbio devices and diagnostic tests:10
• Trueprep Auto DNA extraction system;
• Truelab DuoDx and Truelab QuattroDx micro-PCR machines;
• Truelab MTB chip;
• Truelab MTB Plus chip; and
• Truelab MTB-RIF Dx chip.
The Truenat MTB and MTB Plus assays and the rifampicin-resistance detection reflex assay (Truenat 
MTB-RIF Dx) (Molbio Diagnostics, India) use real-time micro-PCR for detection of M. tuberculosis 
and selected rifampicin resistance in DNA extracted from a patient’s sputum specimen (Fig. 1.3). The 
assays use automated, battery-operated devices to extract, amplify and confirm the presence of 
specific genomic DNA loci, allowing for the rapid diagnosis of TB infections with minimal user input. 
These products are intended to be operated in peripheral laboratories with minimal infrastructure, 
and technicians with only minimal training can easily perform these tests routinely in their facilities 
and report results in under 1 hour. Moreover, with these devices, PCR testing can also be initiated at 
the field level, on-site.
If the Truenat MTB assay result is positive, the user may then take another aliquot of extracted DNA 
and run the MTB-RIF Dx assay, to detect the presence of selected rifampicin-resistance-associated 
mutations. The diagnostic performance of these assays has been evaluated in multicentre prospective 
clinical evaluation study implemented by FIND, a WHO collaborating centre for the evaluation of new 
diagnostic technologies, in settings of intended use in four countries (India, Peru, Ethiopia, Papua 
New Guinea).
10 See http://www.molbiodiagnostics.com/products-listing.php. 
Source: Courtesy of Cepheid.
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Fig. 1.3. Molbio equipment to run the Truenat MTB, MTB Plus and MTB-RIF Dx assays: 
(a) Trueprep instrument for sample preparation, (b) Truelab Uno Dx real-time PCR 
instrument for running the tests, and (c) chip for real-time PCR 
PCR: polymerase chain reaction.   
Source: Courtesy of Molbio Diagnostics
1.3 Justification and evidence
The WHO Global TB Programme has initiated an update of the current guidelines and commissioned a 
systematic review on the use of Xpert MTB/RIF and Xpert Ultra for the diagnosis of TB in people with signs 
and symptoms of TB. The evidence on the use of the Truenat MTB, MTB Plus and MTB-RIF Dx system 
was generated by multisite international evaluations in settings of intended use, implemented by FIND.
The population, intervention, comparator and outcome (PICO) questions were designed to form the 
basis for the evidence search, retrieval and analysis.
PICO 1: Among adults with signs and symptoms of pulmonary TB, seeking care at 
health care facilities, should Xpert MTB/RIF / Xpert Ultra be used as an initial 
test for diagnosis of pulmonary and rifampicin resistance?
1.1. What is the impact of Xpert MTB/RIF on patient-important outcomes (cure, mortality, 
time to diagnosis and time to start treatment)?
1.2 What is the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB and rifampicin 
resistance, as compared with microbiological reference standard (MRS)?11
1.3 What is the diagnostic accuracy of Xpert Ultra for pulmonary TB and rifampicin resistance, 
as compared with MRS?
PICO 2: Among children with signs and symptoms of pulmonary TB, seeking care 
at health care facilities, should Xpert MTB/RIF / Xpert Ultra be used as an 
initial test for diagnosis of pulmonary TB and rifampicin resistance?
2.1 What is the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB and rifampicin 
resistance in children, as compared with MRS and composite reference standard (CRS)?12
2.2 What is the diagnostic accuracy of Xpert Ultra for pulmonary TB and rifampicin resistance 
in children, as compared with MRS and CRS?
Box 1.1. PICO questions and subquestions
11  Culture.
12  Positive culture or a clinical decision to initiate treatment for TB.
invisino
tes
a c b
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PICO 3: Among adults with signs and symptoms of extrapulmonary TB, seeking 
care at health care facilities, should Xpert MTB/RIF / Xpert Ultra be used as 
an initial test for diagnosis of extrapulmonary TB and rifampicin resistance?
3.1 What is the diagnostic accuracy of Xpert MTB/RIF for extrapulmonary TB and rifampicin 
resistance in adults, as compared with MRS and CRS?
3.2 What is the diagnostic accuracy of Xpert Ultra for extrapulmonary TB and rifampicin 
resistance in adults, as compared with MRS and CRS?
PICO 4: Among children with signs and symptoms of extrapulmonary TB and 
rifampicin resistance, seeking care at health care facilities, should Xpert 
MTB/RIF / Xpert Ultra be used as an initial test for diagnosis of extrapulmonary 
TB and rifampicin resistance?
4.1 What is the diagnostic accuracy of Xpert MTB/RIF for extrapulmonary TB and rifampicin 
resistance in children, as compared with MRS and CRS?
4.2 What is the diagnostic accuracy of Xpert Ultra for extrapulmonary TB and rifampicin 
resistance in children, as compared with MRS and CRS?
PICO 5: Among people with signs and symptoms of pulmonary TB, seeking care at 
health care facilities, do repeated Xpert (Ultra) tests on subsequent samples 
as an initial test for diagnosis of pulmonary TB and rifampicin resistance 
increase sensitivity/specificity compared with a single initial test?
5.1 Xpert Ultra repeated test for the diagnosis of pulmonary TB in adults with signs and 
symptoms of pulmonary TB who have an initial Xpert Ultra trace result, as compared 
with MRS?
5.2 More than one Xpert MTB/RIF versus one Xpert MTB/RIF to diagnose pulmonary TB in 
children with signs and symptoms of pulmonary TB, as compared with MRS? 
5.3 More than one Xpert Ultra versus one Xpert Ultra to diagnose pulmonary TB in children 
with signs and symptoms of pulmonary TB, as compared with MRS? 
PICO 6: Among adults either with signs and symptoms of TB or chest radiograph 
with lung abnormalities suggestive of pulmonary TB or both, should Xpert 
MTB/RIF or Xpert Ultra alone be used to define a case of active TB disease 
(10)?
6.1 Xpert MTB/RIF to diagnose pulmonary TB in adults in the general population with signs 
and symptoms of pulmonary TB or chest radiograph with lung abnormalities or both, as 
compared with MRS.
6.2 Xpert Ultra to diagnose pulmonary TB in adults in the general population with signs 
and symptoms of pulmonary TB or chest radiograph with lung abnormalities or both, as 
compared with MRS.
6.3 Two Xpert Ultra versus one Xpert Ultra to diagnose pulmonary TB in adults in the general 
population with signs and symptoms of TB or chest radiograph with lung abnormalities or 
both, as compared with MRS.
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PICO 7: Among people with signs and symptoms of pulmonary TB, seeking 
care at health care facilities, should Molbio Truenat MTB, MTB Plus and 
MTB-RIF Dx be used as an initial test for diagnosis of pulmonary TB and 
rifampicin resistance?
7.1 What is the diagnostic accuracy of Truenat MTB to diagnose pulmonary TB in adults 
with signs and symptoms of pulmonary TB, as compared with MRS?
7.2 What is the diagnostic accuracy of Truenat MTB Plus to diagnose pulmonary TB in adults 
with signs and symptoms of pulmonary TB, as compared with MRS?
7.3 What is the diagnostic accuracy of Truenat MTB-RIF Dx to diagnose rifampicin resistance 
in adults with signs and symptoms of pulmonary TB, as compared with MRS?
Additional questions
1. What are the comparative cost, affordability and cost–effectiveness of implementation of 
Xpert MTB/RIF, Xpert Ultra, and Truenat MTB, MTB Plus and MTB-RIF Dx systems?
2. Are there implications for feasibility, accessibility, patient equity and human rights from 
the implementation of Xpert MTB/RIF, Xpert Ultra, and Truenat MTB, MTB Plus and MTB-RIF 
Dx systems? 
The systematic reviews were conducted to summarize the current literature on the diagnostic accuracy 
of Xpert MTB/RIF and Xpert Ultra for the diagnosis of TB and rifampicin resistance. This was done 
as part of the WHO process to develop updated guidelines for use of molecular assays intended as 
initial tests for the diagnosis of pulmonary and extrapulmonary TB in adults and children. The data 
on children, where possible, were reported separately from adults. 
The evaluation study of Truenat was carried out in 19 clinical sites (each with a microscopy centre 
attached) and seven reference laboratories in four countries. The diagnostic accuracy of the assays 
was evaluated when performed in the intended settings of use (i.e. microscopy centres), against 
microbiological confirmation (culture) as the reference standard. As part of this assessment, the 
performance of the Truenat assays was also compared to Xpert MTB/RIF or Xpert Ultra, on the same 
specimens, in reference laboratories.
The certainty of the evidence was assessed consistently through PICO questions, using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach,13 which produces 
an overall quality assessment (or certainty) of evidence and a framework for translating evidence 
into recommendations. The certainty of the evidence is rated as high, moderate, low or very low. 
These four categories “imply a gradient of confidence in the estimates” (11). In the GRADE approach, 
even if diagnostic accuracy studies are of observational design, they start as high-quality evidence.1
At least two review authors independently completed the quality assessment of diagnostic accuracy 
studies (QUADAS)-2 assessments. Any disagreements were resolved through discussion or consultation 
with a third review author. 
Finally, where applicable, meta-analyses were performed to estimate pooled sensitivity and 
specificity separately for Xpert MTB/RIF and Xpert Ultra, and separately for TB (either pulmonary or 
extrapulmonary) and rifampicin resistance.
Data synthesis was structured around the pre-set PICO questions list below. Details of studies included 
in the current analysis are given in Web Annex 1.1 “Molecular assays as initial tests”. Summary of 
13 See see https://www.gradeworkinggroup.org/. 
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the results and details of the evidence quality assessment are available in Web Annex 2.1 “GRADE 
profiles molecular assays”. 
PICO 1: Among adults with signs and symptoms of pulmonary TB, seeking care 
at health care facilities, should Xpert MTB/RIF / Xpert Ultra be used as an 
initial test for diagnosis of pulmonary TB and rifampicin resistance?
1.1. What is the impact of Xpert MTB/RIF on patient-important outcomes (cure, 
mortality, time to diagnosis and time to start treatment)?
The aim of the review was to assess the impact on patient-important outcomes of diagnostic strategies 
using Xpert MTB/RIF compared with strategies using smear microscopy. The following outcomes were 
considered: all-cause mortality, pretreatment loss to follow-up, cure, time to diagnosis and 
time to treatment initiation.
For the impact of Xpert MTB/RIF on patient-important outcomes for TB, seven studies were included 
(16 421 participants): two individually randomized trials (Mupfumi 2014; Theron 2014), four cluster 
randomized trials (Churchyard 2015; Cox 2014; Ngwira LG 2017; Durovni 2014), and one individual 
patient data (IPD) meta-analysis (Di Tanna 2019) (see Web Annex 1 for details of these and other 
studies). All studies were conducted in high TB burden and high TB/HIV burden countries. There 
were two trials in South Africa (Churchyard 2015; Cox 2014), one in Zimbabwe (Mupfumi 2014), one 
in Malawi (Ngwira LG 2017), one in Brazil (Durovni 2014) and two multi-country studies with sites 
in South Africa, United Republic of Tanzania, Zambia and Zimbabwe (Theron 2014, Di Tanna 2019). 
All studies were conducted in outpatient settings and enrolled participants aged 18 years or older. 
Web Annex 4.1: Impact of diagnostic test Xpert MTB/RIF on patient-important outcomes for 
tuberculosis: a systematic review. 
1.2. What is the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB and 
rifampicin resistance, as compared with MRS?
The aim of the review was to assess the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB and 
rifampicin resistance in adults. Randomized trials, cross-sectional studies and cohort studies were 
included, using respiratory specimens that evaluated Xpert MTB/RIF alone or together with Xpert 
Ultra against the reference standards of culture for TB detection and culture-based DST or MTBDRplus 
for rifampicin resistance. Only studies that enrolled adults (aged >15 years) were eligible. For the 
evaluation of TB detection, studies were included that evaluated the index tests in people with signs 
and symptoms of pulmonary TB, except for studies in PLHIV, where studies were eligible for inclusion 
irrespective of signs and symptoms of pulmonary TB (e.g. studies that performed TB screening in 
PLHIV as part of intensified case finding or before TB preventive therapy).
For detection of pulmonary TB, a total of 94 studies were identified. Of these, 85 studies (40 652 
participants) evaluated Xpert MTB/RIF and nine studies (3881 participants) evaluated both Xpert 
Ultra and Xpert MTB/RIF. Of the 94 studies, 50 (53%) took place in high TB burden and 54 (57%) in 
high TB/HIV burden countries. Most studies had low risk of bias. Also, most studies had low concern 
about applicability because participants in these studies were evaluated in primary care facilities, local 
hospitals or both settings.
For detection of rifampicin resistance, 57 studies (8287 participants) evaluated Xpert MTB/RIF. Of the 
57 studies, 27 took place in high multidrug-resistant TB (MDR-TB) burden countries. Most studies 
were judged as having low risk of bias.
Web Annex 4.2: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs 
and symptoms of pulmonary TB: an updated systematic review.
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1.3. What is the diagnostic accuracy of Xpert Ultra for pulmonary TB and rifampicin 
resistance, as compared with MRS?
For detection of pulmonary TB, a total of nine studies (3881 participants) evaluated both Xpert Ultra 
and Xpert MTB/RIF. For Xpert Ultra, a composite reference standard was also used that included clinical 
components as defined by the primary study authors. For detection of rifampicin resistance, eight 
studies (1039 participants) evaluated Xpert Ultra. The total number of Xpert Ultra studies includes 
one study that provided data for two cohorts; therefore, we classified these as two distinct studies, 
Mishra 2019a and Mishra 2019b. Most studies were judged as having high certainty of evidence.
Web Annex 4.2: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs 
and symptoms of pulmonary TB: an updated systematic review.
PICO 2: Among children with signs and symptoms of pulmonary TB, seeking care 
at health care facilities, should Xpert MTB/RIF / Xpert Ultra be used as an 
initial test for diagnosis of pulmonary TB and rifampicin resistance?
2.1. What is the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB and 
rifampicin resistance in children, as compared with MRS and CRS?
The initial search resulted in 835 individual records, with one additional reference identified through 
other sources, giving a total of 836 records, from which 707 were excluded. Initially, the remaining 
129 articles were retrieved. After full-text review, 50 studies were included in the quantitative meta-
analysis; of these, 40 (80%) took place in high TB burden countries and 10 in high TB/HIV burden 
countries. For pulmonary TB detection, 43 studies were included that evaluated the diagnostic accuracy 
of Xpert MTB/RIF in children, and three that evaluated both Xpert Ultra and Xpert MTB/RIF. Forty-
two studies evaluated pulmonary TB using a reference standard of culture, and one study evaluated 
pulmonary TB using smear microscopy only. 
In terms of methodological quality, in the patient selection domain, most studies (83%) evaluating 
pulmonary TB were judged to have low risk of bias. In the index test domain, all studies were judged to 
have low risk of bias. In the flow and timing domain, most studies (88%) were judged to have low risk 
of bias. In the reference standard domain, with respect to the MRS, 47% of studies were judged to have 
unclear risk of bias because only one culture was used to exclude TB. With respect to the composite 
reference standard, all studies were judged to have unclear risk of bias because of imperfect accuracy 
of the composite reference standard and differing definitions of this standard used by the primary 
study authors. Regarding applicability, in the patient selection domain, 50% of studies were judged 
as having high or unclear risk of bias, because participants were evaluated exclusively as inpatients at 
tertiary care centres, or the clinical setting was unclear. With respect to applicability of the index test, 
most studies (72%) were judged as having low concern owing to standardized application of the index 
tests. Eleven studies evaluating stool as a specimen for Xpert MTB/RIF or Xpert Ultra were judged 
to have unclear risk of bias because of the absence of a standardized protocol for stool preparation. 
Applicability of the reference standard was considered as a low concern for most studies (93%).
To generate evidence about the detection of rifampicin resistance, six studies were included. All of the 
six studies (223 participants) evaluated only Xpert MTB/RIF and were conducted in high TB burden 
countries and in high MDR-TB burden countries. Among the studies, 50% had a low risk of bias 
with respect to patient selection, while all studies had a low risk of bias with respect to the reference 
standard. Risk of bias was considered low for the reference standard if an automated process was 
used or it was clear that the reference standard results were interpreted without knowledge of the 
index tests. For all six studies, there were applicability concerns regarding patient selection because 
of enrolment exclusively from inpatient or tertiary centres. 
For the meta-analysis, a total of 23 studies (6612 participants) evaluated sputum specimens; 
14 studies (3468 participants) evaluated gastric specimens; four studies (1125 participants) evaluated 
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nasopharyngeal specimens; and 11 studies (1592 participants) evaluated stool specimens – all of 
these studies evaluated Xpert MTB/RIF alone. Three studies (753 participants) evaluated both Xpert 
MTB/RIF and Xpert Ultra on frozen sputum specimens. One study (195 participants) evaluated both 
Xpert MTB/RIF and Xpert Ultra on nasopharyngeal specimens. 
2.2. What is the diagnostic accuracy of Xpert Ultra for pulmonary TB and rifampicin 
resistance in children, as compared with MRS and CRS?
No studies evaluated Xpert Ultra alone. Three studies (753 participants) evaluated both Xpert MTB/RIF 
and Xpert Ultra on frozen sputum specimens. One study (195 participants) evaluated both Xpert 
MTB/RIF and Xpert Ultra on nasopharyngeal specimens. 
Web Annex 4.4: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in children: an 
updated systematic review.
PICO 3: Among adults with signs and symptoms of extrapulmonary TB, seeking 
care at health care facilities, should Xpert MTB/RIF / Xpert Ultra be used as 
an initial test for diagnosis of extrapulmonary TB and rifampicin resistance?
3.1. What is the diagnostic accuracy of Xpert MTB/RIF for extrapulmonary TB and 
rifampicin resistance in adults, as compared with MRS and CRS?
There are difficulties in obtaining extrapulmonary specimens both from children and adults, and 
technical limitations of conventional bacteriological methods to aid diagnosis. Thus, various non-
pulmonary specimens and composite reference standards are often used in evaluating the performance 
of new diagnostic technologies in extrapulmonary TB. 
For detection of extrapulmonary TB, 65 studies were included. A total of 63 studies (13 144 participants) 
evaluated Xpert MTB/RIF, including five that evaluated both Xpert MTB/RIF and Xpert Ultra. The 
included studies evaluated Xpert MTB/RIF in cerebrospinal fluid (CSF) specimens comprising lymph 
node aspirate, lymph node biopsy, pleural fluid, urine, synovial fluid, peritoneal fluid, pericardial fluid 
and blood.
Of the total of 65 studies, 39 (60%) took place in high TB burden and 41 (63%) in high TB/HIV burden 
countries. Risk of bias was judged to be low in the domains of patient selection, index test, and flow and 
timing; and high or unclear in the reference standard domain because many studies decontaminated 
sterile specimens before culture inoculation. Regarding applicability, in the patient selection domain, 
high or unclear concern was expressed for most studies because either the participants were evaluated 
exclusively as inpatients at tertiary care centres, or the clinical settings were unclear.
Annex 4.3: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs and 
symptoms of extrapulmonary TB: an updated systematic review.
3.2. What is the diagnostic accuracy of Xpert Ultra for extrapulmonary TB and 
rifampicin resistance in adults, as compared with MRS?
Six studies (507 participants) evaluated Xpert Ultra for the detection of extrapulmonary TB. The 
included studies evaluated the test in CSF specimens comprising lymph node biopsy, pleural fluid, 
urine and synovial fluid. Serious concerns were expressed regarding the indirectness of the evidence; 
these concerns related to applicability (i.e. evidence was generated in tertiary referral medical centres), 
and imprecision of the evidence, related mostly to low numbers of participants included in studies. 
Certainty of evidence was generally judged as being between low and very low.
Web Annex 4.3: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs 
and symptoms of extrapulmonary TB: an updated systematic review.
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PICO 4: Among children with signs and symptoms of extrapulmonary TB and 
rifampicin resistance, seeking care at health care facilities, should 
Xpert MTB/RIF / Xpert Ultra be used as an initial test for diagnosis of 
extrapulmonary TB and rifampicin resistance?
4.1. What is the diagnostic accuracy of Xpert MTB/RIF for extrapulmonary TB and 
rifampicin resistance in children, as compared with MRS and CRS?
4.2. What is the diagnostic accuracy of Xpert Ultra for extrapulmonary TB and 
rifampicin resistance in children, as compared with MRS and CRS?
To evaluate detection of extrapulmonary TB, studies that evaluated the diagnostic accuracy of Xpert 
MTB/RIF in children with signs or symptoms of lymph node TB or TB meningitis were included. 
For diagnosis of lymph node TB, six studies (210 participants) evaluated Xpert MTB/RIF against 
an MRS of smear or culture on lymph node specimens. Two studies (105 participants) evaluated 
Xpert MTB/RIF against a composite reference standard for lymph node TB. For TB meningitis, six 
studies (241 participants) evaluated Xpert MTB/RIF against culture on CSF. In addition, two studies 
(155 participants) assessed Xpert MTB/RIF against a composite reference standard that included a 
clinical diagnosis of TB meningitis. The certainty of evidence was judged to be very low for sensitivity, 
and low for specificity of detection of both TB meningitis and lymph node TB.
No studies evaluating the accuracy of Xpert Ultra for detecting lymph node TB or TB meningitis 
were identified.
Web Annex 4.4: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in children: an 
updated systematic review.
PICO 5: Among people with signs and symptoms of pulmonary TB, seeking care at 
health care facilities, do repeated Xpert (Ultra) tests on subsequent samples 
as an initial test for diagnosis of pulmonary TB and rifampicin resistance 
increase sensitivity/specificity compared with a single initial test?
5.1. Xpert Ultra repeated test for the diagnosis of pulmonary TB in adults with signs 
and symptoms of pulmonary TB who have an initial Xpert Ultra trace result, as 
compared with MRS?
For adults, with initial Xpert Ultra trace results, three studies were identified: Mishra 2019a (4 participants), 
Piersimoni 2019 (4 participants), and Dorman 2018 (42 participants) (see Web Annex 1 for details of 
included studies). Piersimoni 2019 retested the same initial sample, whereas Dorman 2018 retested 
a separately collected sputum sample. Mishra 2019a retested only those participants with discrepant 
results (i.e. Ultra trace positive/culture negative), and retested new specimens obtained a median of 
444 days (range 245–526 days) after initial testing. Owing to limited data, a meta-analysis was not 
performed. The evidence was downgraded one level for inconsistency and two levels for imprecision. 
Serious concerns were expressed for inconsistency, and very serious concerns for imprecision. Certainty 
of evidence was judged to be very low for both sensitivity and specificity. 
Web Annex 4.2: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs 
and symptoms of pulmonary TB: an updated systematic review.
5.2. More than one Xpert MTB/RIF versus one Xpert MTB/RIF to diagnose pulmonary 
TB in children with signs and symptoms of pulmonary TB, as compared with MRS? 
For children, five studies (2119 participants) were included that have evaluated the diagnostic accuracy 
of multiple Xpert MTB/RIF tests compared with a single test. Serious concerns were expressed for 
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indirectness, because patients were enrolled from inpatient tertiary care settings, which could lead 
to the enrolment of children with more advanced disease. Also, serious concerns were expressed for 
imprecision, related to the low number of children with pulmonary TB contributing to this analysis for 
the observed sensitivity. Overall, the certainty of evidence was judged to be very low for sensitivity 
and moderate for specificity.
Web Annex 4.4: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in children: an 
updated systematic review.
5.3. More than one Xpert Ultra versus one Xpert Ultra to diagnose pulmonary TB in 
children with signs and symptoms of pulmonary TB, as compared with MRS? 
For children, one study (163 participants) was included that evaluated the diagnostic accuracy of 
multiple Xpert Ultra tests in sputum compared with a single test. The certainty of evidence was 
judged to be very low for sensitivity and low for specificity owing to serious concerns for indirectness 
and imprecision. In addition, one study (130 participants) was included that evaluated the diagnostic 
accuracy of multiple Xpert Ultra tests in nasopharyngeal aspirates compared with a single test. Overall, 
the certainty of evidence was judged to be very low both for sensitivity and specificity, owing to very 
serious concerns for indirectness and imprecision. 
Web Annex 4.4: Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in children: an 
updated systematic review.
PICO 6: Among adults either with signs and symptoms of TB or chest radiograph 
with lung abnormalities suggestive of pulmonary TB or both, should Xpert 
MTB/RIF or Xpert Ultra alone be used to define a case of active TB disease 
(10)?
The aim of the review was to assess the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for 
pulmonary TB in adults (aged ≥15 years) among the general population. Data from four nationally 
representative and two subnational prevalence surveys for active TB disease, cross-sectional in design, 
were included. These surveys used sputum samples that evaluated Xpert MTB/RIF or Xpert Ultra 
against the reference standard of culture for TB. For the evaluation of TB detection, the surveys 
evaluated the index tests in adults (aged ≥15 years) with chest X-ray abnormalities or symptoms 
suggestive of pulmonary TB (or both). For detection of pulmonary TB, a total of six surveys were 
identified. 
6.1. Xpert MTB/RIF to diagnose pulmonary TB in adults in the general population 
with signs and symptoms of pulmonary TB or chest radiograph with lung 
abnormalities or both, as compared with MRS?
The analysis reported on the results of four surveys, including 49 556 participants. Assessment of the 
quality of the evidence revealed serious deficiencies in the evidence quality. 
Indirectness: the populations in these prevalence surveys differed from the general population with 
respect to prior testing (e.g. symptom screen was limited to cough for 14 days or more) and the 
availability of results of both symptom screen and chest radiography in most participants included in 
the studies. The evidence was downgraded one level for indirectness. 
Inconsistency: the sensitivity estimate for Bangladesh was 84%, which was higher than the sensitivity 
estimates for the other three countries (range, 68–69%). Lower HIV prevalence in Bangladesh could 
only partly explain the inconsistency. The evidence was downgraded one level for inconsistency. 
Overall, the certainty of evidence was judged to be low for sensitivity and moderate for specificity. 
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6.2. Xpert Ultra to diagnose pulmonary TB in adults in the general population with 
signs and symptoms of pulmonary TB or chest radiograph with lung abnormalities 
or both, as compared with MRS.
The analysis reported on the results of four surveys, including 11 488 participants. The included 
countries were Myanmar, South Africa (TREATS project) and Zambia (TREATS project). The average 
prevalence of TB in these countries was 2.8% (range 1.6–6.7%). 
Indirectness: the populations in these prevalence surveys differed from the general population with 
respect to prior testing (e.g. symptom screen was limited to cough for 14 days or more) and the 
availability of results of both symptom screen and chest radiography in most participants included in 
the studies. The evidence was downgraded one level for indirectness.
Imprecision: there were relatively few participants contributing to this analysis, and a wide 95% 
confidence interval (CI). The 95% CI around true positives and false negatives may lead to different 
decisions, depending on which limits are assumed. The evidence was downgraded one level for 
imprecision. Overall, the certainty of evidence was judged to be low for sensitivity and moderate 
for specificity.
6.3. Two Xpert Ultra versus one Xpert Ultra to diagnose pulmonary TB in adults in 
the general population with signs and symptoms of TB or chest radiograph with lung 
abnormalities or both, as compared with MRS.
The analysis reported on the results of three surveys, including 5080 participants. Serious concerns 
were expressed about the indirectness of the available evidence. This was because most of the data 
were from Myanmar, and the results may not be applicable to other settings. In addition, very serious 
concerns were expressed about imprecision because the analysis was based on data for only a small 
number of individuals. The 95% CIs for two Xpert Ultra assays and one Xpert Ultra assay were wide. 
Overall, the certainty of evidence was judged to be very low for sensitivity and moderate for specificity.
PICO 7: Among people with signs and symptoms of pulmonary TB, seeking care at 
health care facilities, should Molbio Truenat MTB, MTB Plus and MTB-RIF 
Dx be used as an initial test for diagnosis of pulmonary TB and rifampicin 
resistance?
7.1. What is the diagnostic accuracy of Truenat MTB to diagnose pulmonary TB in 
adults with signs and symptoms of pulmonary TB, as compared with MRS?
Evidence for the use of Truenat MTB, MTB Plus and MTB-RIF Dx assays to diagnose pulmonary TB 
and rifampicin resistance in adults was generated through a multicentre prospective clinical evaluation 
study implemented by FIND. The study was conducted at 19 clinical sites (each with a microscopy 
centre attached) and seven reference laboratories in four countries. The aim was to determine 
the diagnostic accuracy of the Truenat assays when performed in the intended settings of use (i.e. 
microscopy centres), relative to microbiological confirmation (culture) as the reference standard. The 
performance of the Truenat assays was also compared head-to-head (on the same specimens) to 
Xpert or Ultra in reference laboratories, as part of this assessment. All sites performed Xpert except 
for sites in Peru, which performed Ultra. The analysis for Truenat MTB reported on the results for 1336 
participants. Serious concerns were expressed for imprecision and inconsistency of evidence related to 
sensitivity. Overall, the certainty of evidence was judged to be low for sensitivity but high for specificity.
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7.2. What is the diagnostic accuracy of Truenat MTB Plus to diagnose pulmonary TB 
in adults with signs and symptoms of pulmonary TB, as compared with MRS?
The analysis for Truenat MTB Plus reported on the results for 1336 participants. Serious concerns were 
expressed for imprecision for sensitivity, related to the few participants contributing to the analysis. 
Overall, the certainty of evidence was judged to be low for sensitivity and high for specificity. 
7.3. What is the diagnostic accuracy of Truenat MTB-RIF Dx to diagnose rifampicin 
resistance in adults with signs and symptoms of pulmonary TB, as compared 
with MRS?
The analysis for Truenat MTB-RIF Dx reported on the results for 186 participants. For sensitivity 
there were serious concerns about indirectness (India and Peru contributed most of the data to the 
determination of rifampicin resistance) and inconsistency (variable sensitivity estimates: 100% for 
Peru, based on seven rifampicin-resistant specimens; 100% for Ethiopia, based on one rifampicin-
resistant specimen; 100% for Papua New Guinea, based on one rifampicin-resistant specimen; and 
81% for India, based on 42 rifampicin-resistant specimens). These results may not be applicable to 
other settings. In addition, very serious concerns were expressed for imprecision, owing to the small 
number of participants contributing to this analysis. Overall, the certainty of evidence was judged to 
be very low for sensitivity. Serious concerns were expressed for indirectness for specificity, related to 
the low numbers of rifampicin-resistant cases and the fact that most of them were from India and Peru. 
Web Annex 4.5: Report on the diagnostic accuracy of the Molbio Truenat tuberculosis and rifampicin-
resistance assays in the intended setting of use.
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1.4 Performance of the molecular assays
Table 1.1. PICO 1.1: What is the impact of Xpert MTB/RIF on patient-important outcomes (e.g. cure, mortality, time to 
diagnosis and time to start treatment)?
Patient-important outcome Studies/design Certainty of evidence
Patients with outcome of 
interest/all patients Effect
Xpert MTB/RIF Smear 
microscopy
Relative  Absolute
Mortality 5/RT Moderate 248/5265 (4.7%) 292/5144 (5.7%) RR 0.88 7 fewer per 1000
Cure 2/RT High 1786/2500 (71.4%) 1443/2080 (69.4%) OR 1.09 18 more per 1000
Pretreatment loss to follow-up 3/RT Moderate 81/642 (12.6%) 95/523 (18.2%) RR 0.59 74 fewer per 1000
Time to diagnosis 2/RT High 956 968 (10%) HR 1.05 5 more per 1000
Treatment 4/RT Moderate 4055 4153 (10%) HR 1.00 0 fewer per 1000
Mortality in people with HIV 2/RT Moderate 66/1211 (5.5%) 75/1055 (7.1%) RR 0.76 17 fewer per 1000
HIV: human immunodeficiency virus; HR: hazard ratio; OR: odds ratio; PICO: population, intervention, comparator and outcomes; RR: relative risk; RT: randomized trial.
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Table 1.2. PICO 1.2: What is the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB in adults, as compared with MRS?
Patient population Test accuracy Studies (participants)
Certainty of 
evidence 2.5% prevalence 10% prevalence 30% prevalence
Adults PTB, MRS Se: 0.85 70 (10 409) High TP: 21 / FN: 4 TP: 85 / FN: 15 TP: 255 / FN: 45
Sp: 0.98 70 (26 828) High TN: 965 / FP: 10 TN: 891 / FP: 9 TN: 693 / FP: 7
Adults PTB, SS–, 
MRS 
Se: 0.67 45 (2315) High TP: 17 / FN: 8 TP: 67 / FN: 33 TP: 201 / FN: 99
Sp: 0.98 45 (16 647) High TN: 956 / FP: 19 TN: 882 / FP: 18 TN: 686 / FP: 14
Adults PTB, HIV+, 
MRS 
Se: 0.81 14 (1159) High TP: 20 / FN: 5 TP: 81 / FN: 19 TP: 243 / FN: 57
Sp: 0.98 14 (3505) High TN: 956 / FP: 19 TN: 882 / FP: 18 TN: 686 / FP: 14
Adults PTB, previous 
TB, MRS
Se: 0.86 14 (2197) Low TP: 22 / FN: 3 TP: 86 / FN: 14 TP: 258 / FN: 42
Sp: 0.95 14 (2998) Moderate TN: 924 / FP: 51 TN: 853 / FP: 47 TN: 664 / FP: 36
FN: false negative; FP: false positive; HIV+: human immunodeficiency virus positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; 
Se: sensitivity; Sp: specificity; SS–: sputum smear negative; TB: tuberculosis; TN: true negative; TP: true positive.
Table 1.3. PICO 1.2: What is the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in adults with pulmonary TB, 
as compared with MRS?
Patient population Test accuracy Studies (participants)
Certainty of 
evidence 2% prevalence 10% prevalence 15% prevalence
Adults PTB, RR-TB Se: 0.96 48 (1775) High TP: 19 / FN: 1 TP: 96 / FN: 4 TP: 144 / FN: 6
Sp: 0.98 48 (6245) High TN: 960 / FP: 20 TN: 882 / FP: 18 TN: 833 / FP: 17
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; RR-TB: rifampicin-resistant tuberculosis; Se: 
sensitivity; Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
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Table 1.4. PICO 1.3: What is the diagnostic accuracy of Xpert Ultra for pulmonary TB, as compared with MRS?
Patient population Test accuracy Studies (participants)
Certainty of 
evidence 2.5% prevalence 10% prevalence 30% prevalence
Adults PTB, MRS Se: 0.90 6 (960) High TP: 22 / FN: 3 TP: 90 / FN: 10 TP: 269 / FN: 31
Sp: 0.96 6 (1694) High TN: 932 / FP: 43 TN: 860 / FP: 40 TN: 669 / FP: 31
Adults PTB, SS–, 
MRS 
Se: 0.77 6 (378) High TP: 19 / FN: 6 TP: 77 / FN: 23 TP: 231 / FN: 69
Sp: 0.96 6 (1671) High TN: 932 / FP: 43 TN: 860 / FP: 40 TN: 669 / FP: 31
Adults PTB, HIV+, 
MRS 
Se: 0.88 2 (149) Low TP: 22 / FN: 3 TP: 88 / FN: 12 TP: 265 / FN: 35
Sp: 0.95 2 (430) High TN: 923 / FP: 52 TN: 852 / FP: 48 TN: 663 / FP: 37
Adults PTB, prior 
TB, MRS 
Se: 0.84 4 (127) Low TP: 21 / FN: 4 TP: 84 / FN: 16 TP: 251 / FN: 49
Sp: 0.86 4 (475) Low TN: 842 / FP: 133 TN: 778 / FP: 122 TN: 605 / FP: 95
FN: false negative; FP: false positive; HIV+: human immunodeficiency virus positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; 
Se: sensitivity; Sp: specificity; SS–: sputum smear negative; TB: tuberculosis; TN: true negative; TP: true positive.
Table 1.5. PICO 1.3: What is the diagnostic accuracy of Xpert Ultra for rifampicin resistance in adults with pulmonary TB, as 
compared with MRS?
Patient population Test accuracy Studies (persons)
Certainty of 
evidence 2% prevalence 10% prevalence 15% prevalence
Adults PTB, RR-TB Se: 0.94 5 (240) High TP: 19 / FN: 1 TP: 94 / FN: 6 TP: 141 / FN: 9
Sp: 0.99 5 (690) High TN: 970 / FP: 10 TN: 891 / FP: 9 TN: 842 / FP: 8
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; RR-TB: rifampicin-resistant tuberculosis; Se: 
sensitivity; Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
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Table 1.6. PICO 2.1: What is the diagnostic accuracy of Xpert MTB/RIF for pulmonary TB in children, as compared with MRS 
and CRS?
Patient population Test accuracy Studies (persons)
Certainty of 
evidence 1% prevalence 10% prevalence 20% prevalence
Children sputum, 
MRS 
Se: 0.65 23 (493) Moderate TP: 6 / FN: 4 TP: 65 / FN: 35 TP: 129 / FN: 71 
Sp: 0.99 23 (6119) Moderate TN: 980 / FP: 10 TN: 891 / FP: 9 TN: 792 / FP: 8 
Children sputum, 
CRS 
Se: 0.20 16 (1541) Low TP: 2 / FN:8 TP: 20 / FN: 80 TP: 40 / FN: 160 
Sp: 1.00 16 (2838) Moderate TN: 990 / FP: 0 TN: 900 / FP: 0 TN: 800 / FP: 0 
Children SS–, 
sputum, MRS 
Se: 0.59 12 (184) Low TP: 6 / FN: 4 TP: 59 / FN: 41 TP: 118 / FN: 82 
Sp: 0.99 12 (2934) Moderate TN: 980 / FP: 10 TN: 891 / FP: 9 TN: 792 / FP: 8 
Children HIV+, 
sputum, MRS 
Se: 0.72 10 (88) Low TP: 7 / FN: 3 TP: 72 / FN: 28 TP: 144 / FN: 56 
Sp: 0.99 10 (554) Moderate TN: 980 / FP: 10 TN: 891 / FP: 9 TN: 792 / FP: 8 
Children GA, MRS Se: 0.73 14 (272) Very Low TP: 7 / FN: 3 TP: 73 / FN:27 TP: 146 / FN: 54 
Sp: 0.98 14 (3311) Low TN: 971 / FP: 19 TN: 883 / FP: 17 TN: 785 / FP: 15 
Children GA, CRS Se: 0.32 6 (461) Very Low TP: 3 / FN: 7 TP: 32 / FN: 68 TP: 64 / FN: 136 
Sp: 0.99 6 (472) Moderate TN: 980 / FP: 10 TN: 891 / FP: 9 TN: 792 / FP: 8 
Children HIV+, GA, 
MRS 
Se: 0.73 3 (50) Low TP: 7 / FN: 3 TP: 73 / FN: 27 TP: 146 / FN: 54 
Sp: 0.99 3 (584) Moderate TN: 980 / FP: 10 TN: 891 / FP: 9 TN: 792 / FP: 8 
Children NFA, MRS Se: 0.46 4 (144) Moderate TP: 5 / FN: 5 TP: 46 / FN: 54 TP: 92 / FN: 108 
Sp: 1.00 4 (981) High TN: 990 / FP: 0 TN: 900 / FP: 0 TN: 800 / FP: 0 
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Patient population Test accuracy Studies (persons)
Certainty of 
evidence 1% prevalence 10% prevalence 20% prevalence
Children stool, MRS Se: 0.61 11 (174) Low TP: 6 / FN: 4 TP: 62 / FN: 38 TP: 123 / FN: 77 
Sp: 0.98 11 (1418) Moderate TN: 975 / FP: 15 TN: 887 / FP: 13 TN: 788 / FP: 12 
Children stool, CRS Se: 0.16 10 (879) Low TP: 2 / FN: 8 TP: 16 / FN: 84 TP: 32 / FN: 168 
Sp: 0.99 10 (860) Moderate TN: 980 / FP: 10 TN: 891 / FP: 9 TN: 792 / FP: 8 
Children HIV+, 
stool, MRS 
Se: 0.70 4 (53) Low TP: 7 / FN: 3 TP: 70 / FN: 30 TP: 140 / FN: 60 
Sp: 0.98 4 (473) High TN: 970 / FP: 20 TN: 882 / FP: 18 TN: 784 / FP: 16 
CRS: composite reference standard; FN: false negative; FP: false positive; GA: gastric aspirate; HIV+: human immunodeficiency virus positive; MRS: microbiological reference standard; NFA: nasopharyngeal aspirate; 
PICO: population, intervention, comparator and outcomes; Se: sensitivity; Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
Table 1.7. PICO 2.1: What is the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in children, as compared 
with MRS?
Patient population Test accuracy Studies (persons)
Certainty of 
evidence 2% prevalence 10% prevalence 15% prevalence
Children sputum, 
RR, MRS 
Se: 0.90 6 (20) Very low TP: 18 / FN: 2 TP: 90 / FN: 10 TP: 135 / FN: 15 
Sp: 0.98 6 (203) Moderate TN: 960 / FP: 20 TN: 882 / FP: 18 TN: 833 / FP: 17 
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; RR: rifampicin resistance; Se: sensitivity; Sp: specificity; TN: true negative; 
TP: true positive.
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Table 1.8. PICO 2.2: What is the diagnostic accuracy of Xpert Ultra for pulmonary TB in children, as compared with MRS and 
CRS?
Patient population Test accuracy
Studies 
(persons)
Certainty of 
evidence 1% prevalence 10% prevalence 20% prevalence
Children sputum, MRS Se: 0.73 3 (136) Low TP: 7 / FN: 3 TP: 73 / FN: 27 TP: 146 / FN: 54 
Sp: 0.97 3 (551) High TN: 960 / FP: 30 TN: 873 / FP: 27 TN: 776 / FP: 24 
Children sputum, CRS Se: 0.24 3 (498) Low TP: 2 / FN: 8 TP: 24 / FN: 76 TP: 48 / FN: 152 
Sp: 0.97 3 (255) Low TN: 965 / FP: 25 TN: 878 / FP: 22 TN: 780 / FP: 20 
Children NFA, MRS Se: 0.46 1 (35) Very low TP: 5 / FN: 5 TP: 46 / FN: 54 TP: 92 / FN: 108 
Sp: 0.98 1 (160) Low TN: 970 / FP: 20 TN: 882 / FP: 18 TN: 784 / FP: 16 
CRS: composite reference standard; FN: false negative; FP: false positive; MRS: microbiological reference standard; NFA: nasopharyngeal aspirate; PICO: population, intervention, comparator and outcomes; 
Se: sensitivity; Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
Table 1.9. PICO 3.1: What is the diagnostic accuracy of Xpert MTB/RIF for extrapulmonary TB in adults, as compared with 
MRS and CRS?
Patient population Test accuracy
Studies 
(persons)
Certainty of 
evidence 2.5% prevalence 10% prevalence 20% prevalence
Adults CSF, MRS Se: 0.70 28 (521) Moderate TP: 18 / FN: 7 TP: 70 / FN: 30 TP: 141 / FN: 59 
Sp: 0.97 28 (2582) High TN: 944 / FP: 31 TN: 871 / FP: 29 TN: 774 / FP: 26 
Adults CSF, CRS Se: 0.41 12 (774) Low TP: 10 / FN: 15 TP: 41 / FN:59 TP: 81 / FN: 119 
Sp: 0.99 12 (1123) Moderate TN: 970 / FP: 5 TN: 896 / FP: 4 TN: 796 / FP: 4 
Adults LNA, MRS Se: 0.89 14 (627) Moderate TP: 22 / FN: 3 TP: 89 / FN:11 TP: 177 / FN: 23 
Sp: 0.86 14 (961) Very low TN: 839 / FP: 136 TN: 774 / FP:126 TN: 688 / FP:112 
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Patient population Test accuracy
Studies 
(persons)
Certainty of 
evidence 2.5% prevalence 10% prevalence 20% prevalence
Adults LNA, CRS Se: 0.81 4 (377) Low TP: 20 / FN: 5 TP: 81 / FN: 19 TP: 162 / FN: 38
Sp: 0.96 4 (302) Low TN: 935 / FP: 40 TN: 863 / FP: 37 TN: 767 / FP:33 
Adults LNB, MRS Se: 0.82 11 (220) Low TP: 21 / FN: 4 TP: 82 / FN: 18 TP: 164 / FN: 36 
Sp: 0.79 11 (566) Very low TN: 773 / FP: 202 TN: 714 / FP:186 TN: 634 / FP:166 
Adults, pleural fluid, MRS Se: 0.50 24 (589) Very low TP: 12 / FN: 13 TP: 50 / FN: 50 TP: 99 / FN: 101 
Sp: 0.99 24 (2337) High TN: 962 / FP: 13 TN: 888 / FP: 12 TN: 790 / FP: 10 
Adults, pleural fluid, CRS Se: 0.19 10 (616) Moderate TP: 5 / FN: 20 TP: 19 / FN: 81 TP: 39 / FN: 161 
Sp: 0.99 10 (408) High TN: 964 / FP: 11 TN: 890 / FP: 10 TN: 791 / FP: 9 
Adults, peritoneal fluid, 
MRS 
Se: 0.59 13 (94) Low TP: 15 / FN: 10 TP: 59 / FN: 41 TP: 118 / FN: 82 
Sp: 0.97 13 (486) High TN: 949 / FP: 26 TN: 876 / FP: 24 TN: 778 / FP: 22 
Adults, pericardial fluid, 
MRS 
Se: 0.60 5 (57) Very low TP: 15 / FN: 10 TP: 60 / FN:40 TP: 121 / FN: 79 
Sp: 0.88 5 (124) Low TN: 856 / FP: 119 TN: 790 / FP:110 TN: 702 / FP: 98 
Adults, pericardial fluid, 
CRS 
Se: 0.66 2 (60) Very low TP: 16 / FN: 9 TP: 66 / FN: 34 TP: 132 / FN: 68
Sp: 0.96 2 (17) Very low TN: 936 / FP:39 TN: 864 / FP: 36 TN: 768 / FP: 32 
Adults, urine, MRS Se: 0.85 9 (72) Low TP: 21 / FN: 4 TP: 85 / FN: 15 TP: 169 / FN: 31 
Sp: 0.97 9 (871) Moderate TN: 949 / FP: 26 TN: 876 / FP: 24 TN: 778 / FP: 22 
Adults, synovial fluid, MRS Se: 0.97 6 (110) Moderate TP: 24 / FN: 1 TP: 97 / FN: 3 TP: 194 / FN: 6 
Sp: 0.94 6 (361) Very low TN: 914 / FP: 61 TN: 843 / FP: 57 TN: 750 / FP: 50 
Adults, synovial fluid, CRS Se: 0.88 2 (161) Low TP: 22 / FN: 3 TP: 88 / FN: 12 TP: 177 / FN: 23 
Sp: 0.98 2 (44) Very low TN: 955 / FP: 20 TN: 881 / FP: 19 TN: 783 / FP: 17 
Adults HIV+, blood, MRS Se: 0.56 1 (9) Very low TP: 14 / FN: 11 TP: 56 / FN: 44 TP: 112 / FN: 88 
Sp: 0.94 1 (65) Very low TN: 917 / FP: 58 TN: 846 / FP: 54 TN: 752 / FP: 48 
CRS: composite reference standard; CSF: cerebrospinal fluid; FN: false negative; FP: false positive; HIV+: human immunodeficiency virus positive; LNA: lymph node aspirate; LNB: lymph node biopsy; MRS: microbiological 
reference standard; PICO: population, intervention, comparator and outcomes; Se: sensitivity; Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
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Table 1.10. PICO 3.1: What is the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in adults with 
extrapulmonary TB, as compared with MRS?
Patient population Test accuracy
Studies 
(persons)
Certainty of 
evidence 2% prevalence 10% prevalence 15% prevalence
Adults, RR, MRS Se: 0.96 23 (165) High TP: 19 / FN: 1 TP: 96 / FN: 4 TP: 144 / FN: 6 
Sp: 0.99 23 (919) High TN: 969 / FP: 11 TN: 890 / FP: 10 TN: 841 / FP: 9 
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; RR: rifampicin resistance; Se: sensitivity; Sp: specificity; TB: tuberculosis; 
TN: true negative; TP: true positive.
Table 1.11. PICO 3.2: What is the diagnostic accuracy of Xpert Ultra for extrapulmonary TB in adults, as compared with MRS 
and CRS?
Patient population Test accuracy Studies (persons)
Certainty 
of 
evidence
2.5% prevalence 10% prevalence 20% prevalence
Adults CSF, MRS Se: 0.87 4 (40) Low TP: 22 / FN: 3 TP: 87 / FN: 13 TP: 174 / FN: 26 
Sp: 0.88 4 (143) Low TN: 855 / FP: 120 TN: 789 / FP:111 TN: 702 / FP: 98 
Adults LNA, MRS Se: 0.78 1 (9) Very low TP: 20 / FN: 5 TP: 78 / FN: 22 TP: 156 / FN: 44 
Sp: 0.78 1 (64) Very low TN: 761 / FP: 214 TN: 702 / FP:198 TN: 624 / FP: 176 
Adults LNA, CRS Se: 0.70 1 (30) Very low TP: 17 / FN: 8 TP: 70 / FN: 22 TP: 156 / FN: 44 
Sp: 1.00 1 (43) Low TN: 975 / FP: 0 TN: 702 / FP:198 TN: 624 / FP: 176 
Adults LNB, MRS Se: 0.90–1.00 2 (23) Very low TP: 23–25 / FN: 0–2 TP: 90–100 / FN: 0–10 TP: 180–200 / FN: 0–20 
Sp: 0.38–0.87 2 (108) Very low TN: 371–848 / 
FP: 127–604
TN: 342–783 / 
FP: 117–558
TN: 304–696 /  
FP: 104–496
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Patient population Test accuracy Studies (persons)
Certainty 
of 
evidence
2.5% prevalence 10% prevalence 20% prevalence
Adults LNB, CRS Se: 0.67 1 (22) Very low TP: 18 / FN: 7 TP: 73 / FN: 27 TP: 146 / FN: 54 
Sp: 0.96 1 (57) Very low TN: 936 / FP: 39 TN: 864 / FP:36 TN: 768 / FP: 32
Adults pleural 
fluid, MRS 
Se: 0.71 3 (101) Very low TP: 18 / FN: 7 TP: 71 / FN: 29 TP: 142 / FN: 58 
Sp: 0.71 3 (156) Very low TN: 694 / FP: 281 TN: 641 / FP:259 TN: 570 / FP: 230 
Adults pleural 
fluid, CRS 
Se: 0.38–0.61 2 (156) Very low TP: 10–15 / 
 FN: 10–15 
TP: 38–61 /  
FN: 39–62
TP: 76–122 / 
FN: 78–122
Sp: 0.96–0.99 2 (107) Moderate TN: 936–965 / 
FP: 10–39
TN: 864–891 /  
FP:9–36 
TN: 768–792 /  
FP: 8–32 
Adults synovial 
fluid, MRS 
Se: 0.96 1 (52) Very low TP: 24 / FN: 1 TP: 96 / FN: 4 TP: 192 / FN: 8 
Sp: 0.97 1 (34) Very low TN: 946 / FP: 29 TN: 873 / FP: 27 TN: 776 / FP: 24 
Adults synovial 
fluid, CRS 
Se: 0.96 1 (111) Low TP: 24 / FN: 1 TP: 96 / FN: 4 TP: 192 / FN: 8 
Sp: 0.97 1 (34) Very low TN: 946 / FP: 29 TN: 873 / FP: 27 TN: 776 / FP: 24 
Adults urine, MRS Se: 1.00 1 (12) Very low TP: 25 / FN: 0 TP: 100 / FN: 0 TP: 200 / FN: 0 
Sp: 1.00 1 (12) Very low TN: 975 / FP: 0 TN: 900 / FP: 0 TN: 800 / FP: 0 
CRS: composite reference standard; CSF: cerebrospinal fluid; FN: false negative; FP: false positive; LNA: lymph node aspirate; LNB: lymph node biopsy; MRS: microbiological reference standard; PICO: population, 
intervention, comparator and outcomes; Se: sensitivity; Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
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Table 1.12. PICO 3.2: What is the diagnostic accuracy of Xpert Ultra for rifampicin resistance in adults with extrapulmonary 
TB, as compared with MRS and CRS?
Patient population Test accuracy Studies (persons)
Certainty of 
evidence 2% prevalence 10% prevalence 15% prevalence
Adults, RR, MRS Se: 0.97 3 (19) Low TP: 19 / FN: 1 TP: 97 / FN: 3 TP: 145 / FN: 5 
Sp: 0.99 3 (84) Moderate TN: 968 / FP: 12 TN: 889 / FP: 11 TN: 840 / FP: 10 
CRS: composite reference standard; FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; RR: rifampicin resistance; Se: sensitivity; 
Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
Table 1.13. PICO 4.1: What is the diagnostic accuracy of Xpert MTB/RIF for extrapulmonary TB in children, as compared with 
MRS?
Patient population Test accuracy Studies (persons)
Certainty of 
evidence 1% prevalence 5% prevalence 10% prevalence
Children, CSF, MRS Se: 0.54 6 (28) Very low TP: 5 / FN: 5 TP: 27 / FN: 23 TP: 54 / FN: 46 
Sp: 0.94 6 (213) Low TN: 929 / FP: 61 TN: 891 / FP: 59 TN: 844 / FP: 56 
CSF: cerebrospinal fluid; FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; Se: sensitivity; Sp: specificity; TB: tuberculosis; 
TN: true negative; TP: true positive.
Table 1.14. PICO 5.1: Xpert Ultra repeated test for the diagnosis of pulmonary TB in adults with signs and symptoms of 
pulmonary TB who have an initial Ultra trace result, as compared with MRS?
Patient population Test accuracy
Studies 
(persons)
Certainty of 
evidence 2.5% prevalence 10% prevalence 30% prevalence
Repeated Ultra for 
PTB in adults with 
initial trace result, 
MRS 
Se: 
0.69–1.00
3 (15) Very low TP: 17–25 / FN: 0–8 TP: 69–100 / FN: 0–31 TP: 207–300 / FN: 0–93 
Sp: 
0.47–1.00
3 (25) Very low TN: 458–975 / 
FP: 0–571
TN: 423–900 / 
FP: 0–477
TN: 329–700 / 
FP: 0–371 
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; Se: sensitivity; Sp: specificity; TB: tuberculosis; 
TN: true negative; TP: true positive.
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Table 1.15. PICO 5.2: More than one Xpert MTB/RIF versus one Xpert MTB/RIF to diagnose pulmonary TB in children with 
signs and symptoms of pulmonary TB, as compared with MRS? 
Patient 
population
Studies 
(persons)
Test 
accuracy 
(1 
MTB/RIF)
Test 
accuracy 
(>1 
MTB/RIF)
Certainty 
in 
evidence
1% prevalence 10% prevalence 20% prevalence
1
MTB/RIF
>1
MTB/RIF
1
MTB/RIF
>1
MTB/RIF
1
MTB/RIF
>1
MTB/RIF
1 versus 1+ 
MTB/RIF for 
PTB in sputum 
children, MRS 
5 (180) Se: 0.46 Se: 0.59 Low TP: 5
FN: 5
TP: 6
FN: 4
TP: 46
FN: 54
TP: 59
FN: 41
TP: 92
FN: 108
TP: 118
FN: 82
5 (1939) Sp: 1.00 Sp: 0.99 High TN: 989 
FP: 1
TN: 980
FP: 10
TN: 899
FP: 1
TN: 891
FP: 9
TN: 799
FP: 1
TN: 792
FP: 8
1 versus 1+ 
MBT/RIF for 
PTB in GA in 
children, MRS 
1 (32) Se: 0.09 Se: 0.23 Very low TP: 1
FN: 9
TP: 2
FN: 8
TP: 9
FN: 91
TP: 23
FN: 77
TP: 19
FN: 181
TP: 46
FN: 154
1 (903) Sp: 0.99 Sp: 0.99 Low TN: 980
FP: 10
TN: 980
FP: 10
TN: 891
FP: 9
TN: 891
FP: 9
TN: 792
FP: 8
TN: 792
FP: 8
1 versus 1+ 
MBT/RIF for 
PTB in NPA in 
children, MRS 
2 (91) Se: 0.41 Se: 0.54 Very low TP: 4
FN: 6
TP: 5
FN: 5
TP: 41
FN: 59
TP: 54
FN: 46
TP: 82
FN: 118
TP: 108
FN: 92
2 (614) Sp: 0.99 Sp: 0.98 Moderate TN: 980
FP: 10
TN: 970
FP: 20
TN:891
FP: 9
TN: 882
FP: 18
TN:792
FP: 8
TN: 784
FP: 16
1 versus 1+ 
MTB/RIF for 
PTB in stool 
in children, 
MRS 
1 (17) Se: 0.25 Se: 0.35 Low TP: 3
FN: 7
TP: 3
FN: 7
TP: 25
FN: 75
TP: 35
FN: 65
TP: 50
FN: 150
TP: 70
FN: 130
1 (230) Sp: 0.99 Sp: 0.99 Low TN: 980
FP: 10
TN: 980
FP: 10
TN: 891
FP: 9
TN: 891
FP: 9
TN: 792
FP: 8
TN: 792
FP: 8
FN: false negative; FP: false positive; GA: gastric aspirate; MRS: microbiological reference standard; NPA: nasopharyngeal aspirate; PICO: population, intervention, comparator and outcomes; Se: sensitivity; Sp: specificity; 
TB: tuberculosis; TN: true negative; TP: true positive.
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Table 1.16. PICO 5.3: More than one Xpert Ultra versus one Xpert Ultra to diagnose pulmonary TB in children with signs and 
symptoms of pulmonary TB, as compared with MRS? 
1% prevalence 10% prevalence 20% prevalence
Patient 
population
Studies 
(persons)
Test 
accuracy 
(1 Ultra)
Test 
accuracy 
(>1 Ultra)
Certainty in 
evidence
1
Ultra
>1
Ultra
1
Ultra
>1
Ultra
1
Ultra
>1
Ultra
1 versus 1+ 
Ultra for PTB 
in children, 
MRS 
1 (28) Se: 0.64 Se: 0.75 Very low TP: 6
FN: 4
TP: 8
FN: 2
TP: 64
FN: 36
TP: 75
FN: 25
TP: 128
FN: 72
TP: 150
FN: 50
1 (135) Sp: 1.0 Sp: 0.98 Very low TN: 990
FP: 0
TN: 970
FP: 20
TN: 900
FP: 0
TN: 882
FP: 18
TN: 800
FP: 0
TN: 784
FP: 16
1 versus 1+ 
Ultra for PTB 
in NPA in 
children, MRS 
1 (24) Se: 0.38 Se: 0.54 Very low TP: 4
FN: 6
TP: 5
FN: 5
TP: 38
FN: 62
TP: 54
FN: 46
TP: 76
FN: 124
TP: 108
FN: 92
1 (106) Sp: 0.98 Sp: 0.96 Low TN: 970
FP: 20
TN: 950
FP: 40
TN: 882
FP: 18
TN: 864
FP: 36
TN: 784
FP: 16
TN: 768
FP: 32
FN: false negative; FP: false positive; MRS: microbiological reference standard; NPA: nasopharyngeal aspirate; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; Se: sensitivity; 
Sp: specificity; TB: tuberculosis; TN: true negative; TP: true positive.
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Table 1.17. PICO 6.1–6.2: Among adults in the general population with signs and symptoms of pulmonary TB or chest 
radiograph with lung abnormalities or both, should Xpert MTB/RIF or Xpert Ultra alone be used to define a case of active 
TB disease, as compared with MRS?
Patient population Test accuracy
Studies 
(persons)
Certainty in 
evidence 1% prevalence 3% prevalence 7% prevalence
Xpert MTB/RIF in adults for 
PTB, MRS 
Se: 0.73 4 (867) Low TP: 7 / FN: 3 TP: 22 / FN: 8 TP: 51 / FN: 19
Sp: 0.99 4 (48 689) Moderate TN: 980 / FP: 10 TN: 960 / FP: 10 TN: 921 / FP: 9 
Xpert Ultra in adults for PTB, 
MRS 
Se: 0.68 4 (345) Low TP: 7 / FN: 3 TP: 20 / FN: 10 TP: 48 / FN: 22 
Sp: 0.98 4 (12 025) Moderate TN: 970 / FP: 20 TN: 951 / FP: 19 TN: 911 / FP: 19 
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; Se: sensitivity; Sp: specificity; TB: tuberculosis; 
TN: true negative; TP: true positive.
Table 1.18. PICO 6.3: Two Xpert Ultra versus one Xpert Ultra to diagnose pulmonary TB in adults in the general population 
with signs and symptoms of TB or chest radiograph with lung abnormalities or both, as compared with MRS.
1% prevalence 3% prevalence 7% prevalence
Patient 
population
Studies 
(persons)
Test 
accuracy 
(>1 Ultra) 
Test 
accuracy 
(1 Ultra)
Certainty 
in 
evidence
>1
Ultra 
1
Ultra
>1
Ultra
1
Ultra
>1
Ultra
1
Ultra
1 versus 1+ 
Ultra for PTB 
in adults for 
PTB, MRS 
3 (187) Se: 0.75 Se: 0.64 Very Low TP: 8
FN: 2 
TP: 6
FN: 4
TP: 23
FN: 7
TP: 19
FN: 11
TP: 53
FN: 17
TP: 45
FN: 25
3 (4893) Sp: 0.97 Sp: 0.98 Moderate TN: 960
FP: 30
TN: 970
FP: 20
TN: 941
FP: 29
TN: 951
FP: 19
TN: 902
FP: 28
TN: 911
FP: 19
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; Se: sensitivity; Sp: specificity; TB: tuberculosis; 
TN: true negative; TP: true positive.
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Table 1.19. PICO 7.1: What is the diagnostic accuracy of Molbio Truenat MTB for pulmonary TB in adults, as compared with 
MRS?
Patient population Test accuracy Studies (persons)
Certainty in 
evidence 2.5% prevalence 10% prevalence 30% prevalence
Truenat MTB for PTB, 
MRS 
Se: 0.73 1 (258) Moderate TP: 18 / FN: 7 TP: 73 / FN: 27 TP: 220 / FN: 80
Sp: 0.98 1 (1078) High TN: 957 / FP: 18 TN: 884 / FP: 16 TN: 687 / FP: 13
Truenat MTB for PTB, in 
SS+, MRSa Se: 0.92 1 (174) Moderate TP: 23 / FN: 2 TP: 92 / FN: 8 TP: 276 / FN: 24
Truenat MTB for PTB in 
SS–, MRS 
Se: 0.39 1 (84) Low TP: 10 / FN: 15 TP: 39 / FN: 61 TP: 117 / FN: 183
Sp: 0.98 1 (1078) High TN: 955 / FP: 20 TN: 881 / FP: 19 TN: 685 / FP: 15
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; Se: sensitivity; Sp: specificity; SS–: sputum 
smear negative; SS+: sputum smear positive; TB: tuberculosis; TN: true negative; TP: true positive. 
a Meta-analysis for specificity was not possible because of variability of the data.
Table 1.20. PICO 7.2: What is the diagnostic accuracy of Molbio Truenat MTB Plus for pulmonary TB in adults, as compared 
with MRS?
Patient population Test accuracy Studies (persons)
Certainty in 
evidence 2.5% prevalence 10% prevalence 30% prevalence
Truenat MTB Plus for PTB, 
MRS 
Se: 0.80 1 (258) Moderate TP: 20 / FN: 5 TP: 80 / FN: 20 TP: 239 / FN: 61
Sp: 0.96 1 (1078) High TN: 940 / FP: 25 TN: 868 / FP: 32 TN: 675 / FP: 25
Truenat MTB Plus for PTB, 
in SS+ MRS Se: 0.96 1 (176) Moderate TP: 24 / FN: 1 TP: 96 / FN: 4 TP: 288 / FN: 12
Truenat MTB Plus for PTB 
in SS–, MRS
Se: 0.46 1 (84) Low TP: 12 / FN: 13 TP: 47 / FN: 53 TP: 142 / FN: 158
Sp: 0.97 1 (1078) High TN: 940 / FP: 35 TN: 868 / FP: 32 TN: 675 / FP: 25
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; PTB: pulmonary tuberculosis; Se: sensitivity; Sp: specificity; SS–: sputum 
smear negative; SS+: sputum smear positive; TB: tuberculosis; TN: true negative; TP: true positive.
Recom
m
endations
35
Table 1.21. PICO 7.3: What is the diagnostic accuracy of Molbio Truenat MTB-RIF Dx for rifampicin resistance in adults, as 
compared with MRS?
Patient population Test accuracy Studies (persons)
Certainty in 
evidence 2% prevalence 10% prevalence 15% prevalence
Truenat MTB-RIF Dx for 
RR 
Se: 0.84 1 (51) Very low TP: 17 / FN: 3 TP: 84 / FN: 16 TP: 126 / FN: 24
Sp: 0.97 1 (258) Moderate TN: 954 / FP: 26 TN: 876 / FP: 24 TN: 827 / FP: 23
FN: false negative; FP: false positive; MRS: microbiological reference standard; PICO: population, intervention, comparator and outcomes; RR: rifampicin resistance; Se: sensitivity; Sp: specificity; TN: true negative; 
TP: true positive.
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1.5 Cost–effectiveness analysis
This section deals with the following additional question:
What are the comparative cost, affordability and cost–effectiveness of 
implementation of Xpert MTB/RIF, Xpert Ultra, and Truenat MTB, MTB Plus and 
MTB-RIF Dx systems?
A systematic review was carried out, focusing on economic evaluations of molecular-based tests for 
the diagnosis of active TB. The tests included GeneXpert MTB/RIF (referred to as Xpert MTB/RIF), the 
novel Xpert Ultra and the novel Molbio Truenat MTB test. The objective of the review was to summarize 
current economic evidence and further understand the costs, cost–effectiveness and affordability of 
these molecular tests for TB diagnosis. Twenty-eight studies were identified that met the inclusion 
criteria and addressed one of the PICO questions of interest. Only one study assessing the cost–
effectiveness of Truenat was identified, but no studies assessing the cost–effectiveness of Xpert Ultra. 
Most of the studies assessed Xpert MTB/RIF in outpatient settings in countries in Africa; however, also 
included were studies among outpatients and hospitalized patients in other countries, such as Brazil, 
China, Germany, Hong Kong Special Administrative Region (SAR), India, South Africa and the USA.
Studies employed a variety of different modelling approaches, populations and settings. The 
included studies varied in their costing, effectiveness and epidemiological parameters, making direct 
comparisons across studies challenging. Furthermore, there were variations in what costing elements, 
implementation costs and downstream costs were included in the different studies. 
Although many studies demonstrated that Xpert MTB/RIF may be cost effective in diagnosing 
pulmonary TB, key implementation conditions and settings had a strong effect on cost–effectiveness 
and must be considered when implementing this test. The cost–effectiveness of Xpert MTB/RIF was 
shown to be improved among certain populations: those with higher TB prevalence, in PLHIV and 
those where rates of empirical treatment were low. Cost–effectiveness of Xpert MTB/RIF is strongly 
affected by factors such as location of GeneXpert machines (i.e. centralized versus decentralized 
facilities), test volume, underlying TB prevalence, level of empirical treatment and pretreatment loss 
to follow-up. 
Only one study assessing the cost–effectiveness of Molbio’s Truenat MTB was identified. This study 
suggests that Truenat MTB is likely to be cost effective if implemented at the point of care in India. 
However, the study relies on several important modelling assumptions, including improved linkage 
to care and increased treatment initiation; these assumptions should be evaluated in pragmatic trials 
(as has been done for Xpert MTB/RIF implementation in South Africa).
Caution should be used when generalizing cost–effectiveness and economic evaluations across 
settings. Local implementation conditions and settings should be taken into account, and local 
implementation studies may be helpful to assess the likely impact on case finding, long-term outcomes 
and cost–effectiveness.
There is a substantial amount of economic evidence around implementation and scale-up of Xpert 
MTB/RIF in different settings, most notably among outpatients presenting with signs and symptoms 
of TB. Most of these studies found that Xpert MTB/RIF would probably be cost effective, but there 
were some exceptions, and it was clear that differences in implementation approaches and settings 
could have an important impact on cost–effectiveness. Studies employed a wide variety of modelling 
and analysis approaches, assumptions, diagnostic algorithms and comparators, and they also 
assessed different study settings, making comparisons across studies and generalizations to other 
settings challenging.
Studies highlighted that implementation factors and settings need to be taken into account when 
generalizing cost–effectiveness results to different settings. Important factors in determining whether 
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Xpert MTB/RIF may be cost effective in any given setting include current standard of care, level of 
empirical treatment, existing testing facilities, location of Xpert MTB/RIF (centralized or decentralized 
facilities), TB prevalence, patient volume, pretreatment loss to follow-up and existing linkage to 
care. Other important cost components include whether implementation costs associated with Xpert 
MTB/RIF scale-up are considered, and whether downstream costs (e.g. for TB and MDR-TB treatment, 
and antiretroviral therapy and HIV care) were included.
Web Annex 4.6: Systematic literature review of economic evidence for molecular assays intended as 
initial tests for the diagnosis of pulmonary and extrapulmonary TB in adults and children.
1.6 User perspective
This section deals with the following question:
Are there implications for feasibility, accessibility, patient equity and human rights 
from the implementation of Xpert MTB/RIF, Xpert Ultra, and Truenat MTB, MTB Plus 
and MTB-RIF Dx systems?
The results of the qualitative research show that participants place great value on the ability of Xpert14 
to improve the diagnosis of drug-resistant TB; they also show the impact on patients if they cannot 
access testing for drug resistance through this technology. The impact on case notification and the 
value of Xpert for finding more TB cases was less clear, owing to widespread clinical treatment, 
prolonged turnaround time for results, and the challenges with feasibility and use of Xpert. 
Although access has improved, not everybody who needs it can access Xpert testing. Simple 
laboratory procedures do not automatically translate into feasibility to implement. Rather, the feasibility 
of Xpert testing depends on government commitment to ensure functioning infrastructure and stable 
power, supply of cartridges and functioning laboratory services, investment in expertise for handling 
(discordant) results, effective repair services, staff with monitoring capacities, functioning sample 
transport, sustainable funding models and transparent donor agreements, and simple diagnostic 
algorithms. 
With regard to acceptability, although Xpert has eased laboratory work through convenience and 
automation, the preference for Xpert in the laboratory can have undesired consequences for treatment 
monitoring with microscopy, and for reverting back to microscopy if GeneXpert instruments become 
non-functional. Clinicians’ confidence in Xpert results is fairly high, but the challenges with feasibility 
and use mean that clinicians are at times deterred from ordering Xpert tests.
1.6.1 Summary of the results
1. Xpert is unable to bridge disconnects or lack of capacity in general laboratory services. 
Participants valued the option to use a specimen other than sputum, but having GeneXpert 
machines available in the public sector does not necessarily mean that facilities and capacities are 
available to extract and make use of those specimens. For example, services for histopathology 
and bacteriology in one country may be disconnected, and sending a specimen to histopathology 
in the private sector, for instance, may mean that the sample will not return to a public sector 
GeneXpert machine. 
2. Xpert Ultra trace results complicate decision-making. Laboratory and clinical management 
of trace results was rarely straightforward. Study participants reported challenges with obtaining 
a second fresh sample when patients had left the facility or had been put on treatment and could 
not easily produce sputum. If repeat tests are conducted after trace, they cause confusion if the 
second test has a different result (e.g. is negative). Some laboratory managers are unsure which 
14 When not specified, this term applies to both Xpert MTB/RIF and Xpert Ultra.
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result to report, and clinicians need expertise and experience to conduct more extensive evaluation 
for trace patients. This presents challenges in peripheral settings and where turnaround times of 
confirmatory tests (e.g. phenotypic DST and LPA) slow down clinical decision-making.
3. Discordant results of repeat tests and confirmatory tests can cause confusion around 
what should be considered gold standard. This is particularly the case when specimen quality 
might be poor. Understanding and contextualizing discordant results requires continuous training, 
experience and expertise.
4. Establishing a thorough TB history of patients is uncommon, and “previously treated” is 
defined differently. This has implications for potential false-positive results through Xpert testing. 
Clear guidance is needed on how to define previously treated patients, how to handle their Xpert 
results, and how to accurately capture outcomes in national databases.
5. The lack of trained counsellors and of information provided to patients on diagnostics 
have negative implications. Patients may be unwilling to accept a diagnosis and invest time and 
money for clinic visits, follow-up tests and treatment. Patients need better quality counselling by 
health workers to continue with diagnostic journeys and treatment; such counselling should include 
information about diagnostic technology and considerations for follow-up testing.
6. Persistent underuse of GeneXpert machines is compounded by the challenges of delays due 
to sample transport, module breakdown, stock-out of cartridges or complicated diagnostic 
algorithms. The presence of local Cepheid agents is key for repair. However, high workload and 
staff turnover, combined with infrastructure and environmental conditions, still cause frequent 
module breakdown, and repair work can be slow or services deemed insufficient. The challenges 
of cartridge stock-out lead to important delays and disruption of workflows, which in turn lead 
to underuse.
7. Diagnostic algorithms that are simple to follow in a specific facility (e.g. test all those with 
presumptive TB) are more feasible and enhance use, but this simplicity depends on cost and 
supplies. Cartridge stock-outs or prohibitive costs can complicate diagnostic algorithms, making 
them less feasible to follow and thus further compounding underuse. In Uganda, Xpert testing 
eligibility criteria had to be temporarily restricted to certain patient groups because of cartridge 
shortages that complicated the algorithm.
8. Current donor agreements with governments regarding introduction of new diagnostic 
technologies are not transparent enough for civil society to be able to hold accountable 
and follow up. Involving civil society in negotiating agreements and social contracts at national 
level and local facility levels can enhance accountability and the responsiveness of governments, 
leading to improved implementation processes and access to diagnostics. 
Web Annex 4.7: Report on user perspectives on Xpert testing: results from qualitative research.
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1.7 Summary of changes between the 2013 guidance and the 2020 update
Xpert MTB/RIF assay for the diagnosis of 
pulmonary and extrapulmonary TB in adults 
and children. Policy update (2013) (12)
Molecular assays intended as initial tests for the diagnosis of 
pulmonary and extrapulmonary TB and rifampicin resistance in 
adults and children: rapid communication. Policy update (2020) 
(13)
Changes
Using Xpert MTB/RIF to diagnose pulmonary TB 
and rifampicin resistance in adults and children
1. Xpert MTB/RIF should be used rather than 
conventional microscopy, culture and DST as 
the initial diagnostic test in adults suspected 
of having MDR-TB or HIV-associated 
TB (strong recommendation, high-
quality evidence).
2. Xpert MTB/RIF should be used rather than 
conventional microscopy, culture and DST as 
the initial diagnostic test in children suspected 
of having MDR-TB or HIV-associated TB 
(strong recommendation, very low quality 
evidence). 
3. Xpert MTB/RIF may be used rather than 
conventional microscopy and culture as the 
initial diagnostic test in all adults suspected 
of having TB (conditional recommendation 
acknowledging resource implications, high-
quality evidence). 
4. Xpert MTB/RIF may be used rather than 
conventional microscopy and culture as the 
initial diagnostic test in all children suspected 
of having TB (conditional recommendation 
acknowledging resource implications, very 
low quality evidence).
5. Xpert MTB/RIF may be used as a follow-on 
test to microscopy in adults suspected of 
having TB but not at risk of MDR-TB or HIV-
associated TB, especially when further testing 
of smear-negative specimens is necessary 
(conditional recommendation acknowledging 
resource implications, high-quality evidence).
Xpert MTB/RIF and Xpert Ultra as initial tests in adults and children 
with signs and symptoms of pulmonary TB
1. In adults with signs and symptoms of pulmonary TB, Xpert 
MTB/RIF should be used as an initial diagnostic test for TB and 
for rifampicin-resistance detection rather than smear microscopy/
culture and DST (strong recommendation, high certainty of 
evidence for test accuracy and moderate certainty of evidence for 
patient-important outcomes).
2. In adults with signs and symptoms of pulmonary TB without a prior 
history of TB (<5 years since end of treatment) or with a remote 
history of TB treatment (>5 years since end of treatment), Xpert 
Ultra should be used as the initial diagnostic test for TB and for 
rifampicin-resistance detection rather than smear microscopy/
culture (strong recommendation, high certainty of evidence for 
test accuracy).
3. In adults with signs and symptoms of pulmonary TB and a prior 
history of TB with an end of treatment within the past 5 years, 
Xpert Ultra may be used as the initial diagnostic test for TB and 
for rifampicin-resistance detection rather than smear microscopy/
culture (conditional recommendation, low certainty of evidence for 
test accuracy).
4. In children with signs and symptoms of pulmonary TB, Xpert 
MTB/RIF should be used as the initial diagnostic test for TB rather 
than smear microscopy/culture in sputum (moderate certainty 
of evidence in test accuracy), gastric aspirate (low certainty of 
evidence for test accuracy), nasopharyngeal aspirate (moderate 
certainty of evidence for test accuracy), or stool (low certainty of 
evidence for test accuracy) specimens (strong recommendation).
5. In children with signs and symptoms of pulmonary TB, Xpert Ultra 
should be used as the initial diagnostic test for TB rather than 
smear microscopy/culture in sputum (low certainty of evidence in 
test accuracy) and nasopharyngeal aspirate (very low certainty of 
evidence for test accuracy) specimens (strong recommendation).
1. Strong recommendation for 
use of Xpert MTB/RIF as an 
initial test for TB and rifampicin 
resistance in all adults and 
children with signs and 
symptoms of pulmonary TB.
2. Xpert Ultra is now 
recommended as an initial test 
for TB and rifampicin resistance 
in all adults and children 
with signs and symptoms of 
pulmonary TB.
3. In children, recommended 
use of Xpert MTB/RIF is 
expanded to gastric aspirate, 
nasopharyngeal aspirate, 
nasopharyngeal aspirate 
and stool. Use of Xpert 
Ultra is expanded to 
nasopharyngeal aspirate.
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Xpert MTB/RIF assay for the diagnosis of 
pulmonary and extrapulmonary TB in adults 
and children. Policy update (2013) (12)
Molecular assays intended as initial tests for the diagnosis of 
pulmonary and extrapulmonary TB and rifampicin resistance in 
adults and children: rapid communication. Policy update (2020) 
(13)
Changes
Using Xpert MTB/RIF to diagnose 
extrapulmonary TB and rifampicin resistance in 
adults and children
1. Xpert MTB/RIF should be used in preference 
to conventional microscopy and culture as 
the initial diagnostic test for CSF specimens 
from patients suspected of having TB 
meningitis (strong recommendation given the 
urgency for rapid diagnosis, very low quality 
evidence). 
2. Xpert MTB/RIF may be used as a replacement 
test for usual practice (including conventional 
microscopy, culture or histopathology) for 
testing specific non-respiratory specimens 
(lymph nodes and other tissues) from patients 
suspected of having extrapulmonary TB 
(conditional recommendation, very low 
quality evidence).
Xpert MTB/RIF and Xpert Ultra as initial tests in adults and children 
with signs and symptoms of extrapulmonary TB
1. In adults and children with signs and symptoms of TB meningitis, 
Xpert MTB/RIF or Xpert Ultra should be used in CSF as an initial 
diagnostic test for TB meningitis (strong recommendation, 
moderate certainty of evidence for test accuracy for Xpert 
MTB/RIF, low certainty of evidence for Xpert Ultra).
2. In adults and children with signs and symptoms of extrapulmonary 
TB, Xpert MTB/RIF may be used in lymph node aspirate, lymph 
node biopsy, pleural fluid, peritoneal fluid, pericardial fluid, 
synovial fluid or urine specimens as the initial diagnostic test 
for the corresponding form of extrapulmonary TB (conditional 
recommendation, moderate certainty of evidence for test 
accuracy for pleural fluid; low for lymph node aspirate, peritoneal 
fluid, synovial fluid, urine; very low for pericardial fluid, lymph 
nodes biopsy).
3. In adults and children with signs and symptoms of extra-
pulmonary TB an Xpert Ultra may be used in lymph node aspirate 
and lymph node biopsy as the initial diagnostic test (conditional 
recommendation, low certainty of evidence).
4. In adults and children with signs and symptoms of extrapulmonary 
TB, Xpert MTB/RIF or Xpert Ultra should be used for rifampicin-
resistance detection rather than culture and DST (strong 
recommendation, high certainty of evidence for test accuracy for 
Xpert MTB/RIF; low certainty of evidence for Xpert Ultra).
5. In HIV-positive adults and children with signs and symptoms 
of disseminated TB, Xpert MTB/RIF may be used in blood, as a 
diagnostic test for disseminated TB (conditional recommendation, 
very low certainty of evidence for test accuracy).
1. Improved certainty of evidence 
for test accuracy for Xpert 
MTB/RIF when used in CSF as 
an initial diagnostic test for 
TB meningitis.
2. High certainty of evidence for 
Xpert Ultra when used in CSF 
as an initial diagnostic test for 
TB meningitis.
3. Use of Xpert MTB/RIF in lymph 
node aspirate, lymph node 
biopsy, pleural fluid, peritoneal 
fluid, pericardial fluid, synovial 
fluid or urine specimens as 
the initial diagnostic test for 
the corresponding form of 
extrapulmonary TB.
4. Use of Xpert Ultra in lymph 
node aspirate, lymph node 
biopsy specimens as the 
initial diagnostic test for 
the corresponding form of 
extrapulmonary TB.
5. Use of Xpert Ultra for 
rifampicin-resistance detection 
in adults and children with 
signs and symptoms of 
extrapulmonary TB.
6. Use of Xpert 
MTB/RIF in blood for diagnosis 
of disseminated TB.
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Xpert MTB/RIF assay for the diagnosis of 
pulmonary and extrapulmonary TB in adults 
and children. Policy update (2013) (12)
Molecular assays intended as initial tests for the diagnosis of 
pulmonary and extrapulmonary TB and rifampicin resistance in 
adults and children: rapid communication. Policy update (2020) 
(13)
Changes
Using Xpert MTB/RIF to diagnose 
extrapulmonary TB and rifampicin resistance in 
adults and children
1. Xpert MTB/RIF should be used in preference 
to conventional microscopy and culture as 
the initial diagnostic test for CSF specimens 
from patients suspected of having TB 
meningitis (strong recommendation given the 
urgency for rapid diagnosis, very low quality 
evidence). 
2. Xpert MTB/RIF may be used as a replacement 
test for usual practice (including conventional 
microscopy, culture or histopathology) for 
testing specific non-respiratory specimens 
(lymph nodes and other tissues) from patients 
suspected of having extrapulmonary TB 
(conditional recommendation, very low 
quality evidence).
Xpert MTB/RIF and Xpert Ultra as initial tests in adults and children 
with signs and symptoms of extrapulmonary TB
1. In adults and children with signs and symptoms of TB meningitis, 
Xpert MTB/RIF or Xpert Ultra should be used in CSF as an initial 
diagnostic test for TB meningitis (strong recommendation, 
moderate certainty of evidence for test accuracy for Xpert 
MTB/RIF, low certainty of evidence for Xpert Ultra).
2. In adults and children with signs and symptoms of extrapulmonary 
TB, Xpert MTB/RIF may be used in lymph node aspirate, lymph 
node biopsy, pleural fluid, peritoneal fluid, pericardial fluid, 
synovial fluid or urine specimens as the initial diagnostic test 
for the corresponding form of extrapulmonary TB (conditional 
recommendation, moderate certainty of evidence for test 
accuracy for pleural fluid; low for lymph node aspirate, peritoneal 
fluid, synovial fluid, urine; very low for pericardial fluid, lymph 
nodes biopsy).
3. In adults and children with signs and symptoms of extra-
pulmonary TB an Xpert Ultra may be used in lymph node aspirate 
and lymph node biopsy as the initial diagnostic test (conditional 
recommendation, low certainty of evidence).
4. In adults and children with signs and symptoms of extrapulmonary 
TB, Xpert MTB/RIF or Xpert Ultra should be used for rifampicin-
resistance detection rather than culture and DST (strong 
recommendation, high certainty of evidence for test accuracy for 
Xpert MTB/RIF; low certainty of evidence for Xpert Ultra).
5. In HIV-positive adults and children with signs and symptoms 
of disseminated TB, Xpert MTB/RIF may be used in blood, as a 
diagnostic test for disseminated TB (conditional recommendation, 
very low certainty of evidence for test accuracy).
1. Improved certainty of evidence 
for test accuracy for Xpert 
MTB/RIF when used in CSF as 
an initial diagnostic test for 
TB meningitis.
2. High certainty of evidence for 
Xpert Ultra when used in CSF 
as an initial diagnostic test for 
TB meningitis.
3. Use of Xpert MTB/RIF in lymph 
node aspirate, lymph node 
biopsy, pleural fluid, peritoneal 
fluid, pericardial fluid, synovial 
fluid or urine specimens as 
the initial diagnostic test for 
the corresponding form of 
extrapulmonary TB.
4. Use of Xpert Ultra in lymph 
node aspirate, lymph node 
biopsy specimens as the 
initial diagnostic test for 
the corresponding form of 
extrapulmonary TB.
5. Use of Xpert Ultra for 
rifampicin-resistance detection 
in adults and children with 
signs and symptoms of 
extrapulmonary TB.
6. Use of Xpert 
MTB/RIF in blood for diagnosis 
of disseminated TB.
Xpert MTB/RIF assay for the diagnosis of 
pulmonary and extrapulmonary TB in adults 
and children. Policy update (2013) (12)
Molecular assays intended as initial tests for the diagnosis of 
pulmonary and extrapulmonary TB and rifampicin resistance in 
adults and children: rapid communication. Policy update (2020) 
(13)
Changes
Xpert MTB/RIF and Xpert Ultra repeated testing in adults and children 
with signs and symptoms of pulmonary TB
1. In adults with signs and symptoms of pulmonary TB who have an 
Xpert Ultra trace positive result on the initial test, repeated testing 
with Ultra may not be used (conditional recommendation, very low 
certainty of evidence for test accuracy).
2. In children with signs and symptoms of pulmonary TB in settings 
with pretest probability below 5% and an Xpert MTB/RIF negative 
result on the initial test, repeated testing with Xpert MTB/RIF in 
sputum, gastric fluid, nasopharyngeal aspirate or stool specimens 
may not be used (conditional recommendation, low certainty 
of evidence for test accuracy for sputum and very low for other 
specimen types).
3. In children with signs and symptoms of pulmonary TB in 
settings with pretest probability 5% or more and an Xpert 
MTB/RIF negative result on the initial test, repeated testing with 
Xpert MTB/RIF (for a total of two tests) in sputum, gastric fluid, 
nasopharyngeal aspirate and stool specimens may be used 
(conditional recommendation, low certainty of evidence for test 
accuracy for sputum and very low for other specimen types). 
4. In children with signs and symptoms of pulmonary TB in settings 
with pretest probability below 5% and an Xpert Ultra negative 
result on the initial test, repeated testing with Xpert Ultra in 
sputum or nasopharyngeal aspirate specimens may not be used 
(conditional recommendation, very low certainty of evidence for 
test accuracy).
5. In children with signs and symptoms of pulmonary TB in settings 
with pretest probability 5% or more and an Xpert Ultra negative 
result on the first initial test, repeated one Xpert Ultra test (for 
a total of two tests) in sputum and nasopharyngeal aspirate 
specimens may be used (conditional recommendation, very low 
certainty of evidence for test accuracy).
1. Not recommended repeated 
Xpert Ultra in adults who have 
an Xpert Ultra trace positive 
result on the initial test.
2. Not recommended repeated 
Xpert MTB/RIF in children in low 
prevalence settings.
3. Recommended repeated Xpert 
MTB/RIF in children in high 
prevalence settings in sputum, 
gastric fluid, nasopharyngeal 
aspirate and stool specimens.
4. Recommended repeated 
Xpert Ultra in children in both 
low and high prevalence 
settings in sputum and 
nasopharyngeal specimens.
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Xpert MTB/RIF assay for the diagnosis of 
pulmonary and extrapulmonary TB in adults 
and children. Policy update (2013) (12)
Molecular assays intended as initial tests for the diagnosis of 
pulmonary and extrapulmonary TB and rifampicin resistance in 
adults and children: rapid communication. Policy update (2020) 
(13)
Changes
Xpert MTB/RIF and Xpert Ultra as initial tests for pulmonary TB in 
adults in the general population either with signs and symptoms of 
TB or chest radiograph with lung abnormalities or both 
1. In adults in the general population who had either signs or 
symptoms of TB or chest radiograph with lung abnormalities or 
both, the Xpert MTB/RIF or Xpert Ultra may replace culture as the 
initial test for pulmonary TB (conditional recommendation, low 
certainty of the evidence in test accuracy for Xpert MTB/RIF and 
moderate certainty for Xpert Ultra).
2. In adults in the general population who had either a positive TB 
symptom screen or chest radiograph with lung abnormalities 
or both, one Xpert Ultra test may be used rather than two 
Xpert Ultra tests as the initial test for pulmonary TB (conditional 
recommendation, very low certainty of evidence for test accuracy).
Conditional recommendation 
on use of Xpert MTB/RIF or 
Xpert Ultra for individual case 
management in individuals with 
radiographic abnormalities (but 
not in surveys estimating burden 
of disease).
Truenat MTB, MTB Plus and Truenat MTB-RIF Dx in adults and 
children with signs and symptoms of pulmonary TB
1. In adults and children with signs and symptoms of pulmonary TB, 
the Truenat MTB or MTB Plus may be used as an initial diagnostic 
test for TB (conditional recommendation, low certainty of evidence 
for test accuracy). 
2. In adults and children with signs and symptoms of pulmonary TB 
and a Truenat MTB or MTB Plus positive result, Truenat MTB-RIF Dx 
may be used as an initial test for rifampicin resistance (conditional 
recommendation, very low certainty of evidence for test accuracy).
1. Novel molecular tests Truenat 
MTB and MTB Plus are 
recommended as an initial test 
for TB. 
2. Novel molecular assay Truenat 
MTB-RIF Dx is recommended 
as an initial test for rifampicin 
resistance in those with a 
Truenat MTB or MTB Plus 
positive result. 
CSF: cerebrospinal fluid; DST: drug-susceptibility testing; HIV: human immunodeficiency virus; MDR-TB: multidrug-resistant tuberculosis; TB: tuberculosis.
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Section 2. Loop-mediated isothermal amplification
A commercial molecular assay, the LoopampTM Mycobacterium tuberculosis complex (MTBC) detection 
kit (Eiken Chemical Company, Tokyo, Japan), is based on the loop-mediated isothermal amplification 
(LAMP) reaction. Referred to as TB-LAMP, this is a manual assay that requires less than 1 hour to 
perform and can be read with the naked eye under UV light. Because it requires little infrastructure 
and is relatively easy to use, TB-LAMP is being explored for use as a rapid diagnostic test that would 
be an alternative to smear microscopy in resource-limited settings. LAMP methods have been used 
to detect malaria and several neglected tropical diseases. 
In 2012, WHO convened a GDG that recognized TB-LAMP as offering a manual molecular approach 
to TB detection that could feasibly be implemented in peripheral-level microscopy laboratories once 
laboratory technicians had been adequately trained. The advantages of TB-LAMP are that it has a 
relatively high throughput, does not require sophisticated instruments, and has biosafety requirements 
similar to those of sputum-smear microscopy. Since 2012, some 20 additional studies in 17 countries 
have been conducted. WHO convened a GDG meeting in January 2016 to review evidence from a 
systematic review and meta-analysis of data from individual participants in these studies. 
2.1 Recommendations 
2.2 TB-LAMP may be used as a replacement test for sputum-smear microscopy for 
diagnosing pulmonary TB in adults with signs and symptoms consistent with TB. 
(Conditional recommendation, very low quality evidence)
2.3 TB-LAMP may be used as a follow-on test to smear microscopy in adults 
with signs and symptoms consistent with pulmonary TB, especially 
when further testing of sputum smear-negative specimens is necessary. 
(Conditional recommendation, very low quality evidence)
2.2 Remarks
1. These recommendations apply to settings where conventional sputum-smear microscopy can 
be performed.
2. TB-LAMP should not replace the use of rapid molecular tests that detect TB and resistance to 
rifampicin, especially among populations at risk of MDR-TB.
3. The test has limited additional diagnostic value over sputum-smear microscopy for testing PLHIV 
who have signs and symptoms consistent with TB.
4. These recommendations apply only to the use of TB-LAMP in testing sputum specimens from 
patients with signs and symptoms consistent with pulmonary TB.
5. These recommendations are extrapolated to using TB-LAMP in children, based on the 
generalization of data from adults, while acknowledging the difficulties of collecting sputum 
specimens from children.
2.3 Test description
The fundamental amplification reaction requires four types of primers, which are complementary to 
six regions of the target gene. At about 65 °C, double-stranded DNA is in a condition of dynamic 
equilibrium and one of the LAMP primers can anneal to the complementary sequence of double-
stranded target DNA, initiating DNA synthesis with the DNA polymerase; strand displacement activity 
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then displaces and releases a single-stranded DNA. Owing to the complementarity of the 5′-end 
of the forward inner primer (known as FIP) and the backward inner primer (BIP) in nearby regions 
of the target amplicon, loop structures are formed. This allows variously sized structures, consisting 
of alternately inverted repeats of the target sequence on the same strand, to be formed in rapid 
succession. 
The addition of loop primers, which contain sequences complementary to the single-stranded loop 
region on the 5′-end of the hairpin structure, speeds the reaction by providing a greater number 
of starting points for DNA synthesis. Using loop primers, amplification by 109–1010 times can be 
achieved within 15–30 minutes. The version of TB-LAMP that was evaluated includes loop primers 
for a total of six primers binding to eight locations. This requirement for homogeneous sequences at 
multiple binding sites preserves the specificity of the assay, even in the absence of a probe.
The LAMP method is relatively insensitive to the accumulation of DNA and DNA byproducts 
(pyrophosphate salts), so the reaction proceeds until large amounts of amplicon are generated. This 
feature makes it possible to visually detect successful amplification using double-stranded DNA-
binding dyes, such as SYBR green, by detecting the turbidity caused by precipitating magnesium 
pyrophosphate or by using a non-inhibitory fluorescing reagent that is quenched in the presence 
of divalent cations. Fig. 2.1 shows calcein, unquenched by pyrophosphate consumption of divalent 
cations, fluorescing under UV light. The turbid, fluorescent product is easily seen with the naked eye. 
Fig. 2.1. Visual display of TB-LAMP results under UV light 
- - - - + + + +
LAMP: loop-mediated isothermal amplification; TB: tuberculosis; UV: ultraviolet.
The test procedure has three main steps (Fig. 2.2):
1. Sample preparation – bacteria are heat treated for inactivation and lysis. This step also includes 
the extraction of DNA.
2. Amplification – the sample is placed in a heating block at 67 °C. At this temperature, the polymerase 
enzyme amplifies the target DNA. 
3. Visualization – the test-tube contains a double-stranded DNA-binding molecule that will fluoresce 
under UV light, meaning that detection can easily be performed with the naked eye. 
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Fig. 2.2. Description of the workflow for TB-LAMP
TB-LAMP Workflow 
1. Sample transfer and lysis
> Use the Pipette-60 to collect 
slowly the most purulent portion 
of each sputum sample. Rub the 
end of the tip on the bottom of 
the cup to avoid and cut strings.
> Remove the cap to open the 
heating tube of the  
LoopampTM PURE DNA 
 Extraction Kit.
>  Transfer 60 µl of the sputum. > Mix the contents of the 
 tube by shaking.
> Transfer the sample slowly 
into the heating tube. Slowly 
rinse the tip once to remove 
the sputum.
> Incubate the tube in the 
 HumaLoop T heating unit at 
90°C for 5 min.
2. LoopampTM PURE DNA extraction
> Screw the heating tube onto 
 the adsorbent tube. 
> Remove the cap of the adsorbent 
tube but do not discard it.
> Mix the lysed sample with
 the powder in the adsorbent 
 tube by shaking thoroughly.
> Screw the injection cap onto 
 the other side of the adsorbent 
 tube.
> Shake the tube until a milky 
 solution is obtained. 
> Extract 30 µl of the DNA 
 directly into the reaction tube 
 by squeezing the adsorbent 
 tube.
3. Loop-mediated isothermal amplification 4. Result reading
> Incubate the tube upside down 
 for 2 min (use timer) at room 
temperature to reconstitute the 
reagents in the cap.
> Mix the contents of the 
 tube by inverting five times.
> Flick down the reaction tube 
 until the reaction mixture is 
 collected at the bottom.
> Insert the tube into the 
 detection unit and turn on the 
UV light.
> Positive results fluoresce green.> Incubate the reaction tube at 
 67°C for 40 min in the reaction 
 unit. The reaction is automatically 
inactivated by a further incubati-
on step at 80°C for 5 min.
  
A visualized workflow is shown. Please always refer to the latest versions of the Instructions for Use.
981014/5/2018-08 © 2018 HUMAN
LAMP: loop-mediated isothermal amplification; TB: tuberculosis.
Source: Courtesy of Human Gesellschaft für Biochemica und Diagnostica mbH
2.4 Justification and evidence
The evidence reviewed and this policy guidance apply only to the use of the commercial TB-LAMP 
manual assay. In accordance with WHO’s standards for assessing evidence when formulating 
policy recommendations, the GRADE approach was used. GRADE provides a structured framework 
to determine the quality of the evidence and to provide information on the strength of the 
recommendations, using PICO questions agreed by the GDG. PICO refers to the following four 
elements that should be included in questions that govern a systematic search of the evidence: the 
population targeted by the action or intervention (in the case of systematic reviews of the accuracy of 
diagnostic tests, P is the population of interest), the intervention (I is the index test), the comparator 
(C is the comparator test or tests) and the outcomes (O is usually sensitivity and specificity). The PICO 
questions for the review are given in Box 2.1.
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a pTM PURE DNA extraction
-mediated isothermal ampl fication lt reading
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Re ove the cap to open the 
heating tube of the Loopamp™
PURE DNA Extraction Kit.
Use the Pipette-60 to collect 
slowly the most purulent portion 
of each sputum sample. Rub the 
end of the tip on the bottom of 
the cup to avoid and cut strings.
Transfer 60 µl of the sputum. Transfer the sample slowly into 
the heating tube. Slowly rinse the 
tip once to remove the sputum.
ix the contents of the tube by 
shaking.
Incubate the tube in the 
HumaLoop T heating unit at 90°C 
for 5 min.
e ove the cap of the adsorbent 
tube but do not discard it.
Scre  the heating tube onto the 
adsorbent tube.
ix the lysed sample with the 
powder in the adsorbent tube by 
shaking thoroughly.
Shake the tube until a milky 
solution is obtained.
Screw the injection cap onto the 
other side of the adsorbent tube.
Extract 30 µl of the DNA directly 
into the reaction tube by 
squeezing the adsorbent tube.
Incubate the tube upside down for 
2 min (use timer) at room 
temperature to reconstitute the 
reagents in the cap.
ix the contents of the tube by 
inverting ve times.
Flick down the reaction tube until 
the reaction mixture is collected at 
the bottom.
Incubate the reaction tube at 67°C 
for 40 min in the reaction unit. The 
reaction is automatically 
inactivated by a further incubation 
step at 80°C for 5 min.
Insert the tube into the detection 
unit and turn on the UV light.
Positive results uoresce green.
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1. What is the diagnostic accuracy of TB-LAMP for detecting pulmonary TB in adults when 
TB-LAMP is used as a replacement test for sputum-smear microscopy compared with 
culture as a reference standard? (Results were stratified by HIV status.) 
2. What is the diagnostic accuracy of TB-LAMP for detecting pulmonary TB in adults 
when TB-LAMP is used as an add-on test following negative sputum-smear microscopy 
compared with culture as a reference standard? 
3. What is the difference in diagnostic accuracy between TB-LAMP and the Xpert MTB/RIF 
assay (Cepheid, Sunnyvale, USA) for detecting pulmonary TB in reference to mycobacterial 
culture among all adults? 
4. What is the proportion of indeterminate or invalid results when TB-LAMP is used to detect 
pulmonary TB among all adults and among HIV-positive adults?
Box 2.1. PICO questions addressed by the GDG
The review included all prospective studies that evaluated the use of TB-LAMP on sputum samples 
from adults with signs and symptoms consistent with pulmonary TB that were conducted in settings 
with an intermediate or high burden of TB. Twenty studies were identified, including all studies that 
were directly conducted by FIND or funded through FIND following a request for applications. Study 
participants who could not be classified as TB-positive or TB-negative based on the reference standard 
definitions described below were excluded.
The mycobacterial culture reference standards listed below were used to classify TB status. Eligible 
studies performed one or more sputum cultures on solid media (Löwenstein–Jensen) or on liquid 
media using the BACTEC™ mycobacterial growth indicator tube (MGIT; Becton Dickinson, Franklin 
Lakes, USA), or on both liquid and solid media. To account for the different number of cultures 
performed by studies and the different number of culture results available for participants, three 
hierarchical culture-based reference standards were used to assess diagnostic accuracy.
Standard 1 comprised:
• TB: at least one positive culture confirmed to be MTBC by speciation testing.
• Not TB: no positive and at least two negative cultures performed on two different sputum samples. 
Standard 2 comprised:
• TB: at least one positive culture confirmed to be MTBC by speciation testing.
• Not TB: No positive and at least two negative cultures performed on at least one sputum sample.
Standard 3 comprised:
• TB: at least one positive culture confirmed to be MTBC by speciation testing.
• Not TB: No positive and at least one negative culture.
Across the three standards, there is an expected trade-off between the yield of a confirmed TB diagnosis 
(highest with Standard 1 and lowest with Standard 3) and the number of studies or participants 
included in the analysis (lowest with Standard 1 and highest with Standard 3). Thus, using Standard 
1, the potential for false-negative index test results is highest and for false-positive index test results 
is lowest. Also, using Standard 1, the number of studies and study participants included is expected 
to be lowest because it excludes studies that performed only one culture, and study participants for 
whom only one negative culture result was available due to culture contamination; in contrast, using 
Standard 3, the number of studies and study participants is highest. 
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Of the 4760 adults eligible for inclusion in the analysis, 1810 participants (38%) across seven studies 
qualified for Standard 1 status, 3110 participants (65%) across 10 studies qualified for Standard 2 and 
4596 participants (97%) across 13 qualified for Standard 3 (Table 2.1).
The performance of the test was calculated using the three different reference standards for the 
following scenarios:
1. TB-LAMP as a replacement for sputum-smear microscopy;
2. TB-LAMP as a replacement for sputum-smear microscopy among PLHIV;
3. TB-LAMP as an add-on test for sputum-smear microscopy negative individuals; and
4. TB-LAMP in head-to-head comparison with Xpert MTB/RIF.
Table 2.1. TB-LAMP as a replacement test for smear microscopy: estimates of 
pooled sensitivity and specificity
Reference standarda Pooled sensitivityb Pooled specificityb
Replacement for 
SSM
Standard 1 77.7 (71.2–83.0) 98.1 (95.7–99.2)
Standard 2 76.0 (69.9–81.2) 98.0 (96.0–99.0)
Standard 3 80.3 (70.3–87.5) 97.7 (96.1–98.7)
Replacement for 
SSM for PLHIV
Standard 1 NA NA
Standard 2 63.8 (49.0–76.4) 98.8 (85.1–99.9)
Standard 3 73.4 (51.9–87.6) 95.0 (64.0–99.5)
Add-on for SSM 
negative individuals
Standard 1 42.1 (30.0–55.3) 98.4 (95.9–99.4)
Standard 2 42.2 (27.9–57.9) 98.0 (96.0–99.0)
Standard 3 40.3 (27.9–54.0) 97.7 (96.1–98.6)
Compared to Xpert 
MTB/RIF
Standard 1 81.1 (70.6–88.5) 98.2 (95.9–99.2)
Standard 2 80.4 (73.4–85.9) 97.4 (94.9–98.7)
Standard 3 84.0 (75.6–90.0) 97.2 (94.4–98.6)
LAMP: loop-mediated isothermal amplification; NA: not applicable; PLHIV: people living with human immunodeficiency virus; SSM: sputum-
smear microscopy; TB: tuberculosis.
a All reference standards classify patients as having TB if ≥1 positive culture was confirmed as M. tuberculosis by speciation testing. To be 
classified as not having TB, patients had to have no positive and (i) at least two negative cultures on two different sputum specimens 
(Standard 1), (ii) at least two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative 
culture (Standard 3).
b Values are percentages (95% confidence intervals).
2.5 Cost–effectiveness analysis
For the cost analysis, a bottom-up micro-costing analysis was conducted – the aim being to identify, 
measure and value all resources relevant to providing TB-LAMP and the Xpert MTB/RIF assay 
as routine diagnostic tests in peripheral laboratories in Malawi and Viet Nam. The two TB-LAMP 
strategies (used as a replacement test for sputum-smear microscopy and as an add-on test to 
sputum-smear microscopy for further testing in smear-negative patients) were compared with the 
base case algorithm, with sputum-smear microscopy followed by clinical diagnosis in those patients 
with a negative microscopy result.
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The weighted average per-test cost of TB-LAMP was US$ 13.78–16.22, and for the Xpert MTB/RIF assay 
it was US$ 19.17–28.34 when these tests were used as routine diagnostic tests at all peripheral-level 
laboratories in both countries. The first-year expenditure required for implementation at peripheral 
laboratories with a medium workload (10–15 sputum-smear microscopy tests per day) in Viet Nam 
was US$ 26 917 for TB-LAMP and US$ 43 325 for the Xpert MTB/RIF assay. These costs were about 
US$ 3000 lower in Malawi, because of lower operating and staff costs. Likewise, TB-LAMP was a 
considerably cheaper test to implement, accounting for 9.33% of the reported TB control budget 
for 2014 in Malawi and 17.2% in Viet Nam; in comparison, implementing the Xpert MTB/RIF assay 
accounted for 18% of the reported TB control budget in Malawi and 37% in Viet Nam. In the cost–
effectiveness analyses, both of the TB-LAMP scenarios improved case-detection rates, and both 
strategies were cost effective when compared with WHO’s willingness-to-pay threshold levels. 
The findings of the cost–effectiveness analysis demonstrate that TB-LAMP is potentially a cost-effective 
alternative to the base case of sputum-smear microscopy plus clinical diagnosis in settings where the 
Xpert MTB/RIF assay cannot be implemented because of the infrastructure requirements, including 
a continuous power supply. However, given the inability of TB-LAMP to detect rifampicin-resistant 
TB (RR-TB), and its suboptimal sensitivity for detecting TB among PLHIV, national policy-makers 
must cautiously evaluate the operational feasibility and cost considerations before introducing 
this technology.
2.6 Implementation considerations
The systematic review supports the use of TB-LAMP as a replacement test for smear microscopy, 
for diagnosing pulmonary TB in countries with an intermediate or high burden of TB. However, the 
Xpert MTB/RIF assay should remain the preferred diagnostic test for anyone suspected of having TB, 
provided that there are sufficient resources and infrastructure to support its use, given the evidence, 
its ability to simultaneously identify rifampicin resistance and the fact that it is automated.
• Several operational issues accompany the implementation of TB-LAMP; for example, the need 
for electricity, adequate storage and waste disposal, stock monitoring and temperature control in 
storage settings where temperatures exceed the manufacturer’s recommendation (currently 30 °C 
for TB-LAMP).
• TB-LAMP is designed and has been evaluated to detect M. tuberculosis in sputum specimens. 
Its use with other samples (e.g. urine, serum, plasma, CSF or other body fluids) has not been 
adequately evaluated.
• Adoption of TB-LAMP does not eliminate the need for smear microscopy, which should be used 
for monitoring the treatment of patients with drug-susceptible TB. However, the demand for 
conventional sputum microscopy may decrease in settings where TB-LAMP fully or partially replaces 
conventional sputum microscopy.
• TB-LAMP should not replace the Xpert MTB/RIF assay because the latter simultaneously detects 
M. tuberculosis and rifampicin resistance, is automated and is relatively simple to perform. 
• In settings where the Xpert MTB/RIF assay cannot be implemented (e.g. because of an inadequate 
electric supply, or excessive temperatures, humidity or dust), TB-LAMP may be a plausible alternative. 
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Section 3. First-line LPAs
In 2008, WHO approved the use of commercial LPAs for detecting MTBC in combination with resistance 
to rifampicin and isoniazid in sputum smear-positive specimens (direct testing) and in cultured isolates 
of MTBC (indirect testing). A systematic review at that time evaluated the diagnostic accuracy of two 
commercially available LPAs – the INNO-LiPA Rif.TB assay (Innogenetics, Ghent, Belgium), and the 
GenoType® MTBDRplus (version 1), hereafter referred to as Hain version 1 – and provided evidence 
for WHO’s endorsement (14, 15). Excellent accuracy was reported for both tests in detecting rifampicin 
resistance, but their diagnostic accuracy for isoniazid resistance had lower sensitivity, despite the 
high specificity. Because there were inadequate data to allow stratification by smear status, WHO’s 
recommendation for using LPAs was limited to culture isolates or smear-positive sputum specimens. 
Further data have since been published on the use of LPAs; newer versions of LPA technology have 
now been developed, such as the Hain GenoType MTBDRplus version 2, hereafter referred to as Hain 
version 2; and other manufacturers have entered the market, including Nipro (Tokyo, Japan), which 
developed the Genoscholar™ NTM+MDRTB II, hereafter referred to as Nipro. 
In 2015, FIND evaluated the Nipro and the Hain version 2 LPAs, and compared them with Hain version 
1. The study demonstrated equivalence among the three commercially available LPAs for detecting 
TB and resistance to rifampicin and isoniazid (4).
3.1 Recommendation 
3.1  For persons with a sputum smear-positive specimen or a cultured isolate of 
MTBC, commercial molecular LPAs may be used as the initial test instead of 
phenotypic culture-based DST to detect resistance to rifampicin and isoniazid. 
(Conditional recommendation, moderate certainty in the evidence for the test’s accuracy)
3.2 Remarks
1. These recommendations apply to the use of LPAs for testing sputum smear-positive specimens 
(direct testing) and cultured isolates of MTBC (indirect testing) from both pulmonary and 
extrapulmonary sites.
2. LPAs are not recommended for the direct testing of sputum smear-negative specimens.
3. These recommendations apply to the detection of MTBC and the diagnosis of MDR-TB, but 
acknowledge that the accuracy of detecting resistance to rifampicin and isoniazid differs and, 
hence, that the accuracy of a diagnosis of MDR-TB is reduced overall. 
4. These recommendations do not eliminate the need for conventional culture-based DST, which 
will be necessary to determine resistance to other anti-TB agents and to monitor the emergence 
of additional drug resistance. 
5. Conventional culture-based DST for isoniazid may still be used to evaluate patients when the LPA 
result does not detect isoniazid resistance. This is particularly important for populations with a 
high pretest probability of resistance to isoniazid. 
6. These recommendations apply to the use of LPA in children based on the generalization of data 
from adults.
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3.3 Test description
LPAs are a family of DNA strip-based tests that can detect the MTBC strain and determine its drug 
resistance profile through the pattern of binding of amplicons (DNA amplification products) to probes 
targeting the following: specific parts of the MTBC genome (for MTBC detection), the most common 
resistance-associated mutations to first-line and second-line agents, or the corresponding wild-type 
DNA sequence (for detection of resistance to anti-TB drugs) (3).
LPAs are based on reverse-hybridization DNA strip technology and involve three steps: DNA extraction 
from M. tuberculosis culture isolates or directly from patient specimens, followed by multiplex PCR 
amplification and then reverse hybridization with visualization of amplicon binding (or lack thereof ) 
to wild-type and mutation probes (4).
Although LPAs are more technically complex to perform than the Xpert MTB/RIF assay, they can detect 
isoniazid resistance. Testing platforms have been designed for a reference laboratory setting and are 
thus most applicable to high TB burden countries. Results can be obtained in 5 hours.
Some of these steps can be automated, making the method quicker and more robust, and reducing 
the risk of contamination. 
The Hain version 1 and version 2 assays include rpoB probes to detect rifampicin resistance, katG 
probes to detect mutations associated with high-level isoniazid resistance, and inhA promoter probes 
to detect mutations usually associated with low-level isoniazid resistance. The probes used to detect 
wild-type and specific mutations are the same for both versions of the Hain LPA (Fig. 3.1a). 
Similarly, the Nipro assay allows for the identification of MTBC, and resistance to rifampicin and 
isoniazid. The Nipro assay also differentiates M. avium, M. intracellulare and M. kansasii from other 
non-tuberculous mycobacteria (Fig. 3.1b).
The rpoB, katG and inhA promoter mutation probes are the same for the three assays, with the 
exception of the katG S315N mutation, which is included in the Nipro assay but not in Hain version 1 
or version 2. There are some minor variations in the codon regions covered for the wild type among 
Hain version 1 and version 2, and the Nipro. 
Recommendations 51
Fig. 3.1. Examples of different line probe assay strip readouts: (a) Hain GenoType 
MTBDRplus version 1 and version 2 (Hain Lifescience, Nehren, Germany) and 
(b) Nipro NTM+MDRTB Detection Kit 2 (Nipro, Tokyo, Japan)
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testing of sputum samples from patients with signs 
and symptoms of TB, as well as in the indirect 
testing of cultures of MTBC.
The evidence reviewed and this policy guidance 
apply to the use of only these commercial assays. 
Other assays for detecting MTBC and resistance 
to rifampicin and isoniazid were not evaluated. 
Any new or generic assay intended to detect the 
presence of MTBC and mutations associated with 
drug resistance to rifampicin and isoniazid should 
be adequately evaluated and validated in the 
settings where it is intended to be used, as per 
WHO’s policy.4
1.1 Index tests
The Hain version 1 and version 2 assays include 
rpoB probes to detect rifampicin resistance, katG 
probes to detect mutations associated with high-
level isoniazid resistance, and inhA probes to 
detect mutations usually associated with low-level 
isoniazid resistance. The probes used to detect 
wild-type and specific mutations are the same 
for both versions of the Hain LPA (Fig. 1a). The 
Nipro assay underwent Japanese registration in 
2012 and allows for the identification of MTBC 
and resistance to rifampicin and isoniazid. The 
Nipro assay also differentiates M. avium, M. 
intracellulare and M. kansasii from other non-
tuberculous mycobacteria (Fig. 1b).
The rpoB, katG and inhA mutation probes are 
the same for the three assays with the exception 
of the katG S315N mutation, which is included 
in the Nipro assay but not in Hain version 1 or 
version 2. There are some minor variations in the 
codon regions covered for the wild type among 
Hain version 1 and version 2 and the Nipro. 
Fi ure 1. Exampl   fferent line probe assay strip readouts: (a) H in Ge oType MTBDRplus 
version 1 and ve i n 2 (Hain Life cie ce, Nehren, Germany) and (b) Nipro NTM+MDRTB Detection 
Kit 2 (Nipro, Tokyo, Japan)
(a) (b)
Picture: Courtesy of FIND
4 Implementing tuberculosis diagnostics: policy framework. Geneva: World Health Organization; 2015 (WHO/HTM/
TB/2015.11; http://apps.who.int/iris/bitstream/10665/162712/1/9789241508612_eng.pdf, accessed 18 April 2016).
a  b
Source: Courtesy of the Foundation for Innovative New Diagnostics (FIND).
3.4 Justification and evidence
In 2015, WHO commissioned an updated systematic review of the accuracy of commercial LPAs for 
detecting MTBC, and resistance to rifampicin and isoniazid. A total of 74 studies were identified, 
comprising 94 unique datasets (see Annex 1.3). Of these 94 datasets, 83 evaluated Hain version 1, 
five evaluated Hain version 2, and six evaluated the Nipro assay. Only one of the studies performed 
head-to-head testing of all three target LPAs on directly tested clinical specimens and indirectly tested 
isolates, and these data were included as six separate datasets (16). No studies performed LPA testing 
on specimens and culture isolates from the same patients, precluding direct within-study comparisons.
Following the 2015 systematic review, WHO’s Global TB Programme convened a GDG in March 2016 
to assess the data and update the 2008 policy recommendations on using commercial LPAs to detect 
MTBC, and resistance to isoniazid and rifampicin. The PICO questions are given in Box 3.1.
LPAs were compared with a phenotypic culture-based DST reference standard, and a composite 
reference standard that combined the results from genetic sequencing with results from phenotypic 
culture-based DST. Phenotypic DST was the primary reference standard applied to all participants 
for all analyses. These analyses were stratified – first, by susceptibility or resistance to rifampicin or 
isoniazid (or both) and second, by type of LPA testing (indirect testing or direct testing).
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1. Should LPAs be used to guide clinical decisions to use rifampicin in the direct testing 
of specimens and the indirect testing of culture isolates from patients with signs and 
symptoms consistent with TB?
2. Should LPAs be used to guide clinical decisions to use isoniazid in the direct testing 
of specimens and the indirect testing of culture isolates from patients with signs and 
symptoms consistent with TB?
3. Should LPAs be used to diagnose MDR-TB in patients with signs and symptoms consistent 
with TB?
4. Should LPAs be used to diagnose TB in patients with signs and symptoms consistent with 
TB but for whom sputum-smear results are negative?
Box 3.1. PICO questions
Several studies contributed to either sensitivity (no true negatives and no false positives) or specificity 
(no true positives and no false negatives) but not to both. For these studies, a univariate, random 
effects meta-analysis of the estimates of sensitivity or specificity was performed separately, to make 
optimal use of the data. The results from the univariate analysis (using all studies) were compared 
with the results from the bivariate analysis of the subset of studies that contributed to estimates of 
both sensitivity and specificity. 
If there were at least four studies for index tests with data that contributed only to sensitivity or 
specificity, a univariate, random effects meta-analysis was performed to assess one summary estimate, 
assuming no correlation between sensitivity and specificity. In cases in which there were fewer 
than four studies, or where substantial heterogeneity was evident on forest plots that precluded a 
meta-analysis, a descriptive analysis was performed for these index tests. Forest plots were visually 
assessed for heterogeneity among the studies within each index test and in the summary plots, for 
variability in estimates and the width of the prediction region (a wider prediction region suggests 
more heterogeneity). 
The performance of the tests is summarized in Table 3.1. The results are based on various numbers 
of studies and specimens tested. In some cases, too few studies were available for meta-analysis. The 
results from the only head-to-head comparison of the three tests are presented in the right-hand 
columns for comparison. The data presented are all comparisons with phenotypic culture-based DST 
as the reference standard.
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Table 3.1. Performance of the three LPA tests for detection of rifampicin 
and isoniazid resistance with phenotypic culture-based DST as the reference 
standard
Meta-analysis pooled 
performance
Nathavitharana et al. 
2017 (16)a
  Line probe 
assay
Sensitivity 
(%)b
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
Rifampicin 
sputum 
specimens
Hain version 1 96.8 
(94.7–98.1)
98.1 
(96.9–98.8)
97.1 
(93.3–99.0)
97.1 
(94.3–98.7)
Hain version 2 95.8 
(92.6–97.6)
98.4 
(96.9–99.2)
98.2 
(95.0–99.6)
97.8 
(95.3–99.2)
Nipro 75–100c 96.5–100c 96.5 
(92.5–98.7)
97.5 
(94.8–99.0)
 
Isoniazid 
sputum 
specimens
Hain version 1 88.4 
(84.4–91.6)
98.3 
(97.4–98.9)
94.4 
(90.2–97.2)
96.4 
(93.2–98.3)
Hain version 2 94.5 
(91.4–96.5)
99.3 
(92.6–100.0)
95.4 
(91.5–97.9)
98.8 
(96.5–99.8)
Nipro 50–94.9c 96.5–97.8c 94.9 
(90.9–97.5)
97.6 
(94.8–99.1)
Rifampicin 
culture 
isolates
Hain version 1 97.3 
(95.7–98.3)
99.5 
(98.8–98.8)
91.3 
(86.0–95.0)
97.1 
(94.3–98.7)
Hain version 2 91.3d 98.0d 91.3 
(86.0–95.0)
97.1 
(94.3–98.7)
Nipro 92.8–98.9 c 97.3–98.2c 92.4 
(87.4–95.9)
97.5 
(94.3–99.2)
Isoniazid  
culture 
isolates
Hain version 1 91.5 
(89.0–93.5)
99.8 
(99.3–100)
89.4 
(84.3–93.3)
98.9 
(96.0–99.9)
Hain version 2 89.4d 98.9d 89.4 
(84.3–93.3)
98.9 
(96.0–99.9)
Nipro 61.6–91.6C 99.4–100c 89.9 
(84.9–93.8)
99.4 
(96.9–100)
DST: drug-susceptibility testing; LPA: line probe assay.
a Results of the head-to-head comparison of the three LPA tests by Nathavitharana et al. 2017. (16) 
b Sensitivity and specificity values are shown with 95% confidence interval in parenthesis. 
c Less than four studies – meta-analysis not possible.
d One study.
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3.5 Implementation considerations
Adopting LPAs for detecting rifampicin and isoniazid resistance does not eliminate the need for 
capacity for conventional culture and DST. Culture and phenotypic culture-based DST have critical 
roles in monitoring patients’ responses to treatment and detecting additional resistance to second-
line agents.
• The adoption of LPA should be phased in, starting at national or central reference laboratories, or 
those with proven capability to conduct molecular testing. Expansion could be considered, within 
the context of a country’s plans for laboratory strengthening, the availability of suitable personnel 
in peripheral centres and the quality of specimen transport systems.
• Adequate and appropriate laboratory infrastructure and equipment should be provided, to ensure 
that the required precautions for biosafety and the prevention of contamination are met – specimen 
processing for culture and procedures for manipulating cultures must be performed in biological 
safety cabinets in TB-containment laboratories.
• Laboratory facilities for LPAs require at least three separate rooms, one each for DNA extraction, 
pre-amplification procedures, and amplification and post-amplification procedures. To avoid 
contamination, access to molecular facilities must be restricted, a unidirectional workflow must be 
implemented and stringent cleaning protocols must be established.
• Appropriate laboratory staff should be trained to conduct LPA procedures. Staff should be 
supervised by a senior staff member with adequate training and experience in molecular assays. 
A programme for the external quality assessment of laboratories using LPAs should be developed 
as a priority. 
• Mechanisms for rapidly reporting LPA results to clinicians must be established, to provide patients 
with the benefit of early diagnosis. The same infrastructure used for performing LPAs can be used 
also to perform second-line LPAs.
• LPAs are designed to detect TB and resistance to rifampicin and isoniazid in the direct testing 
of processed sputum samples, and in the indirect testing of culture isolates of MTBC. The use 
of LPAs with other respiratory samples (e.g. from bronchoalveolar lavage or gastric aspiration) 
or extrapulmonary samples (e.g. tissue samples, CSF or other body fluids) have not been 
adequately evaluated.
• The availability of second-line agents is critical in the event that resistance to rifampicin or isoniazid, 
or both, is detected.
• For patients with confirmed MDR- or rifampicin-resistant TB (MDR/RR-TB), second-line LPAs are 
recommended to detect additional resistance to second-line anti-TB agents.
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Section 4. Second-line LPAs
Genotypic (molecular) methods have considerable advantages for scaling up programmatic 
management and surveillance of drug-resistant TB, offering rapid diagnosis, standardized testing, 
potential for high throughput and fewer requirements for laboratory biosafety. Molecular tests for 
detecting drug resistance – for example, the GenoType MTBDRsl assay (Hain Lifescience, Nehren, 
Germany), hereafter referred to as MTBDRsl (17) – have shown promise for the diagnosis of drug-
resistant TB. These tests are rapid (can be performed in a single working day) and detect the presence 
of mutations associated with drug resistance. MTBDRsl belongs to a category of molecular genetic 
tests called second-line LPAs (SL-LPAs).
MTBDRsl (version 1.0) was the first commercial SL-LPA for detection of resistance to second-line TB 
drugs. In 2015, the manufacturer developed and made commercially available version 2.0 of the 
MTBDRsl assay. Version 2.0 detects the mutations associated with fluoroquinolones and second-line 
injectable drug (SLID) resistance detected by version 1.0, and additional mutations. Once a diagnosis 
of MDR/RR-TB has been established, an SL-LPA can be used to detect additional resistance to second-
line drugs. 
The MTBDRsl assay incorporates probes to detect mutations within genes that are associated with 
resistance to either fluoroquinolones or SLIDs (gyrA and rrs for version 1.0 and those genes plus 
gyrB and the eis promoter for version 2.0). The presence of mutations in these regions does not 
necessarily imply resistance to all the drugs within a particular class. Although specific mutations within 
these regions may be associated with different levels of resistance (i.e. different minimum inhibitory 
concentrations) to each drug within these classes, the extent of cross-resistance is not completely 
understood. 
4.1 Recommendations
4.1 For patients with confirmed MDR/RR-TB, SL-LPA may be used as the initial test, instead 
of phenotypic culture-based DST, to detect resistance to fluoroquinolones. 
4.2 For patients with confirmed MDR/RR-TB, SL-LPA may be used as the initial test, instead 
of phenotypic culture-based DST, to detect resistance to the SLIDs.
4.2 Remarks
• These recommendations apply to the use of SL-LPA for testing sputum specimens (direct testing) 
and cultured isolates of M. tuberculosis (indirect testing) from both pulmonary and extrapulmonary 
sites. Direct testing on sputum specimens allows for the earlier initiation of appropriate treatment. 
• These recommendations apply to the direct testing of sputum specimens from MDR/RR-TB, 
irrespective of the smear status, while acknowledging that the indeterminate rate is higher when 
testing smear-negative sputum specimens than with smear-positive sputum specimens.
• These recommendations apply to the diagnosis of extensively drug-resistant TB (XDR-TB), while 
acknowledging that the accuracy for detecting resistance to the fluoroquinolones and to the SLIDs 
differs, and hence the accuracy of a diagnosis of XDR-TB overall is reduced.
• These recommendations do not eliminate the need for conventional phenotypic DST capacity, 
which will be necessary to confirm resistance to other drugs and to monitor the emergence of 
additional drug resistance.
• Conventional phenotypic DST can still be used in the evaluation of patients with negative SL-LPA 
results, particularly in populations with a high pretest probability for resistance to fluoroquinolones 
or SLID (or both).
WHO consolidated guidelines on tuberculosis: 
rapid diagnostics for tuberculosis detection56
• These recommendations apply to the use of SL-LPA in children with confirmed MDR/RR-TB, based 
on the generalization of data from adults.
• Resistance-conferring mutations detected by SL-LPA are highly correlated with phenotypic resistance 
to ofloxacin and levofloxacin. However, the correlation of these mutations with phenotypic resistance 
to moxifloxacin and gatifloxacin is unclear, and the inclusion of moxifloxacin or gatifloxacin in an 
MDR-TB regimen is best guided by phenotypic DST results.
• Resistance-conferring mutations detected by SL-LPA are highly correlated with phenotypic resistance 
to SLID and are an indication to use an MDR-TB regimen that is appropriately strengthened.
• Given the high specificity for detecting resistance to fluoroquinolones and SLID, the positive results 
of SL-LPA could be used to guide the implementation of appropriate infection control precautions.
4.3 Test description
The SL-LPA is based on the same principle as the first-line LPA. The assay procedure can be performed 
directly using a processed sputum sample or indirectly using DNA isolated and amplified from a 
culture of M. tuberculosis. Direct testing involves the following steps: 
1. Decontamination (e.g. with sodium hydroxide) and concentration of a sputum specimen 
by centrifugation.
2. Isolation and amplification of DNA.
3. Detection of the amplification products by reverse hybridization.
4. Visualization using a streptavidin-conjugated alkaline phosphatase colour reaction. 
Indirect testing includes only Steps 2–4. The observed bands, each corresponding to a wild-type or 
resistance-genotype probe, can be used to determine the drug susceptibility profile of the analysed 
specimen. The assay can be performed and completed within a single working day. 
The index test used was MTBDRsl, and the different characteristics of versions 1.0 and 2.0 are 
presented in Table 4.1. SL-LPAs detect specific mutations associated with resistance to the class of 
fluoroquinolones (including ofloxacin, levofloxacin, moxifloxacin and gatifloxacin) and SLIDs (including 
kanamycin, amikacin and capreomycin) in the MTBC. Version 1.0 detects mutations in the gyrA 
quinolone resistance-determining region (codons 85–97) and rrs (codons 1401, 1402 and 1484). 
Version 2.0 additionally detects mutations in the gyrB quinolone resistance-determining region 
(codons 536–541) and the eis promoter region (codons –10 to –14) (17). Mutations in these regions 
may cause additional resistance to the fluoroquinolones or SLIDs, respectively; thus, version 2.0 is 
expected to have improved sensitivity for resistance to these drug classes. Mutations in some regions 
(e.g. the eis promoter region) may be responsible for causing resistance to one drug in a class more 
than other drugs within that class. For example, the eis C14T mutation is associated with kanamycin 
resistance in strains from Eastern Europe (18). Version 1.0 also detects mutations in embB that may 
encode for resistance to ethambutol. Because ethambutol is a first-line drug and was omitted from 
version 2.0, this review did not determine the accuracy for ethambutol resistance.
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Table 4.1. Characteristics of GenoType MTBDRsl versions 1.0 and 2.0, as per 
manufacturer 
Detection
Version 1.0
MTBC and resistance to 
fluoroquinolones, SLIDs and 
ethambutol
Version 2.0
MTBC and resistance to 
fluoroquinolones and SLIDs
Samples Smear-positive specimens and 
culture isolates
Smear-positive and smear-negative 
specimens and culture isolates
Fluoroquinolone 
resistance
Mutations in the resistance-
determining region of the gyrA 
gene
Mutations in the resistance-
determining regions of the gyrA and 
gyrB genes
SLID resistance Mutations in the resistance-
determining region of the rrs 
gene
Mutations in the resistance-
determining region rrs gene and the 
eis promoter region
Ethambutol 
resistance
Mutations in the embB gene Not included
MTBC: Mycobacterium tuberculosis complex; SLID: second-line injectable drug.
More data are needed to better understand the correlation of the presence of certain fluoroquinolone 
resistance-conferring mutations with phenotypic DST resistance and with patient outcomes.
Fig. 4.1 shows an example of MTBDRsl results for version 1.0 and 2.0. A band for the detection of 
the MTBC (the “TUB” band) is included, as well as two internal controls (conjugate and amplification 
controls), and a control for each gene locus (version 2.0: gyrA, gyrB, rrs, eis). The two internal controls 
plus each gene locus control should be positive, otherwise the assay cannot be evaluated for that 
particular drug. A result can be indeterminate for one locus but valid for another (on the basis of a 
gene-specific locus control failing).
Fig. 4.1. Examples of different GenoType MTBDRsl strip readouts
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Direct detection and drug susceptibility testing
GenoType MTBDRsl
Benefi ts of using GenoType MTBDRsl
Sensitive detection: The fi rst version of GenoType MTBDRsl can be processed from smear-positive pulmonary or 
cultivated samples. The second version is even more sensitive and can therefore also be performed using smear-
negative pulmonary samples.
Effi cient diagnosis: Both test systems are perfectly suitable for the detection of XDR-TB in patients previously diagnosed 
with MDR-TB. For step-wise diagnostics the test systems can be performed subsequent to GenoType MTBDRplus using 
the same DNA isolate.
Rapid results: Results are available within fi ve hours in comparison to several weeks when using conventional methods.
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Molecular genetic assay for detection of M. tuberculosis complex and its resistances to fl uoro-
quinolones and aminoglycosides/cyclic peptides (and ethambutol)
Test principle of GenoType MTBDRsl
GenoType MTBDRsl is based on PCR and the DNA•STRIP technology. Mycobacterial DNA is extracted from the pati-
ent specimen or cultivated material, specifi cally amplifi ed via PCR and detected on a membrane strip using reverse 
hybridization and an enzymatic colour reaction. 
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Amplification Control 
M. tuberculosis complex 
gyrA Locus Control (gyrA)
gyrA wild type probe 1 (gyrA WT1)
gyrA wild type probe 2 (gyrA WT2)
gyrA wild type probe 3 (gyrA WT3)
gyrA mutation probe 1 (gyrA MUT1)
gyrA mutation probe 2 (gyrA MUT2)
gyrA mutation probe 3A (gyrA MUT3A)
gyrA mutation probe 3B (gyrA MUT3B)
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embB Locus Control (embB)
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embB mutation probe 1A (embB MUT1A)
embB mutation probe 1B (embB MUT1B)
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eis Locus Control (eis)
eis wild type probe 1 (eis WT1)
eis wild type probe 2 (eis WT2)
eis wild type probe 3 (eis WT3)
eis mutation probe 1 (eis MUT1)
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M. tuberculosis complex 
gyrA Locus Control (gyrA)
gyrA wild type probe 1 (gyrA WT1)
gyrA wild type probe 2 (gyrA WT2)
gyrA wild type probe 3 (gyrA WT3)
gyrA mutation probe 1 (gyrA MUT1)
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M. tuberculosis complex and its 
resistances to fl uoroquinolones, amino-
glycosides/cyclic peptides and ethambutol
smear-positive 
pulmonary and cultivated samples

-
-
M. tuberculosis complex and its 
resistances to fl uoroquinolones and ami-
noglycosides/cyclic peptides
smear-positive and -negative
pulmonary and cultivated samples
-


Mutations in the embB gene that are involved in ethambutol resistance
Mutations in the gyrB gene that are involved in fl uoroquinolone resistance
Mutations in the eis gene that are involved in kanamycin resistance
GenoType MTBDRsl VER 1.0 GenoType MTBDRsl VER 2.0 
Kanamycin
Fluoroquinolone
Ethambutol
Detection of
Sample Material
Direct detection and drug susceptibility testing
GenoType MTBDRplus VER 2.0
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The GenoType MTBDRplus enables the simultaneous molecular genetic identifi cation of
• the M. tuberculosis complex 
• its resistance to rifampicin by the detection of the most common mutations in the rpoB gene
• its resistance to isoniazid (For the detection of high level isoniazid resistance the katG gene and for low level isoniazid 
resistance the promoter region of the inhA gene is examined.)
from smear-positive or -negative pulmonary clinical specimens or cultivated samples.
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Benefi ts of using GenoType MTBDRplus
• Effi cient: M. tuberculosis complex and its resistances to rifampicin and isoniazid are simultaneously detected in a 
single patient specimen. The test is therefore perfectly suitable for MDR-TB screening, for the identifi cation of MTB 
complex and mono-resistances. Pulmonary patient specimens and cultivated samples can be used as starting ma-
terial.
• Rapid: Results are available within fi ve hours compared to several months with conventional DST.
• User-friendly: A ready-to-use amplifi cation mix including the Taq polymerase is provided with the kit.
• Flexible: DNA extraction can be performed either manually or automated using the nucleic acid isolation instrument 
GenoXtract®. Amplifi cation, detection and evaluation can also be automated. The test is thus suitable for low, mid 
and high throughput.
• Cost-effi cient: For the implementation only minimum technical equipment is required, therefore an economical set-
up is possible for laboratories of every potential size.
Molecular genetic assay for detection of M. tuberculosis complex and its resistances to rifampicin 
and/or isoniazid
Test principle of GenoType MTBDRplus
GenoType MTBDRplus is based on PCR and the DNA•STRIP technology. Mycobacterial DNA is extracted from the pa-
tient specimen or cultivated material, specifi cally amplifi ed via PCR and detected on a membrane strip using reverse 
hybridization and an enzymatic colour reaction. Valid results are documented by internal controls, Conjugate and 
Amplifi cation Control. 
(CC)
(AC)
(TUB)
(CC)
(AC)
(TUB)
Source: Courtesy of the Foundation for Innovative New Diagnostics (FIND).
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A template is supplied by the manufacturer to help the user to read the strips where the banding 
patterns are scored by eye, transcribed and reported. In high-volume settings, the GenoScan®, an 
automated reader, can be incorporated to interpret the banding patterns automatically and give a 
suggested interpretation. If the operator agrees with the interpretation, the results are automatically 
uploaded, thereby reducing possible transcription errors. 
4.4 Justification and evidence
In March 2016, WHO’s Global TB Programme convened a GDG to assess available data on the use 
of the MTBDRsl assay. WHO commissioned a systematic review on the accuracy and clinical use of 
assays for the detection of mutations associated with resistance to fluoroquinolones and SLID in 
people with MDR/RR-TB.
The PICO questions in Box 4.1 were designed to form the basis for the evidence search, retrieval and 
analysis. 
1. Should the MTBDRsl test be used to guide clinical decisions to use fluoroquinolones 
in patients with confirmed MDR/RR-TB? 
 y Direct testing (stratified by smear grade: smear negative; scanty; 1+; ≥2+).
 y Indirect testing.
2. Should the MTBDRsl test be used to guide clinical decisions to use SLIDs in patients 
diagnosed with MDR/RR-TB?
 y Direct testing (stratified by smear grade: smear negative; scanty; 1+; ≥2+).
 y Indirect testing.
Box 4.1. PICO questions
Twenty-nine unique studies were identified; of these, 26 evaluated the MTBDRsl version 1.0 assay 
(including 21 studies from the original Cochrane review). Three studies (one published and two 
unpublished) evaluated version 2.0. Data for version 1.0 and version 2.0 of the MTBDRsl assay were 
analysed separately. A phenotypic culture-based DST reference standard was used for the primary 
analyses. These analyses were stratified first by susceptibility or resistance to a particular drug, and 
second by type of SL-LPA testing (indirect testing or direct testing). 
4.4 Performance of SL-LPA on sputum specimens and culture isolates
In patients with MDR/RR-TB, a positive SL-LPA result for fluoroquinolone resistance (as a class) or SLID 
resistance (as a group) can be treated with confidence. The diagnostic accuracy of SL-LPA is similar 
when performed directly on sputum specimens or indirectly on cultured isolates of M. tuberculosis. 
Given the confidence in a positive result and the ability of the test to provide rapid results, the GDG 
felt that SL-LPA may be considered for use as an initial test for resistance to the fluoroquinolones 
and SLIDs. However, when the test shows a negative result, phenotypic culture-based DST may be 
necessary, especially in settings with a high pretest probability for resistance to either fluoroquinolones 
or SLIDs (or both). The use of SL-LPA in routine care should improve the time to the diagnosis of 
fluoroquinolone and SLIDs, especially when used for the direct testing of sputum specimens of patients 
with confirmed MDR/RR-TB. Early detection of drug resistance should allow for the earlier initiation of 
appropriate patient therapy and improved patient health outcomes. Overall, the test performs well 
in the direct testing of sputum specimens from patients with confirmed MDR/RR-TB, although the 
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indeterminate rate is higher when testing smear-negative sputum specimens compared with smear-
positive sputum specimens. 
When the MTBDRsl assay is used in the direct testing of smear-negative sputum specimens from a 
population of patients with confirmed drug-resistant TB, up to 44% of the results may be indeterminate 
(less with version 2.0, although very limited data) and hence require repeat or additional testing. 
However, if the same test were to be applied to the testing of smear-negative sputum specimens from 
patients without confirmed TB or drug-resistant TB (i.e. patients suspected of having drug-resistant 
TB), the indeterminate rate for the test would be significantly higher. Given the test’s sensitivity and 
specificity when an SL-LPA is done directly on sputum, the GDG felt that SL-LPAs can be used for the 
testing of all sputum specimens from patients with confirmed MDR/RR-TB, irrespective of whether 
the microscopy result is positive or negative. 
Table 4.2. Accuracy of GenoType MTBDRsl (version 1.0) for fluoroquinolone 
and SLID resistance and XDR-TB, indirect and direct testing (smear-positive 
specimens), culture-based DST reference standard
Pooled 
sensitivity 
(95% CI)
Pooled 
specificity 
(95% CI)
Pooled 
sensitivity 
(95% CI)
Pooled 
specificity 
(95% CI)
Pooled 
sensitivity 
P valuea
Pooled 
specificity 
P valuea
Fluoroquinolones, 
indirect testing 
(19 studies, 2223 participants)
Fluoroquinolones, 
direct testing
(9 studies, 1771 participants)
85.6% 
(79.2–90.4%)
98.5% 
(95.7–99.5%)
86.2% 
(74.6–93.0%)
98.6% 
(96.9–99.4%)
0.932 0.333
SLID, indirect testing
(16 studies, 1921 participants)
SLID, direct testing
(8 studies, 1639 participants)
76.5% 
(63.3–86.0%)
99.1% 
(97.3–99.7%)
87.0% 
(38.1–98.6%)
99.5% 
(93.6–100.0%)
0.547 0.664
XDR-TB, indirect testing 
(8 studies, 880 participants)
XDR-TB, direct testing 
(6 studies, 1420 participants)
70.9% 
(42.9–88.8%)
98.8% 
(96.1–99.6%)
69.4% 
(38.8–89.0%)
99.4% 
(95.0–99.3%)
0.888 0.855
CI: confidence interval: DST: drug-susceptibility testing; SLID: second-line injectable drugs; XDR-TB: extremely drug-resistant tuberculosis.
a   Likelihood ratio test for evidence of a significant difference between accuracy estimates.
For the reasons mentioned above (inadequate data owing to too few studies on version 2.0), results 
are not presented here for version 2.0. For MTBDRsl version 2.0, the data were either too sparse or 
too heterogeneous to combine in a meta-analysis or to compare indirect and direct testing.
Three studies evaluated the MTBDRsl version 2.0 in 562 individuals, including 111 confirmed cases 
of TB with fluoroquinolone resistance by indirect testing on a culture of M. tuberculosis compared 
with a phenotypic culture-based DST reference standard. Estimates of sensitivity ranged from 84% 
to 100% and specificity from 99% to 100%.
See Web Annex 4.8 for details of the drug concentrations used in culture-based DST to evaluate 
the performance of SL-LPAs in each included study.
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4.5 Implementation considerations
The SL-LPA should only be used to test specimens from patients with confirmed MDR/RR-TB. Adoption 
of SL-LPAs does not eliminate the need for conventional culture and DST capability. Despite good 
specificity of SL-LPAs for the detection of resistance to fluoroquinolones and the SLIDs, culture and 
phenotypic DST is required to completely exclude resistance to these drug classes as well as to other 
second-line drugs. The following implementation considerations apply:
• SL-LPAs cannot determine resistance to individual drugs in the class of fluoroquinolones. Resistance-
conferring mutations detected by SL-LPAs are highly correlated with phenotypic resistance to 
ofloxacin and levofloxacin. However, the correlation of these mutations with phenotypic resistance 
to moxifloxacin and gatifloxacin is unclear, and the inclusion of moxifloxacin or gatifloxacin in an 
MDR-TB regimen is best guided by phenotypic DST results.
• Mutations in some regions (e.g. the eis promoter region) may be responsible for causing resistance 
to one drug in a class more than other drugs within that class. For example, the eis C14T mutation 
is associated with kanamycin resistance in strains from Eastern Europe.
• SL-LPAs should be used in the direct testing of sputum specimens, irrespective of whether samples 
are smear negative or smear positive.
• SL-LPAs are designed to detect TB and resistance to fluroquinolones and SLIDs from sputum samples. 
Other respiratory samples (e.g. bronchoalveolar lavage and gastric aspirates) or extrapulmonary 
samples (tissue samples, CSF or other body fluids) have not been adequately evaluated.
• Culture and phenotypic DST plays a critical role in the monitoring of a patient’s response to 
treatment, and in detecting additional resistance to second-line drugs during treatment.
• SL-LPAs are suitable for use at the central or national reference laboratory level; they can also be 
used at the regional level if the appropriate infrastructure can be ensured (three separate rooms 
are required).
• All patients identified by SL-LPAs should have access to appropriate treatment and 
ancillary medications.
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Section 5. Lateral flow urine lipoarabinomannan assay
Tests based on the detection of the lipoarabinomannan (LAM) antigen in urine have emerged as 
potential point-of-care tests for TB. The currently available urinary LAM assays have suboptimal 
sensitivity, and are therefore not suitable as general diagnostic tests for TB. However, unlike traditional 
diagnostic methods, they demonstrate improved sensitivity for the diagnosis of TB among individuals 
coinfected with HIV. The estimated sensitivity is even greater in patients with low CD4 cell counts. The 
lateral flow urine LAM assay (LF-LAM) strip-test – the Alere Determine TB LAM Ag (USA), hereafter 
referred to as AlereLAM – is currently the only commercially available urinary LAM test that potentially 
could be used as a rule-in test for TB in patients with advanced HIV-induced immunosuppression, 
and facilitate the early initiation of anti-TB treatment. 
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5.1 Recommendations
In inpatient settings
5.1 WHO strongly recommends using LF-LAM to assist in the diagnosis of active TB in 
HIV-positive adults, adolescents and children: 
1. with signs and symptoms of TB (pulmonary and/or extrapulmonary)  
(strong recommendation, moderate certainty in the evidence about the intervention 
effects); or 
2. with advanced HIV disease15 or who are seriously ill16  
(strong recommendation, moderate certainty in the evidence about the intervention 
effects) [1];17 or
3. irrespective of signs and symptoms of TB and with a CD4 cell count of less than 
200 cells/mm3  
(strong recommendation, moderate certainty in the evidence about the intervention 
effects) [2].
In outpatient settings
5.2 WHO suggests using LF-LAM to assist in the diagnosis of active TB in HIV-positive 
adults, adolescents and children: 
1. with signs and symptoms of TB (pulmonary and/or extrapulmonary) or seriously ill  
(conditional recommendation, low certainty in the evidence about test accuracy) [3]; 
and 
2. irrespective of signs and symptoms of TB and with a CD4 cell count of less than 
100 cells/mm3  
(conditional recommendation, very low certainty in the evidence about test 
accuracy) [4].
In outpatient settings
5.3 WHO recommends against using LF-LAM to assist in the diagnosis of active TB in 
HIV-positive adults, adolescents and children: 
1. without assessing TB symptoms  
(strong recommendation, very low certainty in the evidence about test accuracy) [5];
2. without TB symptoms and unknown CD4 cell count or without TB symptoms and 
CD4 cell count greater than or equal to 200 cells/mm3  
(strong recommendation, very low certainty in the evidence about test accuracy) [6]; 
and
3. without TB symptoms and with a CD4 cell count of 100–200 cells/mm3  
(conditional recommendation, very low certainty in the evidence about test 
accuracy) [7].
15 For adults, adolescents, and children aged 5 years or more, “advanced HIV disease” is defined as a CD4 cell count of less than 
200 cells/mm³ or a WHO clinical stage 3 or 4 event at presentation for care. All children with HIV aged under 5 years should be 
considered as having advanced disease at presentation.
16 “Seriously ill” is defined based on four danger signs: respiratory rate of more than 30/minute, temperature of more than 39 °C, heart 
rate of more than 120/minute and unable to walk unaided. 
17 Numbers in square brackets indicate the number of the relevant “evidence to decision” (EtD) table in Web Annex 3.
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5.2 Remarks
1. The reviewed evidence and recommendations apply to the use of AlereLAM only, because other 
in-house LAM-based assays have not been adequately validated or used outside limited research 
settings. Any new or generic LAM-based assay should be subject to adequate validation in the 
settings of intended use. 
2. All patients with signs and symptoms of pulmonary TB who are capable of producing sputum should 
submit at least one sputum specimen for Xpert MTB/RIF (Ultra) assay, as their initial diagnostic 
test. This also includes children and adolescents living with HIV who are able to provide a sputum 
sample. 
3. These recommendations also apply to adolescents and children living with HIV, based on 
generalization of data from adults, while acknowledging that there are very limited data for these 
population groups. 
4. LF-LAM should be used as an add-on to clinical judgement in combination with other tests; it 
should not be used as a replacement or triage test.
5.3 Test description
The urine-based LF-LAM AlereLAM is a commercially available point-of-care test for active 
TB (19). AlereLAM is an immunocapture assay that detects LAM antigen in urine, LAM being a 
lipopolysaccharide present in mycobacterial cell walls that is released from metabolically active or 
degenerating bacterial cells during TB disease (19, 20). 
AlereLAM is performed manually by applying 60 µL of urine to the test strip (the white pad marked 
by the arrow symbols in Fig. 5.1A) and incubating at room temperature for 25 minutes. The strip is 
then inspected by eye for visible bands. The intensity of any visible band on the test strip is graded 
by comparing it with the intensities of the bands on a manufacturer-supplied reference scale card (as 
shown in the example in Fig. 5.1). 
WHO consolidated guidelines on tuberculosis: 
rapid diagnostics for tuberculosis detection64
Fig. 5.1. Alere Determine TB LAM Ag tests (AlereLAM): (A) individual test strip, and 
(B) reference card accompanying test strips to “grade” the test result and determine 
positivity
38
plunger to collect the sample on the inside surfaces of the tube. The plunger is then 
twisted to smear the concentrated sample across the peptide-coated prism at the base 
of the tube. This coating is dry and no mixing of additional fluids is required. Each test 
takes 10 minutes to screen a patient. The limit of sensitivity of the device has not been 
determined but is anticipated to be in the range of 50–75 cfu.90 A prototype device was 
piloted in a field trial in Ethiopia where it had a sensitivity of 79%.90 Rapid Biosensor 
Systems Ltd has designed a unit with a production capacity of >500 000 per batch run, 
where the price per test would be close to US$ 5. 
Alere Inc. (USA) introduced the DetermineTM TB Lipoarabinomannan (LAM) Ag rapid 
assay (Figure 6), in 2012. This is a LF immunochromatographic strip or RDT that targets 
the LAM antigen in urine via a polyclonal antibody capture and detection method on a 
nitrocellulose strip. LAM, a lipopolysaccharide, is a metabolite of mycobacterial species 
representing a key component of the cell wall and is produced by both growing cells 
and the degradation of the cell wall.91 As such, it should be noted that this assay is 
not only specific for MTB, but will also detect the presence of other NTMs. LAM from 
mycobacterial infection anywhere in the body is ultimately expelled from the body 
in urine and can be detected in it. The test requires a 60 μL aliquot of urine, with no 
other tools necessary. The test result is visually noted on the test stripe after 25 minutes 
incubation. The simple format of the assay does not require significant training for the 
user and the product is stable for 15 months at 30 °C.
Figure 6. Determine™ TB LAM Ag rapid assay, with strip ready for use shown on the right
Source: Image reproduced with permission of Alere Inc.
Control window
Patient window
Specimen 
placed here
Individual LF-LAM strip
• Hold the card alongside the patient window and read the result
• If the result line is hard to define refer to the package insert
• Store the card in the kit pouch away from direct light and heat
• Do not use the card beyond the expiration date
Urine loading platform 
(60 µL urine)
Patient window 
(band intensity interpreted 
with reference scale card)
Control window 
(band required for valid test)
a
 b
Copyright© (2019) Abbott Inc: reproduced with permission (19).
AlereLAM is being considered as a diagnostic test that may be used in combination with existing tests 
for the diagnosis of HIV-associated TB. 
5.4 Justification and evidence
WHO commissioned a systematic review to summarize the current scientific literature on the accuracy 
of AlereLAM for the diagnosis of TB in PLHIV as part of a WHO process to develop updated guidelines 
for use of the AlereLAM assay. 
The PICO questions shown in Box 5.1 were designed to form the basis for the evidence search, 
retrieval and analysis. 
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AlereLAM is being considered as a diagnostic test that may be used in combination with existing tests 
for the diagnosis of HIV-associated TB. 
5.4 Justification and evidence
WHO commissioned a systematic review to summarize the current scientific literature on the accuracy 
of AlereLAM for the diagnosis of TB in PLHIV as part of a WHO process to develop updated guidelines 
for use of the AlereLAM assay. 
The PICO questions shown in Box 5.1 were designed to form the basis for the evidence search, 
retrieval and analysis. 
1. What is the diagnostic accuracy of LF-LAM for the diagnosis of TB in all HIV-
positive adults and children with signs and symptoms of TB? 
 y in inpatient settings (adults, adolescents and older children)
 y in outpatient settings (adults, adolescents and older children)
 y in all settings (adults, adolescents and older children)
 y in inpatient settings (children aged ≤5 years)
 y in outpatient settings (children aged ≤5 years)
 y in all settings (children aged ≤5 years)
2. What is the diagnostic accuracy of LF-LAM for the diagnosis of TB in all HIV-
positive adults and children irrespective of signs and symptoms of TB?
 y in inpatient settings (adults, adolescents and older children)
 y in outpatient settings (adults, adolescents and older children)
 y in all settings (adults, adolescents and older children)
 y in inpatient settings (children aged ≤5 years)
 y in outpatient settings (children aged ≤5 years)
 y in all settings (children aged ≤5 years)
3. What is the diagnostic accuracy of LF-LAM for the diagnosis of TB in adults with 
advanced HIV disease irrespective of signs and symptoms of TB?
 y in inpatient settings, CD4 cell count ≤200 
 y in outpatient settings, CD4 cell count ≤200
 y in all settings, CD4 cell count ≤200
 y in inpatient settings, CD4 cell count ≤100
 y in outpatient settings, CD4 cell count ≤100
 y in all settings, CD4 cell count ≤100
4. Can the use of LF-LAM in HIV-positive adults reduce mortality associated with 
advanced HIV disease?
 y in all settings
 y in inpatient settings
 y in outpatient settings
 y in individuals with CD4 cell count ≤200
 y in inpatient settings, CD4 cell count ≤200 
 y in outpatient settings, CD4 cell count ≤200
 y in individuals with CD4 cell count ≤100
 y in inpatient settings, CD4 cell count ≤100
 y in outpatient settings, CD4 cell count ≤100
Box 5.1. PICO questions
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The review identified 15 unique published studies that assessed the accuracy of AlereLAM in adults, 
and integrated nine new studies identified since the original WHO and Cochrane reviews in 2015 
and 2016, respectively (21, 22). All studies included in the systematic review were performed in 
high TB/HIV burden countries. The positive AlereLAM results were reported in accordance with the 
manufacturer’s updated recommendations for test interpretation (graded on a scale of 1 to 4, based 
on band intensity). All analyses were performed with respect to an MRS. 
The 15 included studies involved 6814 participants, of whom 1761 (26%) had TB. Eight of the studies 
evaluated the accuracy of AlereLAM for TB diagnosis in participants with signs and symptoms 
suggestive of TB; these studies involved 3449 participants, of whom 1277 (37%) had TB. Seven studies 
evaluated the accuracy of AlereLAM for diagnosis of unselected participants who may or may not 
have had TB signs and symptoms at enrolment; these studies involved 3365 participants, of whom 
439 (13%) had TB. 
All studies were performed in high TB/HIV burden countries that were classified as low-income or 
middle-income countries. The studies had substantial differences in the following characteristics: 
study population (“studies with symptomatic participants” and “studies with unselected participants”), 
setting (inpatients versus outpatients), median CD4 cell count, TB prevalence, inclusion and exclusion 
of participants based on whether or not they could produce sputum, and whether patients were 
evaluated for pulmonary TB or extrapulmonary TB, or both. 
Most studies reported that a valid AlereLAM result was obtained on the first attempt for all tests. 
Uninterpretable test results (<1%) were reported in only three studies (23–25). 
5.4 Summary of the results
For TB diagnosis in HIV-positive adults presenting with signs and symptoms of TB, the diagnostic 
accuracy of AlereLAM is as follows:
• in inpatient settings, sensitivity 52% (40–64%)18 and specificity 87% (78–93%);
• in outpatient settings, sensitivity 29% (17–47%) and specificity 96% (91–99%); and
• in all settings, sensitivity 42% (31–55%) and specificity 91% (85–95%).
For TB diagnosis in HIV-positive adults, irrespective of signs and symptoms of TB, the diagnostic 
accuracy of AlereLAM is as follows:
• in inpatient settings, sensitivity 62% (41–83%) and specificity 84% (48–96%);
• in outpatient settings, sensitivity 31% (18–47%) and specificity 95% (87–99%); and
• in all settings, sensitivity 35% (22–50%) and specificity 95% (89–98%).
18 The numbers in brackets show the 95% credible interval (CrI).
5. Additional questions: 
 y What are the comparative cost, affordability and cost–effectiveness of implementation 
of LF-LAM (AlereLAM versus FujiLAM) – based on review of the published literature 
and estimations?
 y Are there possible implications for patient equity from the implementation of LF-LAM 
(AlereLAM versus FujiLAM) – based on review of the published literature and estimations?
 y What are the human rights implications from the implementation of LF-LAM – based on 
review of the published literature and comparative analysis of the two available LF-LAM 
(AlereLAM versus FujiLAM)?
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For diagnosis of TB in adults with advanced HIV disease, irrespective of signs and symptoms of TB, 
the diagnostic accuracy of AlereLAM (limited data available) is as follows:
• in inpatient settings, CD4 cell count ≤200, sensitivity 64% (35–87%) and specificity 82% (67–93%) 
(one study);
• in outpatient settings, CD4 cell count ≤200, sensitivity 21% (8–48%) and specificity 96% (89–99%); 
• in all settings, CD4 cell count ≤200, sensitivity 26% (9–56%) and specificity 96% (87–98%);
• in inpatient settings, CD4 cell count ≤100, sensitivity 57% (33–79%) and specificity 90% (69–97%);
• in outpatient settings, CD4 cell count ≤100, sensitivity 40% (20–64%) and specificity 87% (68–
94%); and
• in all settings, CD4 cell count ≤100, sensitivity 47% (30–64%) and specificity 90% (77–96%).
For diagnosis of TB in HIV-positive children, the diagnostic accuracy of AlereLAM (limited data 
available) is as follows:
• in all settings, including all children, for individual studies, sensitivity and specificity were:
 – 42% (15–72%) and 94% (73–100%) (one study conducted in an outpatient setting); 
 – 56% (21–86%) and 95% (90–98%) (one study conducted in an inpatient setting); and 
 – 43% (23–66%) and 80% (69–88%) (one study conducted in both inpatient and outpatient 
settings). 
For use of AlereLAM to reduce mortality associated with advanced HIV disease (two randomized trials): 
• the pooled risk ratio for mortality was 0.85 (0.76–0.94); and
• the absolute effect was 35 fewer deaths per 1000 (from 14 fewer to 55 fewer) (PICO 4). 
Table 5.1 presents pooled sensitivity and specificity results for AlereLAM against an MRS grouped 
by the study population, TB diagnosis among “symptomatic participants” and TB diagnosis among 
“unselected participants”.
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Table 5.1. AlereLAM pooled sensitivity and specificity for TB diagnosis, by study population
Type of 
analysis
Symptomatic participants Unselected participants
Studies 
(total  
participants)
Participants 
with TB
Pooled 
sensitivity 
(95% CrI)
Pooled 
specificity 
(95% CrI)
Studies 
(total  
participants)
Participants 
with TB
Pooled 
sensitivity 
(95% CrI)
Pooled 
specificity 
(95% CrI)
Overall 
accuracy 
8 studies
(3449)
1277
(37%)
42%
(31–55%)
91%
(85–95%)
7 studies
(3365)
432
(13%)
35%
(22–50%)
95%
(89–98%)
By setting
Inpatient 6 studies
(2253)
868
(39%)
52% 
(40–64%)
87% 
(78–93%)
3 studies
(537)
159
(30%)
62% 
(41–83%)
84% 
(48–96%)
Outpatient 4 studies
(1196)
409
(34%)
29%
(17–47%)
96%
(91–99%)
6 studies
(2828)
273
(10%)
31%
(18–47%)
95%
(87–99%)
By CD4 cell count
CD4 >200 3 studies
(738)
163
(22%)
16% 
(8–31%)
94% 
(81–97%)
1 studya
(156)
11
(7%)
Not 
applicable
Not 
applicable
CD4 ≤200 4 studies
(1825)
722
(40%)
45% 
(31–61%)
89% 
(77–94%)
2 studies
(706)
82
(12%)
26% 
(9–56%)
96% 
(87–98%)
CD4 >100 4 studies
(1519)
425
(28%)
17% 
(10–27%)
95% 
(89–98%)
4 studies
(952)
115
(12%)
20% 
(10–35%)
98% 
(95–99%)
CD4 ≤100 4 studies
(1239)
512
(41%)
54% 
(38–69%)
88% 
(77–94%)
3 studies
(417)
130
(31%)
47% 
(40–64%)
90% 
(77–96%)
CD4 
101–200
4 studies
(586)
210
(36%)
24% 
(14–38%)
90% 
(77–96%)
1 studyb
(103)
13
(13%)
Not 
applicable
Not 
applicable
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Type of 
analysis
Symptomatic participants Unselected participants
Studies 
(total  
participants)
Participants 
with TB
Pooled 
sensitivity 
(95% CrI)
Pooled 
specificity 
(95% CrI)
Studies 
(total  
participants)
Participants 
with TB
Pooled 
sensitivity 
(95% CrI)
Pooled 
specificity 
(95% CrI)
By CD4 and setting
CD4 ≤200
inpatient
2 studies
(1009)
348
(34%)
54%
(34–73%)
80%
(58–91%)
1 studyc
(54)
14
(26%)
Not 
applicable
Not 
applicable
CD4 ≤100
inpatient
2 studies
(734)
270
(37%)
61%
(40–78%)
81%
(61–91%)
2 studies
(200)
84
(42%)
57%
(33–79%)
90%
(69–97%)
CD4 
101–200
inpatient
2 studies
(275)
78
(28%)
32%
(16–57%)
81%
(55–92%)
1 studyd
(9)
4
(44%)
Not 
applicable
Not 
applicable
CD4 ≤200
outpatient
1 studye
(249)
97
(39%)
Not 
applicable
Not 
applicable
2 studies
(652)
68
(10%)
21%
(8–48%)
96%
(89–99%)
CD4 ≤100
outpatient
1 studyf
(121)
48
(40%)
Not 
applicable
Not 
applicable
2 studies
(217)
46
(21%)
40%
(20–64%)
87%
(68–94%)
CD4 
101–200
outpatient
1 studyg
(128)
51
(40%)
Not 
applicable
Not 
applicable
1 studyh
(94)
9
(10%)
Not 
applicable
Not 
applicable
AlereLAM: Alere Determine™ TB lipoarabinomannan assay; CrI: credible interval; TB: tuberculosis.
a (7, 26), sensitivity 27% (6–61%); specificity 99% (96–100%).
b (7, 26), sensitivity 38% (14–68%); specificity 99% (94–100%).
c (7, 26), sensitivity 64% (35–87%); specificity 82% (67–93%).
d (7, 26), sensitivity 75% (19–99%); specificity 100% (48–100%).
e (4, 23), sensitivity 24% (16–33%); specificity 94% (89–97%).
f (4, 23), sensitivity 30% (18–46%); specificity 93% (85–98%).
g (4, 23), sensitivity 18% (8–31%); specificity 95% (87–99%).
h (7, 26), sensitivity 22% (3–60%); specificity 99% (94–100%).
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More details are given in Web Annex 4.9 LF-LAM for detecting active tuberculosis in people living 
with HIV: an updated systematic review. 
5.5 Cost–effectiveness analysis
Economic evidence for the implementation and scale-up of LF-LAM is limited. The studies that have 
been done show a consistent trend, suggesting that LF-LAM could be cost effective in a population 
of African adults living with HIV (particularly among hospitalized patients). 
More details are given in Web Annex 4.10 Economic evaluations of LF-LAM for the diagnosis of 
active tuberculosis in HIV-positive individuals: an updated systematic review. 
5.6 User perspective
For a qualitative study on user perspectives, 15 semi-structured interviews were conducted during 
February and March 2019 with clinicians, nurses, programme officers, laboratory staff and patient 
advocates in Kenya, South Africa and Uganda. The results showed that LF-LAM clearly addresses a 
need and makes an important difference in a population in which TB is hard to diagnose. In line with 
the global discourse on LF-LAM, the participants in this study generally saw LF-LAM as an easy-to-use, 
rapid test that requires little maintenance and equipment, and crucially does not rely on sputum but 
on urine, a specimen that is easier to obtain and safer to work with. However, the perceived benefits 
of specimen, turnaround time, user friendliness, cost and maintenance requirements can also pose a 
challenge, depending on the particular situation and the capacities in which the test is used. Similarly, 
the infrastructure requirements are minimal but there can still be challenges with stock-outs, lack of 
urine containers and shelf life. Finally, even though the turnaround time is in theory only 25 minutes, 
in many settings, treatment is not initiated until the next day.
Overall, the results from the qualitative study suggest that the benefits outweigh the challenges, 
especially given the absence of viable diagnostic alternatives for this particular patient group. These 
results also show that it is essential to pay attention to how diagnostics are operationalized. Just 
because a technology is quicker, easier to conduct and cheaper than existing diagnostics, this does 
not mean it is necessarily more successful in being implemented.
More details are given in Web Annex 4.11 User perspectives on TB-LAM for the diagnosis of active 
tuberculosis: results from qualitative research. 
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5.7 Summary of changes between the 2015 guidance and the 2019 update 
The use of lateral flow urine 
lipoarabinomannan assay (LF-LAM) 
for the diagnosis and screening of 
active tuberculosis in people living 
with HIV. Policy guidance (2015) (22)
Lateral flow urine lipoarabinomannan assay (LF-LAM) for 
the diagnosis of active tuberculosis in people living with 
HIV. Policy update (2019) (27)
Changes
LF-LAM may be used to assist in the 
diagnosis of TB in HIV-positive adults 
in patients with signs and symptoms of 
TB (pulmonary and/or extrapulmonary) 
who have a CD4 cell count ≤100 cells/
µL, or HIV-positive patients who are 
seriously illa regardless of CD4 cell 
count or with unknown CD4 cell count 
(conditional recommendation, low quality 
of evidence).
In inpatient settings, WHO strongly recommends using 
LF-LAM to assist in the diagnosis of active TB in HIV-positive 
adults, adolescents and children:
• with signs and symptoms of TB (pulmonary and/or 
extrapulmonary) (strong recommendation, moderate 
certainty in the evidence about the intervention effects); or
• with advanced HIV disease;b or 
• who are seriously ill (strong recommendation, moderate 
certainty in the evidence about the intervention effects); or
• irrespective of signs and symptoms of TB and with a CD4 
cell count <200 (strong recommendation, moderate 
certainty in the evidence about the intervention effects). 
 
Increased strength of 
the recommendation.
Improved quality of evidence.
Increased scope of 
the recommendation:
 ‒ all symptomatic or seriously ill 
inpatients, irrespective of CD4 
cell count;
 ‒ all inpatients with advanced HIV 
disease; and
 ‒ inpatients with or without signs and 
symptoms of TB who have a CD4 cell 
count <200.
This recommendation also applies to 
HIV-positive adult outpatients with signs 
and symptoms of TB (pulmonary and/
or extrapulmonary) who have a CD4 
cell count ≤100 cells/µL, or HIV-positive 
patients who are seriously ill regardless 
of CD4 cell count or with unknown CD4 
cell count, based on the generalization of 
data from inpatients.
In outpatient settings, WHO suggests using LF-LAM to 
assist in the diagnosis of active TB in HIV-positive adults, 
adolescents and children:
• with signs and symptoms of TB (pulmonary and/
or extrapulmonary) or seriously ill (conditional 
recommendation, low certainty in the evidence about test 
accuracy); and
• irrespective of signs and symptoms of TB and with a CD4 
cell count <100 (conditional recommendation, very low 
certainty in the evidence about test accuracy). 
Increased scope of 
the recommendation:
 ‒ all outpatients with signs and 
symptoms of TB or seriously ill; and
 ‒ outpatients with a CD4 cell count 
<100, irrespective of signs and 
symptoms of TB.
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The use of lateral flow urine 
lipoarabinomannan assay (LF-LAM) 
for the diagnosis and screening of 
active tuberculosis in people living 
with HIV. Policy guidance (2015) (22)
Lateral flow urine lipoarabinomannan assay (LF-LAM) for 
the diagnosis of active tuberculosis in people living with 
HIV. Policy update (2019) (27)
Changes
Except as specifically described below 
for persons with HIV infection with low 
CD4 cell counts or who are seriously 
ill, LF-LAM should not be used for the 
diagnosis of TB (strong recommendation, 
low quality of evidence).
 
In outpatient settings, WHO recommends against using 
LF-LAM to assist in the diagnosis of active TB in HIV-positive 
adults, adolescents and children:
• without assessing TB symptoms (strong recommendation, 
very low certainty in the evidence about test accuracy);
• without TB symptoms and unknown CD4 cell count, or 
without TB symptoms and CD4 cell count ≥200 (strong 
recommendation, very low certainty in the evidence about 
test accuracy); or
• without TB symptoms and with a CD4 cell count of 100–
200 (conditional recommendation, very low certainty in the 
evidence about test accuracy). 
Better definition of patient populations 
for negative recommendation against 
use of LF-LAM.
LF-LAM should not be used as 
a screening test for TB (strong 
recommendation, low quality 
of evidence).
See inpatient and outpatient recommendations above for 
situations in which LF-LAM is suggested for use among 
individuals, irrespective of signs and symptoms of TB.
See outpatient recommendations above for situations in 
which WHO recommends against LF-LAM use.
Clarification of recommendation for 
usage among individuals with and 
without TB signs and symptoms (i.e. 
irrespective of signs and symptoms):
 ‒ LF-LAM is strongly recommended for 
inpatients with advanced HIV disease, 
and individuals with a CD4 cell count 
<200, irrespective of symptoms; and
 ‒ LF-LAM is suggested for outpatients 
with a CD4 cell count <100, 
irrespective of symptoms.
See above for patient populations with 
a recommendation against usage.
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The use of lateral flow urine 
lipoarabinomannan assay (LF-LAM) 
for the diagnosis and screening of 
active tuberculosis in people living 
with HIV. Policy guidance (2015) (22)
Lateral flow urine lipoarabinomannan assay (LF-LAM) for 
the diagnosis of active tuberculosis in people living with 
HIV. Policy update (2019) (27)
Changes
This recommendation also applies to 
HIV-positive children with signs and 
symptoms of TB (pulmonary and/
or extrapulmonary) based on the 
generalization of data from adults while 
acknowledging very limited data and 
concern regarding low specificity of the 
LF-LAM assay in children. 
These recommendations also apply to adolescents and 
children living with HIV, based on generalization of data from 
adults, while acknowledging that data for these population 
groups are limited.
 
 
HIV: human immunodeficiency virus; LF-LAM: lateral flow urine lipoarabinomannan assay; TB: tuberculosis; WHO: World Health Organization.
a “Seriously ill” is defined based on four danger signs: respiratory rate of more than 30/minute, temperature of more than 39 °C, heart rate of more than 120/minute and unable to walk unaided.
b For adults, adolescents, and children aged 5 years or more, “advanced HIV disease” is defined as a CD4 cell count of less than 200 cells/mm3 or a WHO clinical stage 3 or 4 event at presentation for care. All 
children with HIV who are aged under 5 years should be considered as having advanced disease at presentation.
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Research gaps
Current recommendations on the various methods and tools should not prevent or restrict further 
research on new, rapid molecular drug-susceptibility tests, especially for assays that can be used 
as close as possible to where patients with a presumptive diagnosis of TB are identified and where 
treatment can be initiated. Priorities for further operational research on diagnostics are listed below, 
grouped for each technology.
Molecular assays intended as initial tests
• Evaluation of the impact of Xpert Ultra testing on patient-important outcomes (cure, mortality, 
time to diagnosis and time to start treatment).
• Evaluation of the diagnostic accuracy of Xpert Ultra in gastric or stool specimens for pulmonary 
TB and extrapulmonary TB in children. 
• Evaluation of the combinatorial benefit of multiple specimen types. There were limited data 
suggesting that the combination of non-invasive specimens performs comparably with traditional 
gastric specimens or induced sputum specimens. 
• Additional operational and qualitative research to determine the best approach to less-invasive 
specimen collection. 
• Implementation studies on a method of suction for nasopharyngeal aspiration that is appropriate 
for low-skill or low-resource environments.
• Extensive operational research into the use of stool as a diagnostic specimen in terms of integration 
into normal diagnostic clinical pathways, definition of laboratory protocols that successfully balance 
ease of implementation and diagnostic performance, and the impact of stool testing on patient-
important outcomes. There is a dearth of qualitative research identifying child and family preferences 
for and acceptability of comparative diagnostic approaches.
• Identification of an improved reference standard that accurately defines TB disease in children and 
in paucibacillary specimens because sensitivity of all available diagnostics is suboptimal. 
• Development of new tools that correctly diagnose a higher proportion of child TB cases. Ideally, 
the new tools will be rapid, affordable, feasible, and acceptable to children and their parents. 
• Comparison of different tests, including Xpert MTB/RIF and Xpert Ultra, to determine which tests 
(or strategies) yield superior diagnostic accuracy. The preferred study design is one in which all 
participants receive all available diagnostic tests or are randomly assigned to receive a particular 
test. Studies should include children and HIV-positive people. Future research should acknowledge 
the concern associated with culture as a reference standard, and should consider ways to address 
this limitation.
• Development of rapid point-of-care diagnostic tests for extrapulmonary TB. Research groups should 
focus on developing diagnostic tests and strategies that use readily available clinical specimens 
such as urine, rather than specimens that require invasive procedures for collection. 
• Operational research to ensure that tests are used optimally in settings of intended use. 
• Evaluation of the diagnostic accuracy of Truenat (MTB, MTB Plus and MTB-RIF) in specific patient 
populations such as PLHIV, former TB patients for pulmonary TB and extrapulmonary TB in adults 
and children.
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TB-LAMP
• Evaluation of diagnostic algorithms in different epidemiological and geographical settings and 
patient populations.
• Conducting of more rigorous studies with higher quality reference standards (including multiple 
specimen types and extrapulmonary specimens) to improve confidence in specificity estimates. 
• Determination of training needs, and assessments of competency and quality.
• Gathering of more evidence on the impact on TB treatment initiation, morbidity and mortality.
• Performance of country-specific cost–effectiveness and cost–benefit analyses of targeted TB-LAMP 
use in different programmatic settings.
• Meeting the Standards for Reporting Diagnostic Accuracy Studies (STARD) for future studies.19
First-line LPA
• Development of improved understanding of the correlation between the detection of resistance-
conferring mutations using culture-based DST and patient outcomes.
• Review of evidence to confirm or revise different critical concentrations used in culture-based 
DST methods.
• Determination of the limit of detection for LPA in detecting heteroresistance.
• Determination of needs for training, assessing competency and ensuring quality assurance.
• Gathering of more evidence on the impact on mortality of initiating appropriate treatment for 
MDR-TB.
• Meeting the STARD for future diagnostic studies.
• Performance of country-specific cost–effectiveness and cost–benefit analyses of LPA use in different 
programmatic settings.
Second-line LPA
• Development of improved understanding of the correlation between the detection of resistance-
conferring mutations with phenotypic DST results and with patient outcomes.
• Development of improved knowledge of the presence of specific mutations detected with SL-LPA 
correlated with minimum inhibitory concentrations for individual drugs within the classes of 
fluoroquinolones and SLIDs.
• Determination of the limit of detection of SL-LPA for the detection of heteroresistance.
• Gathering of more evidence on the impact of MTBDRsl on appropriate MDR-TB treatment initiation 
and mortality.
• Strongly encourage that future studies follow the recommendations in the STARD (28) statement 
to improve the quality of reporting.
• Performance of country-specific cost–effectiveness and cost–benefit analyses of the use of SL-LPA 
in different programmatic settings.
LF-LAM
• Development of simple, more accurate tests based on LAM detection, with the potential to be 
used for HIV-negative populations.
• Evaluation of the use of LF-LAM in PLHIV without signs and symptoms of TB.
• Evaluation of the use of LF-LAM in children and adolescents with HIV.
• Evaluation of the combination of parallel use of LF-LAM and rapid qualitative CD4 cell count systems.
• Undertaking of implementation research into the acceptance, scale-up and impact of LF-LAM in 
routine clinical settings.
• Undertaking of qualitative research on user perspectives of LF-LAM for feasibility, accessibility and 
equity issues.
19 See http://www.equator-network.org/reporting-guidelines/stard/.
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• Undertaking of implementation research on LF-LAM integrated into HIV care packages.
• Evaluation of the performance of LF-LAM as the HIV epidemic evolves and more people on 
treatment with viral load suppression are hospitalized.
• Evaluation of the cost–effectiveness of LF-LAM.
• Evaluation of other rapid LAM-based tests such as FujiLAM.
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Annex 1: Guideline development 
methods
Methods used to develop World Health Organization guidelines
To develop new or update existing guidelines for methods and tools to diagnose tuberculosis (TB), 
the Global TB Programme commissions systematic reviews on the performance or use of the tool or 
method in question. A systematic review provides a summary of the current literature on diagnostic 
accuracy or user aspects, for the diagnosis of TB or the detection of anti-TB drug resistance in adults 
or children (or both) with signs and symptoms of TB. 
The certainty of the evidence is assessed consistently for documented evidence using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach. GRADE produces 
an overall quality assessment (or certainty) of evidence and a framework for translating evidence into 
recommendations. The certainty of the evidence is rated as high, moderate, low or very low. These 
four categories imply a gradient of confidence in the estimates. Even if a diagnostic accuracy study is of 
observational design, it would initially be considered high-quality evidence in the GRADE approach.20
In addition, the Global TB Programme commissions systematic reviews to collect evidence in the 
field of resource use (i.e. cost and cost–effectiveness), as well as end-user perspectives on particular 
diagnostic tests or interventions. This evidence-to-recommendation process will inform domains such 
as feasibility, accessibility, equity and end-user values. 
If systematic review evidence is unavailable or is scarce, the potential subsequent effects can be 
modelled for both diagnostic accuracy as well as cost and cost–effectiveness. For instance, the 
prevalence of the disease in question, combined with the sensitivity and specificity of a certain test, can 
be used to estimate the number of false positives and false negatives in a population. Similarly, data 
on expenditures and cost–effectiveness ratios can be estimated and modelled, based on economical 
and epidemiological data. Finally, qualitative evidence on the end-user perspective of using a particular 
test may be generated through end-user interviews if data are scarce in the public domain. 
Following a systematic review, the Global TB Programme convenes a Guideline Development Group 
(GDG) meeting to review the collected evidence. The GDG is made up of external experts whose 
central task is to develop evidence-based recommendations. The GDG also performs the important 
task of finalizing the scope and key questions of the guideline in PICO (i.e. population, intervention, 
comparator and outcomes) format.
This group should be established early in the guideline development process, once the Steering 
Group has defined the guideline’s general scope and target audience, and has begun drafting the 
key questions. The GDG should be composed of relevant technical experts; end-users, such as 
programme managers and health professionals, who will adopt, adapt and implement the guideline; 
representatives of groups most affected by the guideline’s recommendations, such as service users 
and representatives of disadvantaged groups; experts in assessing evidence and developing guidelines 
informed by evidence; and other technical experts as required (e.g. a health economist or an expert 
on equity, human rights and gender).21
20 Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE et al. Grading quality of evidence and strength of recommendations 
for diagnostic tests and strategies. Bmj. 2008;336(7653):1106–10 (https://pubmed.ncbi.nlm.nih.gov/18483053/, accessed 1 June 2020).
21 Handbook for guideline development. Geneva: World Health Organization; 2014 (https://www.who.int/publications/guidelines/
handbook_2nd_ed.pdf?ua=1, accessed 12 June 2020).
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Recommendations are developed based on consensus among GDG members, where possible. When 
it is not possible to reach consensus, a vote is taken. When a draft guideline is developed by a WHO 
steering committee, it is reviewed initially by GDG members and subsequently by an External Review 
Group (ERG). The ERG is made up of individuals interested in the subject, and may include the same 
categories of specialists as the GDG. When the ERG reviews the final guideline, its role is to identify 
any errors or missing data, and to comment on clarity, setting, specific issues and implications for 
implementation – not to change the recommendations formulated by the GDG.21
Formulation of the recommendations
Evidence is synthesized and presented in GRADE evidence tables. The evidence to decision (EtD) 
framework is used subsequently to facilitate consideration of the evidence and development of 
recommendations in a structured and transparent manner. Finally, recommendations are developed 
based on consensus among GDG members where possible. If it is not possible to reach consensus, 
then voting takes place. Decisions on the direction and strength of the recommendations are also 
made using the EtD framework.
Factors that influenced the direction and strength of a recommendation in this guideline were: 
• priority of a problem;
• test accuracy;
• balance between desirable and undesirable effects;
• certainty of:
 – evidence of test accuracy;
 – evidence on direct benefits and harms from the test;
 – management guided by the test results;
 – link between test results and management;
• confidence in values and preferences and their variability;
• resource requirements;
• cost–effectiveness;
• equity;
• acceptability; and
• feasibility.
These factors are discussed below.
Priority of a problem
The GDG considers whether the overall consequences of a problem (e.g. increased morbidity, mortality 
and economic effects) are serious and urgent. The global situation is considered and available data 
reviewed. In most cases, the problem must be serious and urgent to be considered by a GDG.
Test accuracy
The pooled sensitivity and specificity presented in the GRADE evidence profile is assessed. Preferably 
and if available the review includes studies with both microbiological reference standards (culture) 
as well as composite reference standards (e.g. in children and in patients with extrapulmonary TB). 
Balance between desirable and undesirable effects
Under this component, GDG members are asked to judge the anticipated benefits and harms from 
the test in question, including direct effects of the test (e.g. benefits such as faster diagnosis, and 
harms such as adverse effects from administration of the test). In addition, the possible subsequent 
effects of the test must be included; for instance, effects of treatment after a positive diagnosis (cure 
or decrease in mortality), and the effect of no treatment or further testing after a negative test result. 
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Evidence, ideally retrieved from systematic reviews of randomized controlled trials (RCTs) of the test, 
should inform the GDG of these downstream effects. If evidence from RCTs is not available, diagnostic 
accuracy studies can be used. In the latter, true positive and true negative diagnosed cases are taken 
as benefits, whereas false positive and false negative cases are taken as harms. 
Certainty of the evidence
Certainty of the evidence of test accuracy is judged scored on a scale from very low, via low and 
moderate, to high. Certainty of the evidence on direct benefits and harms from the test are assessed 
and scored in a similar way.
Certainty of management
For certainty of patient management being guided by the test results, the GDG focuses on whether 
the management would be any different, should it be guided by the test results. 
For certainty of the link between test results and management, the panel assesses how quickly and 
effectively test results can transfer to management decisions. 
Confidence in values and preferences and their variability
The value of the test to improve diagnosis and its impact on patient care is evaluated and scored 
with the help of evidence from qualitative research. The impact on notification and, moreover, the 
ability of the test to increase case notification is also evaluated and scored, taking into account the 
entire diagnostic cascade, including, for example, issues related to feasibility of implementation, rate 
of use, staff’s confidence in test results and turnaround time of results.
Resource requirements
In relation to resource requirements, the following questions are answered:
• How large are the resource requirements for test implementation? 
• What is the certainty of the evidence about resource requirements? 
• Does the cost–effectiveness of the intervention favour the intervention or the comparison? 
Cost–effectiveness
Available evidence on cost–effectiveness is evaluated and scored. 
Equity
GDG members consider whether implementing the tool or method will positively or negatively affect 
access to health care (e.g. will it be possible to implement the test in distinct levels of health care 
or through self-administration, or are there other ways to make the tools or method available to all 
levels of the health care system). 
Acceptability
In terms of acceptability, the panel considers whether the tool or method will be acceptable by all 
relevant stakeholders, such as health workers, health managers and patients. 
Feasibility
The GDG considers how feasible it is to implement a tool or method in various settings. Aspects 
such as training and refresher training needs, hands-on time, biosafety requirements, time to results, 
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service and maintenance, calibration, and effect on diagnostic algorithms are all taken into account 
in the final score. 
For more details on the transition from evidence to recommendations, see Web Annex 3. Evidence 
to decision tables.
Management of conflict of interest
Before being invited to be a GDG member, each potential GDG member is asked to submit a 
completed declaration of interests (DOI) form and provide a curriculum vitae (CV). In addition, an 
abbreviated and focused internet search is performed “to identify any obvious public controversies 
or interests that may lead to compromising situations for WHO and the expert concerned”. Members 
of the steering committee evaluate a potential member’s CV, DOI and information retrieved from the 
internet to determine whether there are, or may be, conflicts of interest (COI) and, if so, whether these 
require a management plan. COI management is based on the WHO guidelines for DOI for experts,22 
one-on-one consultation with a member of the Ethics Team from the WHO Office of Compliance, 
Risk Management and Ethics, and the WHO Handbook for guideline development.23
Both financial and non-financial interests are considered. A “significant” COI would include: 
• “intellectual bias”, when an individual may have repeatedly taken a public position on an issue 
under review, which may affect the individual’s objectivity and independence in the global policy 
development process; 
• involvement in research or the publication of materials related to the issue under review; and
• financial interest above US$ 5000. 
For obvious reasons, developers of any assay are never involved in the process of policy development. 
22 Declaration of interests for WHO experts – forms for submission. Geneva: World Health Organization; 2019 (https://www.who.int/about/
declaration-of-interests/en/, accessed 12 June 2020).
23 Handbook for guideline development. Geneva: World Health Organization; 2014 (https://www.who.int/publications/guidelines/
handbook_2nd_ed.pdf?ua=1, accessed 12 June 2020).
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Web Annex 4. Evidence synthesis and analysis
Web Annex 4.1 Impact of diagnostic test Xpert MTB/RIF on patient-important 
outcomes for tuberculosis: a systematic review
Web Annex 4.2 Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in 
adults with signs and symptoms of pulmonary TB: an updated systematic review
Web Annex 4.3 Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis 
in adults with signs and symptoms of extrapulmonary TB: an updated systematic 
review
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Web Annex 4.5 Report on the diagnostic accuracy of the Molbio Truenat 
Tuberculosis and Rifampicin-Resistance assays in the intended setting of use
Web Annex 4.6 Systematic literature review of economic evidence for molecular 
assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary 
TB in adults and children
Web Annex 4.7 Report on user perspectives on Xpert testing: results from 
qualitative research
Web Annex 4.8 Drug concentrations used in culture-based DST SL-LPA
Web Annex 4.9 LF-LAM for detecting active tuberculosis in people living with HIV: 
an updated systematic review
Web Annex 4.10 Economic evaluations of LF-LAM for the diagnosis of active 
tuberculosis in HIV-positive individuals: an updated systematic review
Web Annex 4.11 User perspectives on TB-LAM for the diagnosis of active 
tuberculosis: results from qualitative research 
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For further information, please contact:
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20, Avenue Appia CH-1211 Geneva 27 Switzerland
Global TB Programme
Web site: www.who.int/tb
